U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

S ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended July 31, 2012

 

£ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from _______________ to _________________

 

Commission file number: 0-11485

 

ACCELR8 TECHNOLOGY CORPORATION

 

(Exact name of Registrant as Specified in Its Charter)

 

Colorado 84-1072256
(State or Other Jurisdiction  
of Incorporation or Organization) (I.R.S. Employer Identification No.)
   
7000 North Broadway, Bldg 3-307  
Denver, Colorado 80221
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:

(303) 863-8088

 

SECURITIES REGISTERED PURSUANT TO SECTION 12 (b) OF THE ACT:  

 

 Name of each exchange on which registered: The NYSE AMEX EQUITIES

 

COMMON STOCK, NO PAR VALUE PER SHARE

 

SECURITIES REGISTERED PURSUANT TO SECTION 12 (G) OF THE ACT: NONE

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. £  Yes

  S   No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. 

£  Yes  S  No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   S   Yes     £   No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

S Yes £ No

 

 

 

 

 
 

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  £

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated

filer  £

Accelerated

filer  £

Non-accelerated  filer  £

Smaller reporting

company  S

    (Do not check if a smaller reporting company)  

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  

£   Yes  S   No

 

 

The aggregate market value of the shares of Common Stock, no par value per share, of the registrant held by non-affiliates on January 31, 2012 was $12,274,828, which was computed based upon the closing price of the Registrant’s Common Stock on that date.

 

There were 25,231,939 shares of Common Stock of the registrant outstanding as of October 15, 2012.

 

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive Proxy Statement relating to its 2012 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

 

2

 

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I      
  Item 1 Business 3
  Item 1A Risk Factors 8
  Item 1B Unresolved Staff Comments 13
  Item 2 Properties 13
  Item 3 Legal Proceedings 13
  Item 4 Mine Safety Disclosures 13
       
PART II      
  Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 14
  Item 6 Selected Financial Data 15
  Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
  Item 7A Quantitative and Qualitative Disclosures About Market Risk 20
  Item 8 Financial Statements and Supplementary Financial Data 20
  Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 37
  Item 9A Controls and Procedures 37
  Item 9B Other Information 37
       
PART III      
  Item 10 Directors, Executive Officers and Corporate Governance 38
  Item 11 Executive Compensation 38
  Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 39
  Item 13 Certain Relationships and Related Transactions, and Director Independence 39
  Item 14 Principal Accountant Fees and Services 39
       
PART IV      
  Item 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 39

 

 

 

 

 

 

 

 

 

 

 

 
 

 

  Introductory Note

 

Except as otherwise indicated by the context, references in this Annual Report on Form 10-K (this “Form 10-K”) to the “Company,” “Accelr8,” “we,” “us” or “our” are references to the combined business of Accelr8 Technology Corporation.  

 

Special Note Regarding Forward-Looking Statements

 

This report contains forward-looking statements and information relating to Accelr8 that are based on the beliefs of our management as well as assumptions made by and information currently available to us.  When used in this Form 10-K, forward-looking statements include, but are not limited to, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as well as statements regarding technologies and products we are developing or intend to develop in the future, the ability of such technologies and products to work as intended and bring to market, opportunities for the Company and its technologies, statements regarding competition, the market and industry in which we intend to compete, demand and acceptance of new products, any statements of the plans, strategies and objectives of management for future operations, any statements regarding future economic conditions or performance, any statements of belief or intention, and any statements or assumptions underlying any of the foregoing.  These statements reflect our current view concerning future events and actions and are subject to risks, uncertainties and assumptions.  There are important factors that could cause actual results to vary materially from those described in this Form 10-K as anticipated, estimated or expected, including, but not limited to the factors listed in Item 1A – Risk Factors in this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward- looking statements, even if new information becomes available in the future.  

 

 

 

 

2

 

 

 

 

 
 

 

 

PART I

Item 1. Business

 

Overview

 

Accelr8 Technology Corporation is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company’s BACcel TM platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity.

 

Background

 

Every six minutes another American dies from a hospital-acquired infection (HAI). The US Centers for Disease Control and Prevention estimates that almost 100,000 HAI fatalities occur annually that are attributable to bacterial infections acquired in a US healthcare facility. HAI occurs when a patient enters the hospital for some reason other than an infectious disease, then contracts infection more than two days after admission. The HAI mortality rate is more than double that from auto accidents, far more than any type of cancer except lung cancer, and more than seven and one-half times that from AIDS. Despite intensive efforts to improve prevention and care, mortality has remained the same for more than ten years.

 

Yet, in theory, none of these patients should die. An effective antibiotic exists for almost every HAI. Although bacterial strains exist that may resist any particular drug, strains that resist all antibiotics remain rare.

 

Lab delay is a major culprit leading to the high HAI mortality rate. Medical experts believe that inadequate initial therapy substantially elevates the risk of severe morbidity and mortality in critically ill patients. For critically ill patients, the physician must start adequate antibiotics within 2-4 hours of symptom onset. But lab cultures typically take 2-3 days to identify organisms and assess their antibiotic susceptibility. The physician has no choice but to start therapy without knowing the organism or its drug susceptibility. Most often, the physician must choose a combination of two or three broad-spectrum antibiotics, based on the patient’s history, clinical indicators, and the hospital’s recent history of antibiotic effectiveness in similar infections. Unfortunately, widespread and increasingly complex multiple antibiotic resistance typically causes such “empiric therapy” to prove inadequate in 20% to 40% of cases.

 

Further, switching to adequate therapy as soon as the next day fails to improve outcomes. Once an infection passes a critical point, antibiotics have little to no impact on its condition.

 

Popular news media have reported widely about methicillin-resistant Staphylococcus aureus (“MRSA”) as a multi-resistant "superbug." Organizations such as the US Centers for Disease Control and Prevention (“CDC”) and the Infectious Diseases Society of America have also identified other multi-drug resistant organisms as presenting even greater threats. They include Pseudomonas, Acinetobacter, and Klebsiella. In the hospital intensive care unit (“ICU”), “Staph” infections (including MRSA) typically cause approximately 30% of fatal HAI’s. This increase in multi-drug resistant organisms creates an opportunity for the Company by driving demand for rapid identification.

 

We believe that the development of new classes of antibiotics has significantly declined. Improved prevention and infection control have limited potential. In the meantime, bacteria continue to evolve and develop additional drug resistance. Bacteria have become so well adapted to the hospital that even the best preventive efforts do not eradicate them. Hospitals that lead in best preventive practices still suffer from endemic hospital-adapted strains that continue to cause high rates of attributable morbidity and mortality. Such examples suggest that each passing year sees a reduction in the number of cases that can be treated successfully with any particular drug.

 

3

 

 

 

 
 

 

 

 

We believe that dramatically speeding up laboratory diagnostics will help to improve the success rate for initial therapy for HAIs.

 

Products

 

BACcel™ System Development

 

Since 2004, we have focused our efforts on the development of an innovative rapid diagnostic platform, the BACcel™ system, intended for rapid diagnosis in life-threatening bacterial infections. Our goal is to reduce the failure rate of initial therapy by shortening the lab turnaround time to less than eight hours, rather than the 2-3 days now required. Rapid testing would provide guidance in time to influence initial therapy.

 

The BACcel™ system applies our proprietary technology to eliminate time-consuming bacterial culturing, thus eliminating the major source of delay with current testing methods. Our system includes a fixed instrument and proprietary single-use (disposable) test cassettes. Each cassette tests a single patient specimen and is then discarded.

 

BACcel™ uses long-accepted bacteriological testing principles, but applies our proprietary technology to adapt them to analyze live bacteria extracted directly from a patient specimen. The instrumentation uses automated digital microscopy to measure the responses of extracted live bacterial cells to various test conditions. Our system analyzes thousands of these individual cells to arrive at organism identification and antibiotic resistance characteristics.

 

Based on internal lab data, we believe that the BACcel™ system will identify the organisms present in a patient's specimen and count the number of organisms of each type in less than one hour after receiving a specimen. We believe that the BACcel™ system will then additionally report antibiotic resistance for each type of organism within a total of 4-6 hours after receiving a specimen. The clinical purpose of reporting antibiotic resistance is to narrow the drug choices available for therapy and rule out antibiotic classes that are most likely to fail. Quantitative identification in less than one hour enables first-dose therapy guidance that can improve the efficacy of antimicrobial treatment. In addition, de-escalation before the second dose helps to prolong the effectiveness of broad-spectrum antibiotics when lower-cost and older narrow-spectrum agents can provide at least equivalent activity (drug “stewardship”).

 

Additional Products

 

In addition to BACcel™ system development, we have developed and licensed OptiChem surface coatings for use in microarraying components. As a coating for analytical devices, management believes that OptiChem offers superior noise rejection (non-specific binding by interfering substances) and high capacity for target binding, compared with other bio-coatings. For example, in microarraying this results in higher sensitivity and simplified sample preparation. OptiChem also offers the ability to apply micro-patterns, enabling novel advanced analyzer designs. The coating is widely adaptable to virtually any base material, such as plastics, and even highly sophisticated designs can be economically scaled to high-volume production. We have licensed various OptiChem microarraying coatings to SCHOTT (Germany), NanoString (WA), and Nanosphere (IL). See “Sales, Licensing, and Alliances” below.

 

Research and Development

 

We have used two developmental instruments in our laboratory since 2006. In March 2011 we upgraded one of the systems to test engineering improvements. In April 2011, we installed a completely upgraded third system that substantially increases analytical sensitivity and scanning speed. This next-generation system includes a separate fluidic robot and a custom high-speed scanning microscope. The latest prototype increases scan rate approximately 40-fold relative to the original prototypes. This speed substantially improves detection sensitivity for working with specimens that have low microbial counts. It also improves our ability to analyze specimens that require dilution because of high levels of interfering materials, such as endotracheal aspirates used to monitor treatment effectiveness during therapy for pneumonia. We have used the latest prototype for formal proof of concept testing under independent outside observation of testing and outside performance assessment.

 

4

 

 

 

 

 
 

 

During the fiscal year ended July 31, 2008, the Company placed two identical development systems in collaborating research institutions: Denver Health , and Barnes-Jewish Hospital at Washington University in St. Louis. The two institutions have replicated and extended the Company’s own pre-clinical research using analytical methods developed by the Company. Both institutions have also begun pilot clinical studies on specimens from ICU patients using experimental protocols authorized by their respective Institutional Review Boards.

 

Management believes that joint studies will expand and continue and will be presented periodically to the relevant scientific and medical communities. Since 2006, we have made 21 technical presentations at major peer-reviewed national scientific and clinical congresses. The 12 most recent were co-authored with principal investigators at Denver Health, and Barnes-Jewish Hospital. At the annual meeting of the American Thoracic Society in March 2011, our principal investigators at Denver Health presented preliminary results from a prospective clinical pilot study with ICU patients under informed consent. This was our first presentation of a clinical study solely to specialists in Critical Care Medicine. We intend to continue our presentation and publication program as a permanent part of our business development program. (See Note 13 to the footnotes to the consolidated financial statements included in this Annual Report on Form 10-K.)

 

In June 2010, the Company entered into an Evaluation Agreement and Letter of Intent with Novartis Vaccines and Diagnostics, Inc. (“Novartis”), a division of Novartis Corporation. Pursuant to the Evaluation Agreement, Novartis evaluated the results of the Company’s BACcel™ system in identifying the type and quantity of bacterial pathogens in clinical specimens. Pursuant to the Letter of Intent, the Company and Novartis agreed to negotiate in good faith a formal business relationship and definitive agreement regarding the design, development, commercialization and support strength of each party. The Letter of Intent was non-binding and granted Novartis the exclusive right (the “Exclusive Right”) to evaluate and negotiate a license or other comparable agreement for access to the Company’s BACcel™ system intellectual property.

 

In connection with the Evaluation Agreement, the Company successfully performed a series of technical studies, including formal Proof of Concept studies, with Novartis that demonstrated performance of the advanced BACcel™ laboratory prototype. Further, Novartis independently tested Accelr8’s key business assumptions and found general concurrence.

 

Pursuant to the Evaluation Agreement and the Letter of Intent, Novartis made up-front payments and funded the project on a monthly basis until September 30, 2011. Novartis also funded additional activities within its own organization, funded independent engineering firms to advance the product technology, and retained other outside providers to perform due diligence investigations on relevant business areas.

 

The Evaluation Agreement with Novartis expired on September 30, 2011 without Novartis exercising its option for licensing the Company’s BACcel™ system intellectual property.

 

In ongoing technical development of the BACcel™ system, our internal technical team designs the analytical methods and validates them through well-controlled experiments. Studies include comparisons of results between standard methods and the BACcel™ system using well-characterized bacterial strains and clinical patient specimens. Examples of patient specimens tested to date include lower respiratory tract specimens (endotracheal aspirates, visually-guided bronchoalveolar lavage – BAL, and mini-BAL,) urine and cerebrospinal fluid. We have also tested positive blood cultures that originally contained extremely low numbers of infectious pathogens.

 

In addition to developing analytical methods, our internal team proactively guides engineering development and originates additional new technology. As one example, we internally conceived and proved feasibility of a rapid specimen preparation method that appears to enable complete and practical automation for all BACcel™ associated operations. We filed a patent application for this technology in March 2011. This subsystem can also stand alone as a product, and integrate into other medical devices that require specimen pre-processing by automated methods. We created specifications for an outside engineering firm to provide test fixtures and advance toward product development.

 

5

 

 

 

 
 

 

 

 

In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program ("DMRDP") recommended $2 million of funding for a proposed 35-month project of which the Company estimates it will receive direct monies for internal research and development of $750,000.  The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections.  The project will apply the Company’s BACcel rapid diagnostic system to wound infections and other serious infections secondary to trauma.

 

In June 2012, the company began a reorganization, resulting in a significant planned increase in internal research and development staff. This team - including engineers, chemists, and microbiologists - has significant experience in the diagnostics field, having developed and commercialized numerous IVD instruments and tests.

 

During the fiscal years ended July 31, 2012 and 2011, we spent $431,906 and $454,997 respectively, on research and development activities.

 

Sales, Licensing, and Alliances

 

The Company signed a licensing agreement for microarraying slides using OptiChem coatings with Schott Jenaer Glas GmbH ("SCHOTT") on November 4, 2004. Since this time, SCHOTT and the Company have extended this license. On August 15, 2011, Schott Technical Glass Solutions GmbH renewed and expanded its licenses for OptiChem microarray slide products, designated as Schott Nexterion Slide H and Slide HS. The terms remain substantially the same as in previous agreements, with the expansion to include microarray slide products intended for use in medical diagnostic devices. Previous agreements excluded medical applications. This expansion makes SCHOTT the second company that intends to use OptiChem coatings on medical devices.

 

The new agreement extends the non-exclusive license through November 24, 2014. SCHOTT paid the Company $150,000 comprised of a one-time license fee ($50,000) and non-refundable prepaid royalties ($100,000). Royalties consist of 5% of SCHOTT’s net product sales. For medical applications, SCHOTT agrees to refer individual customers directly to the Company for licensing if annual purchases by a customer exceed 20,000 units.

 

On October 5, 2007, the Company entered into an exclusive seven-year license with NanoString Technologies, Inc. (“NanoString”). The license grants NanoString the right to apply OptiChem coatings to NanoString's proprietary molecular detection products.

 

Effective June 14, 2010, the Company entered into the Evaluation Agreement and Letter of Intent with Novartis discussed above. During the fiscal years ended July 31, 2012 and 2011, total revenues from Novartis were $140,000 and $842,408, respectively or 59.3% and 75.1% of total revenues.

 

On July 9, 2010 the Company entered into a non-exclusive license to Nanosphere, Inc. The license grants to Nanosphere the right to apply OptiChem coatings to Nanosphere’s proprietary analytical products. The products may also include FDA-regulated diagnostics devices. Pursuant to the license agreement, Nanosphere paid the Company a non-refundable first-year fee of $150,000 plus a $15,000 technology transfer fee. On each anniversary of the agreement date, the license calls for Nanosphere to pay to the Company the amounts of $350,000 in 2011; $600,000 in 2012, and $750,000 in 2013 in order to complete the payments for rights under the remaining patent life. Pursuant to the Company’s revenue recognition policies and generally accepted accounting principles, all of the amounts due from Nanosphere were recognized as OptiChem revenue during the fiscal year ended July 31, 2010.

 

Competition

 

To the best of our knowledge, no other company now has a product with capabilities similar to those of the BACcel™ system. However, the industry in which we compete is subject to rapid technological changes, and we may face competition for the BACcel™ system.

 

6

 

 

 

 

 
 

 

Publicity frequently appears in the press concerning new products for rapid bacterial identification using genes or other molecular markers (“molecular diagnostics”). Numerous acquisitions, licenses, and distribution arrangements have been announced over the last few years for such products. However, we do not believe that any of these technologies appears applicable to treatment decision support for active, life-threatening infections. For example, gene detection can be highly sensitive and specific, but very few antibiotic resistance mechanisms are simple enough to allow accurate guidance for drug selection only by using the presence or absence of specific genes. Even in those rare instances that have a direct relationship between a gene and effective resistance, such as “MRSA” strains, leading literature has reported novel mutations that escape detection by recently commercialized tests.

 

Fundamental biological limitations arise from the complexity of the majority of drug resistance expression mechanisms. This complexity precludes direct interpretation of molecular marker presence or absence and extrapolating to prescription guidance. Many new diagnostic technologies also require prior isolation of cultured colonies in order to assure accuracy. The time required to obtain such isolates, with a minimum of overnight turnaround, prevents these technologies from serving as rapid diagnostics for treatment decision support.

 

Nevertheless, commercial suppliers of gene marker tests, such as Cepheid, have gained approval for direct analysis of positive blood cultures. Blood cultures also typically require a minimum of overnight growth to produce enough organisms to detect. Existing marker-based tests identify a very small number of organism genera or species, and none identify enough of the high-threat organisms to provide an alternative to standard culturing. Furthermore, the inability to identify multiple drug resistance mechanisms precludes them from effective treatment decision support for critically ill patients.

 

The leading companies with automated microbiological testing include Becton Dickinson, bioMerieux, MicroScan, and Trek Diagnostics. These companies provide products for the broad-based culturing and analysis of a wide variety of bacteria. Such products require purified bacterial strains or “isolates” for analysis, which requires at least overnight culturing to produce enough organisms to test. These products then require at least one additional growth cycle as part of the test. These products use standard culturing methods, including enrichment growth and colony isolation, and therefore cannot achieve the necessary speed for the applications addressed by the BACcel™ system.

 

Another new technology receiving wide attention is mass spectrometry, and particularly the MALDI-TOF (matrix-assisted laser desorption ionization time of flight) version, such as the Biotyper® system from Bruker which awaits FDA clearance. Bruker has agreements with a number of companies for distribution, including Becton Dickinson, Trek, and Siemens. bioMerieux has a similar system for distribution with Shimadzu Corporation. These systems build an empiric database from protein spectra acquired from many thousands of purified bacterial and fungal strains. They require a pure strain isolate for analysis, and enrichment culturing to produce enough material to analyze. Some research papers report attempts to directly analyze isolate or blood culture smears, but results are not as reliable as those from samples prepared using a cleanup process to produce crude protein extracts.

 

MALDI-TOF systems have a major advantage over other molecular methods in identifying a very broad range of organisms. Cost of ownership is also substantially below that of older molecular methods. But the requirement for extensive organism enrichment and purification, as well as the inability to quantify live organisms or distinguish samples derived from viable organisms, substantially limits this technology from time-critical decision support. Finally, as with the older molecular methods, MALDI-TOF systems cannot identify major drug resistance expression and faces the same fundamental biological barriers as gene detection.

 

Many potential competitors have greater research and development, financial, manufacturing, marketing and sales resources than we do. In addition, some potential competitors may, individually or together with companies affiliated with them, have greater human and scientific resources than we do. Potential competitors could develop technologies and methods for materials that render the BACcel™ system and our technologies and methodologies less competitive. However, management is not aware of any development programs that address the same applications as the BACcel™ system.

 

7

 

 

 

 

 
 

 

Operations

 

We own all of our laboratory equipment. We lease approximately 6,400 square feet of laboratory and administrative space in Denver, Colorado. Within our laboratory facility, we constructed a cleanroom for research and development and pilot production. We are also under contract to Denver Health for approximately $3,000 per month for use of its facilities and oversight by an ICU Physician.

 

BACcel™ system development requires certain components that are custom-fabricated to our specifications. Such components include injection-molded plastic components, die-cut laminates, and machined mechanical components. In all applicable cases, we own the production tooling and believe that we will be able to qualify secondary sources. We plan to maintain inventory levels sufficient to bridge second-source response times and include an adequate safety factor to support ongoing development.

 

Intellectual Property

 

We rely upon a combination of patent, copyright, trademark and trade secret laws; employee and third party non-disclosure agreements, license agreements and other intellectual property protection methods to protect our proprietary rights. We are committed to developing a continuing stream of intellectual property and aggressive protection of our position in key technologies. As of July 31, 2012, we have eight issued patents plus four United States and eight international patent filings pending.

 

Accelr8's first patent on the OptiChem technology, U.S. Patent No. 6,844,028 titled "Functional Surface Coating" was issued on January 18, 2005. The patent specification covers the core OptiChem technology. On June 27, 2006, the United States Patent Office issued Patent No. 7,067,194 which awarded the Company a patent for devices that use OptiChem coatings.

 

Accelr8's first patent on the core BACcel™ technology, U.S. Patent No. 7,341,841 titled "Rapid Microbial Detection and Antimicrobial Susceptibility Testing" was issued on March 11, 2008. The patent specification covers methods used to derive identification and antibiotic susceptibility from tests on individual immobilized bacterial cells.

 

There can be no assurance that third parties will not assert infringement or other claims against us with respect to any existing or future products. We cannot assure you that licenses would be available if any of our technology was successfully challenged for infringement by a third party, or if it became desirable to use any third-party technology to enhance the Company's products. Litigation to protect our proprietary information or to determine the validity of any third-party claims could result in a significant expense to us and divert the efforts of our technical and management personnel, whether or not such litigation is determined in our favor.

 

While we have no knowledge that we are infringing upon the proprietary rights of any third party, there can be no assurance that such claims will not be asserted in the future with respect to existing or future products. Any such assertion by a third party could require us to pay royalties, to participate in costly litigation and defend licensees in any such suit pursuant to indemnification agreements, or to refrain from selling an alleged infringing product or service.

 

Employees

 

We have six full-time employees. We have not entered into any collective bargaining agreements and consider our labor practices and employee relations to be good.

 

Item 1A. Risk Factors

 

Investing in our securities involves risk. In evaluating the Company, careful consideration should be given to the following risk factors, in addition to the other information included or incorporated by reference in this Annual Report. Each of these risk factors could materially adversely affect our business, operating results or financial condition, as well as adversely affect the value of an investment in our common stock. In addition, the “Forward-Looking Statements” located in this Form 10-K, and the forward-looking statements included or incorporated by reference herein describe additional uncertainties associated with our business that should be carefully evaluated prior to making a decision to invest in our securities.

 

8

 

 

 

 
 

 

 

Risks Relating to Our Business

 

Our future success, profitability and continued existence is dependent in large part upon the successful development of the BACcel system. We have spent a significant amount of resources developing the BACcel™ system and intend to spend a significant amount more in the future and there can be no assurance that we will successfully develop the BACcel™ system. If we are not successful in the development of the BACcel™ system, or if we are unable to sell it into the marketplace or license it to a third party strategic partner for its development, manufacturing and marketing, it would have a material adverse effect upon the Company’s revenues and results of operations, it could lead to impairment of certain of our intellectual property and would likely have a material adverse effect upon the price of the our Common Stock, our results of operations and may result in us having to cease operations.

 

Our success depends partly on our ability to successfully introduce and the market acceptance of our current and new products. In a market primarily driven by the need for innovative products, our revenue growth will depend on overcoming various technological challenges to successfully introduce our current and new products, including but not limited to the BACcel™ system or other technology based upon the intellectual property included in the BACcel™ system into the marketplace in a timely manner. In addition, we must continue to develop new applications for our existing technologies, including but not limited to, additional commercial applications for the BACcel™ system proprietary technology. Market acceptance of these products will depend on many factors, including, but not limited to, demonstrating that our technologies perform as intended and are superior to other technologies and products that are currently available or may become available in the future. If we are unable to successfully develop new products or if the market does not accept our products, or even if we experience difficulties or delays in the development of our products, including the BACcel™ system, we may be unable to attract additional customers for our products or license our products to other strategic partners, which would seriously harm our business and future growth prospects.

 

Limited revenues from our products and no assurance of future revenues. We have received limited revenue from sales based on products using our OptiChem technology. There is no assurance that we will be successful in marketing our OptiChem products in the future or will receive any revenue from such products. Further, there can be no assurance that we will be successful in marketing the BACcel™ system or will receive any revenues from it. During the fiscal years ended July 31, 2012 and 2011, we experienced losses from operations. If we are unsuccessful in completing the development of the BACcel™ system and generating revenues from such product, we will likely continue to experience losses from operations and negative cash flow as we have in the past, which may have a material adverse effect upon the Company, its results of operations and the price of our Common Stock may be adversely affected.

 

Dependence on key employees. The loss or failure to attract and retain key personnel could significantly impede our performance, including product development, strategic plans, marketing and other objectives. Our success depends to a substantial extent not only on the ability and experience of our senior management, but particularly upon Lawrence Mehren, our Chief Executive Officer and President. We do not have key man life insurance on Mr. Mehren. To the extent that the services of Mr. Mehren would be unavailable to us, we would be required to find another person to perform the duties Mr. Mehren otherwise would perform. We may be unable to employ another qualified person with the appropriate background and expertise to replace Mr. Mehren on terms suitable to us. Further, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled technical, managerial, sales and marketing personnel. There can be no assurance that we will be successful in attracting and retaining the personnel we require to develop and market our products, develop new products and to conduct our operations successfully.

 

9

 

 

 

 
 

 

 

If we are unable to effectively protect our intellectual property, we may be unable to prevent infringement. Our success depends in part on our ability to obtain and maintain patent protection for the technology underlying our products, especially that used in the BACcel™ system, both in the United States and in other countries. We cannot assure you that any of the presently pending or future patent applications will result in issued patents, or that any patents issued to us or licensed by us will not be challenged, invalidated or held unenforceable. Further, we cannot guarantee that any patents issued to us will provide us with a significant competitive advantage. If we fail to successfully enforce our proprietary technology or otherwise maintain the proprietary nature of our intellectual property with respect to our significant current and proposed products, our competitive position, our ability to complete the development of the BACcel™ system and future sales or license of this product or technology could suffer, which would have a material adverse effect upon the Company and its results of operations. Notwithstanding our efforts to protect our intellectual property, our competitors may independently develop similar or alternative technologies or products that are equal to or superior to our technology and proposed products without infringing on any of our intellectual property rights or design around our proprietary technologies. If customers prefer these alternative technologies and products as compared to our technology and proposed products, it may have a material adverse effect upon the Company, our results of operations and the price of our Common Stock may be adversely affected.

 

Our products could infringe on the intellectual property rights of others. Due to the significant number of U.S. and foreign patents issued to, and other intellectual property rights owned by entities operating in the industry in which we operate, we believe that there is a significant risk of litigation arising from infringement of these patents and other rights. Third parties may assert infringement or other intellectual property claims against us or our licensees. We may have to pay substantial damages, including treble damages, for past infringement if it is ultimately determined that our products infringe on a third party's proprietary rights. In addition, even if such claims are without merit, defending a lawsuit may result in substantial expense to us and divert the efforts of our technical and management personnel. We may also be subject to significant damages or injunctions against development and sale of some of our products, which could have a material adverse effect on our future revenues. Furthermore, claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties, and we may be unable to obtain royalty or license agreements on commercially acceptable terms, if at all.

 

Third parties may seek to challenge, invalidate or circumvent issued patents owned by or licensed to us or claim that our products and operations infringe their patent or other intellectual property rights. In addition to our patents, we possess an array of unpatented proprietary technology and know-how and we license intellectual property rights to and from third parties. The measures that we employ to protect this technology and these rights may not be adequate. We may incur significant expense in any legal proceedings to protect our proprietary rights or to defend infringement claims by third parties. In addition, claims of third parties against us could result in awards of substantial damages or court orders that could effectively prevent us from manufacturing, using, importing or selling our products in the United States or abroad.

 

Competition. The industry in which we compete is subject to rapid technological changes, and we face and expect to continue to face competition for our products. We may also face competition from non-medical device companies, including pharmaceutical companies that may offer alternatives to our products. Many of our competitors have greater research and development, financial, manufacturing, marketing and sales resources than we do. In addition, some of our competitors may, individually or together with companies affiliated with them, have greater human and scientific resources than we do. Our competitors could develop technologies and methods that render our technologies and methodologies less competitive. Accordingly, if competitors introduce products that are more effective than our current and proposed technologies, including but not limited to the BACcel™ system, it could have a material adverse effect upon the Company, our results of operations and the price of our Common Stock may be adversely affected.

 

Ability to respond to technological change. Our future success will depend significantly on our ability to enhance our current products and develop or acquire and market new products that keep pace with technological developments and evolving industry standards as well as respond to changes in customer needs. There can be no assurance that we will be successful in developing or acquiring product enhancements or new products to address changing technologies and customer requirements adequately, that we can introduce such products on a timely basis or that any such products or enhancements will be successful in the marketplace. Our delay or failure to develop or acquire technological improvements or to adapt our products to technological change would have a material adverse effect on our business, results of operations and financial condition.

 

10

 

 

 

 
 

 

 

We use hazardous materials in some of our research, development and manufacturing processes. Our research activities sometimes involve the controlled use of various hazardous materials. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. We could be held liable for any damages that might result from any accident or release involving such materials. Any such liability could have a material adverse effect on our business, financial condition and results of operations.

 

Changes in governmental regulations may reduce demand for our products or increase our expenses. We compete in markets in which we or our customers must comply with federal, state, local and foreign regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by these regulations. Any significant change in these regulations could reduce demand for our products.

 

We have a single research and development facility and we may lose revenue and be unable to continue to conduct our research and development and product development activities if we lose this facility. We currently conduct all of our research and development and product development activities in our existing facility in Denver, Colorado. The lease expires in February 2013, at which time we intend to move into a single facility in Tucson, Arizona. If we were unable to use these facilities to conduct our research and development and product development activities, we would have no other means of conducting such activities until we were able to restore such capabilities at the current facility or develop an alternative facility. Further, in such an event, we may lose revenue and significant time during which we might otherwise have conducted research and development and product development activities. Further, we may not be able to maintain our relationships with our licensees or customers. While we carry a nominal amount of business interruption insurance to cover lost revenue and profits, this insurance does not cover all possible situations. In addition, our business interruption insurance would not compensate us for the loss of opportunity and potential adverse impact on relations with our licensees or customers. The loss of facility may have a material adverse effect upon the Company and its results of operations.

 

Our business strategy approach may be adversely affected by additional healthcare reform and changes in managed healthcare. Our vision is to develop and commercialize the BACcel™ system, an innovative, integrated system for rapid identification of bacterial and its antibiotic resistance in critically ill patients. Healthcare reform and the growth of managed care organizations have been considerable forces in the medical diagnostics industry and in recent political discussions. These forces continue to and are expected in the future to place constraints on the levels of overall pricing and thus could have a material adverse effect on our future profit margins of our products or the amounts that we are able to receive from third parties for the licensing of such products. Such continuing changes in the United States healthcare market could also force us to alter our approach to selling, marketing, distributing and servicing our products and customer base. In and outside the United States, changes to government reimbursement policies could reduce the funding that healthcare service providers have available for diagnostic product expenditures, which could have a material adverse impact on the use of the products we are developing and our future sales, license and royalty fees and /or profit margin.

  

We have and intend to make significant additional investments in research and development, but there is no guarantee that any of these investments will ultimately result in a commercial product that will generate revenues. The BACcel™ system integrates several of our component products, systems and processes. For the year ended July 31, 2012, we spent $431,906 and during the fiscal year ended July 31, 2011 we spent $454,997 on research and development expenses and we intend to spend significantly more on research and development activities during the fiscal year ending July 31, 2013 and thereafter. Notwithstanding these investments, we anticipate that we will have to spend additional funds in the research and development of the BACcel™ system. There can be no assurance that the BACcel™ system will be successful, or even if it is successful will be accepted in the marketplace. Further, we might also encounter substantial delays in getting products to market in a timely fashion. There can be no assurance that we will complete the development of the BACcel System, will bring it to market or will generate revenues from licensing or sales.

 

11

 

 

 

 
 

 

 

Changes in our business strategy or plans may adversely affect our operating results and financial condition. If our business strategy or plans change, whether in response to changes in economic conditions or developments in the diagnostics industry, or otherwise, we may be required to expend significantly more resources than planned to develop the BACcel™ system, may have to cease developing the BACcel™ system or develop other products. The expense of such change could adversely affect our operating results and financial condition.

 

The regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals could prevent us from commercializing our future products. We are investing in the research and development of new diagnostic tests, as well as to develop our novel BACcel™ system. Our products are subject to 510(k) clearance or pre-market approval by the FDA prior to their marketing for commercial use in the United States, and to any approvals required by foreign governmental entities prior to their marketing outside the United States. The 510(k) clearance and pre-market approval processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve months from submission to obtain 510(k) clearance, and from one to three years from submission to obtain pre-market approval; however, it may take longer, and 510(k) clearance or pre-market approval may never be obtained. Delays in receipt of, or failure to obtain, clearances or approvals for future products, including tests that are currently in design or development, would result in delayed, or no, realization of revenues from such products and in substantial additional costs which could decrease our profitability. We have limited experience in filing FDA applications for 510(k) clearance and pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory requirements once we have obtained clearance or approval for a product. There can be no assurance that we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and results of operations.

 

Colorado law and our Articles of Incorporation may protect our directors from certain types of lawsuits. Colorado law provides that our directors will not be liable to us or our stockholders for monetary damages for all but certain types of conduct as directors. Our Articles of Incorporation permit us to indemnify our directors and officers against all damages incurred in connection with our business to the fullest extent provided or allowed by law. The exculpation provisions may have the effect of preventing stockholders from recovering damages against our directors caused by their negligence, poor judgment or other circumstances. The indemnification provisions may require us to use our limited assets to defend our directors and officers against claims, including claims arising out of their negligence, poor judgment, or other circumstances.

 

Risks Related to Our Common Stock

 

Our stock price has been volatile and may continue to be volatile; Dividend Policy. The trading price of our Common Stock has been, and is likely to continue to be, highly volatile, in large part attributable to developments and circumstances related to factors identified in "Forward-looking Statements" and "Risk Factors" and the markets response to our operations and financial condition. The market value of your investment in our Common Stock may rise or fall sharply at any time because of this volatility, and also because of significant short positions that may be taken by investors from time to time in our stock. During the fiscal year ended July 31, 2012, the closing sale price for our Common Stock ranged from $0.77 to $3.80 per share. The market prices for securities of medical technology companies historically have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Further, we do not intend to pay any cash dividends on our Common Stock in the foreseeable future.

 

We may require additional capital in the future and you may incur dilution to your stock holdings.   We have historically relied upon our existing cash balance, revenues and capital from the sale of our securities to fund our operating losses and we expect that we will continue to incur operating losses until we are able to complete the development of the BACcel™ system and sell it into the marketplace or license it to a third party.  If capital requirements vary materially from those currently planned, we may require additional capital sooner than expected.  There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all.  Further, any sale of a substantial number of additional shares will cause dilution to an investment in our Common Stock and could also cause the market price of our Common Stock to decline. We have the authority to issue up to 45,000,000 shares of Common Stock, of which, as of October 15, 2012, 25,231,939 shares were outstanding) and to issue options and warrants to purchase shares of our Common Stock (of which 4,140,000 options and 14,171,430 warrants to acquire shares of our Common Stock were issued and outstanding).  Issuances of additional shares of our stock in the future could dilute existing shareholders and may adversely affect the market price of our Common Stock.

 

12

 

 

 

 
 

 

 

Item 1B. Unresolved Staff Comments

 

Not Applicable.

 

Item 2. Properties

 

We lease approximately 6,400 square feet of office and laboratory space in Denver, Colorado. The monthly rent and utilities average approximately $6,000 per month. The lease was due to expire on September 30, 2012. On August 3, 2012, the Company entered into an extension of this lease on similar terms whereby it will now expire on February 1, 2013.

 

On August 20, 2012, the Company entered into a Lease Agreement (“Lease”) with Pima County, a political subdivision of the State of Arizona (“Landlord”), pursuant to which the Company will lease approximately 15,100 square feet of office space located in Tucson, Arizona for a period of three years (the “Initial Term”), which may be extended by the Company for up to three additional one-year periods (each a “Renewal Term”). The Lease also provides that the Company has the option, with six months prior notice to Landlord, to lease either or both of two additional areas with an aggregate size of approximately 7,900 square feet.

 

Pursuant to the Lease, the Company agreed to: (i) pay rent equal to $9.25 per usuable square foot per year (approximately $139,600 per year or approximately $11,600 per month) during the Initial Term and $19.80 per usuable square foot per year (approximately $298,900 per year or approximately $24,900 per month) during any Renewal Term; (ii) relocate its corporate offices to the Tucson area and begin operations within 30 days of the date that the tenant improvements are substantially completed (the “Commencement Date”); and (iii) within 18 months of the Commencement Date, employ at least 30 individuals with a median salary of at least $70,000, which median salary must be maintained throughout the term of the Lease. If the Company fails to satisfy the condition described in clause (iii) of the preceding sentence, the rental rate under the Lease will be increased by a percentage that is twice the percentage by which the Company’s annual payroll has fallen short of the specified goal (subject to a cap equal to $19.80 per usuable square foot per year). The Lease also provides that Landlord will pay for tenant improvements (up to a cap of $1,400,000) as well as certain repairs, utilities and insurance. When completed, the Company believes this facility will be adequate for its needs for the foreseeable future.

 

Item 3. Legal Proceedings

 

We are not currently a party to any material legal proceedings.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

 

13

 

 

 

 
 

 

 

PART II

 

Item 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

 

The Company's Common Stock is traded on the NYSE Amex Equities Exchange under the trading symbol AXK. The information in the following table sets forth the high and low sales price information for our Common Stock for the period from August 1, 2010 through July 31, 2012.

 

Quarter Ended       High (1)       Low (1)  
                   
October 31, 2010     $ 1.16     $ 0.67  
January 31, 2011     $ 1.37     $ 0.89  
April 30, 2011     $ 4.90     $ 1.30  
July 31, 2011     $ 7.17     $ 3.54  
October 31, 2011     $ 3.80     $ 2.42  
January 31, 2012     $ 2.98     $ 1.12  
April 30, 2012     $ 2.86     $ 0.77  
July 31, 2012     $ 3.80     $ 2.25  

 

(1)   The above table sets forth the range of high and low closing prices per share of our Common Stock as reported by the finance page at www.yahoo.com for the periods indicated.

 

Holders

 

As of October 15, 2012, we had approximately 226 record owners of our Common Stock.

 

Dividends Paid and Dividend Policy

 

Holders of Common Stock are entitled to receive dividends as may be declared by the Board of Directors out of funds legally available therefore. To date, no dividends have been declared by the Board of Directors. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our Common Stock for the foreseeable future.

 

Future cash dividends, if any, will be at the discretion of our Board of Directors and will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors as our Board of Directors may deem relevant.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

14

 

 

 

 

 
 

 

Equity Compensation Plan Information

 

The table set forth below presents the securities authorized for issuance with respect to compensation plans under which equity securities are authorized for issuance as of July 31, 2012:

 

Plan category Number of securities to be issued upon exercise of outstanding options, warrants and rights Weighted average exercise price of available outstanding options, warrants and rights Number of securities remaining for future issuance under equity compensation plans (excluding securities reflected in the 1st column )
Equity compensation plans approved by security holders 3,180,000 $1.56 2,812,500
Equity compensation plans not approved by security holders

 

-

 

-

 

-

Total 3,180,000 $1.56 2,812,500

 

Item 6. Selected Financial Data.

 

Not applicable to smaller reporting companies.

 

Item 7. Management's Discussion and Analysis and Results of Operation

 

Overview

 

On June 26, 2012, we closed upon the sale to Abeja at a purchase price of $1.03 per share for an aggregate purchase price of $14,420,000 of 14,000,000 shares of the Company’s Common Stock, a warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $1.03 per share and another warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share (collectively the “Investment”).

 

On August 22, 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority will provide certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1,000,000 (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:

· Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).
· Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).
· Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).
· Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4,520,000.

 

For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties.

 

During the fiscal year ending July 31, 2013 we intend to continue technical validation of the BACcel™ system methods, continue field studies including pilot clinical studies at Denver Health and Barnes-Jewish Hospital among others, and continue to publish the results of internal and collaborative studies.

 

Changes in Results of Operations: Year ended July 31, 2012 compared to year ended July 31, 2011

 

Technical development fee revenues were $140,000 for the year ended July 31, 2012 as compared to $842,408 for the year ended July 31, 2011, a decrease of $702,408 or 83.4%. The decrease in technical development fees was the result of the conclusion of work under the Novartis Technical Development Agreement during the 2012 fiscal year.

 

15

 

 

 

 

 
 

 

OptiChem slide revenues for the year ended July 31, 2012 were $45,910 as compared to $34,279 for the year ended July 31, 2011, an increase of $11,631, or 33.9%. The increase in OptiChem revenues was primarily due to an increase in revenue recognized under our license arrangements with NanoString and SCHOTT.

 

License fees for the year ended July 31, 2012 were $50,000 as compared to $0 during the fiscal year ended July 31, 2011. The increase in license fees was the result of the licensing agreement executed with SCHOTT during the period which consisted of an upfront license fee of $50,000 and $100,000 in prepaid royalties. Pursuant to the Company’s revenue recognition policy and generally accepted accounting policies, the upfront payment was recognized upon receipt and the prepaid royalties recognized in the period in which they are earned based on sales reported by SCHOTT.

 

During the fiscal year ended July 31, 2011, we received a Qualified Therapeutic Discovery Grant in the amount of $244,479 that was not presented during the 2012 fiscal year.

 

During the fiscal year ended July 31, 2012 and 2011, there were no cost of sales due to the fact that the slides are manufactured by SCHOTT and NanoString pursuant to license agreements.

 

Research and development expenses for the year ended July 31, 2012, were $431,906 as compared to $454,997 during the year ended July 31, 2011, a decrease of $23,091 or 5.1%. This decrease was primarily the result of reductions in clinical trial expenditures. Clinical trial expenditures decreased to $27,342 for the year ended July 31, 2012 from $35,871 for the year ended July 31, 2011, a decrease of $8,529 or 23.8%.

 

General and administrative expenses for the year ended July 31, 2012 were $2,945,309 as compared to $810,078 during the year ended July 31, 2011, an increase of $2,135,231 or 264.0%. The following summarizes the major components of the changes:

 

      2012       2011       Increase/(Decrease )  
                         
Audit and Accounting   $ 49,849     $ 79,539     $ (29,690 )
Consulting and change of control fees     2,159,043       90,021       2,069,022  
Corporate and Shareholder     100,749       84,598       16,151  
Corporate Insurance     35,619       34,704       915  
Deferred Compensation     106,936       95,985       10,951  
Employee Benefits     3,751       3,402       349  
Payroll Taxes     42,949       32,804       10,145  
Salaries     327,429       316,421       11,008  
Travel     4,952       3,489       1,463  
Legal     69,804       21,770       48,034  
Other General Administrative Expenses     44,228       47,345       (3,117 )
    $ 2,945,309     $ 810,078     $ 2,135,231  

 

 

The increase in consulting fees of $2,069,022 was primarily due to an increase in the charge against earnings, as calculated using the Black-Scholes method, for the cost of stock options granted or extended and the obligation to pay a change of control payment to a former officer of $1,350,000 in each case relating to the Investment.

 

The decrease in amortization for the year ended July 31, 2012 was negligible.

 

 

16

 

 

 

 

 
 

 

Depreciation for the year ended July 31, 2012 was $2,097 as compared to $2,396 during the year ended July 31, 2011 a decrease of $299 or 12.4%. The decreased depreciation was primarily due to equipment becoming fully depreciated.

 

Marketing and sales expenses were $8,315 for the year ended July 31, 2012 as compared to $9,621 during the year ended July 31, 2011, a decrease of $1,306 or 13.6%. The decrease was primarily the result of decreased travel during the fiscal year 2012 to industry trade shows.

 

As a result of these factors, loss from operations for the year ended July 31, 2012 was $5,351,760 as compared to a loss of $409,425 for the year ended July 31, 2011, resulting in a greater loss of $4,942,335.

 

Interest and dividend income for the year ended July 31, 2012 was $16,297, consistent with $16,092 for the year ended July 31, 2011.

 

During the fiscal years ended July 31, 2012 and 2011, the Company maintained a deferred compensation trust held for the benefit of a director and a former executive officer of the Company. Unrealized gains on marketable securities (which specifically excludes shares of the Company’s Common Stock held in the deferred compensation trust) held in the deferred compensation trust for the year ended July 31, 2012 was $23,987 as compared to an unrealized gain of $14,572 during the year ended July 31, 2011. The increased unrealized gain was a result of market fluctuations on the securities that are held in the deferred compensation trust.

 

As a result of these factors, net loss for the year ended July 31, 2012 was $5,310,476 as compared to a net loss of $378,761 during the year ended July 31, 2011, a greater loss of $4,931,715.

 

Capital Resources and Liquidity

 

During the fiscal year ended July 31, 2012, we did not generate positive cash flows from operating activities, as compared with cash provided by operations for fiscal year 2011. Our primary sources of liquidity have been from sales of shares of our Common Stock and revenues from operations. As of July 31, 2012, the Company had $14,263,248 in cash and cash equivalents, an increase of $13,487,392 from $775,856 at July 31, 2011. The primary reasons for the change in cash and cash equivalents was the infusion of $14,420,000 for issuance of Common Stock from the Investment. The Company has recently entered into a Lease Agreement whereby it plans to move the Company’s principal offices to Tucson, Arizona. The Company has contractual obligations to a director and a former officer of the Company in the amount of $876,000 during the fiscal year ending July 31, 2013 and $40,000 during the fiscal year ending July 13, 2014.

 

As of July 31, 2012, management believes that current cash balances will be sufficient to fund our capital and liquidity needs for the next fiscal year.

 

The following summarizes the Company’s capital resources at July 31, 2012 compared with July 31, 2011:

 

    July 31, 2012       July 31, 2011        Amount of Change  
                         
Cash and cash equivalents   $ 14,263,248     $ 775,856     $ 13,487,392  
Accounts receivable (short term)   $ 750,947     $ 596,128     $ 154,819  
Current assets   $ 15,042,386     $ 1,422,839     $ 13,619,547  
Total assets   $ 17,213,742     $ 6,264,338     $ 10,949,404  
Current liabilities   $ 1,391,716     $ 69,340     $ 1,322,376  
Working Capital   $ 13,650,670     $ 1,353,499     $ 12,297,171  
Net cash (used)/provided by operating activities   $ (815,672 )   $ 448,481     $ (1,264,153 )
Net cash (used in)/provided by investing activities   $ (245,505 )   $ (150,336 )   $ (95,169 )
Net cash (used) provided by financing activities   $ 14,548,569     $ 194,438     $ 14,354,131  

   

17

 

 

 

 
 

 

 

Our primary use of capital has been for the research and development of the BACcel™ system. We believe our capital requirements will continue to be met with our existing cash balance, revenues provided by licensors of our products and/or, additional issuance of equity or debt securities. Further, if capital requirements vary materially from those currently planned, we may require additional capital sooner than expected. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current Common Stockholders.

 

Off-Balance Sheet Arrangements

 

For the year ended July 31, 2012, we did not have any off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

In May 2011, the FASB issued additional guidance on fair value disclosures. This guidance contains certain updates to the measurement guidance as well as enhanced disclosure requirements. The most significant change in disclosures is an expansion of the information required for Level 3 measurements including enhanced disclosure for: (1) the valuation processes used by the reporting entity; and (2) the sensitivity of the fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. The Company’s adoption of this guidance on February 1, 2012 did not have a material effect on the Company’s financial statements.

 

In June 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2011-05, “Comprehensive Income (Topic 820).” This ASU seeks to improve comparability, consistency, and transparency of financial reporting with respect to comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholder’s equity, among other amendments. The amendments of this ASU require all non-owner changes in stockholder’s equity to be presented either in single continuous statement of comprehensive income or two separate but consecutive statements. This ASU is effective for fiscal years and interim periods beginning after December 15, 2011 and early adoption is permitted. The Company’s adoption on February 1, 2012 did not have a material effect on the Company’s financial statements.

 

In December 2011, the FASB issued ASU 2011-11, “Disclosures about Offsetting Assets and Liabilities” (Topic 210). This ASU seeks to enhance current disclosures and increase the comparability of Balance Sheets prepared on the basis of U.S. generally accepted accounting principles and those prepared on the basis of International Financial Reporting Standards, by requiring all entities to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements, and reverse sale and repurchase agreements and securities borrowing and securities lending arrangements. This ASU is effective for fiscal years and interim periods beginning after January 1, 2013. The adoption of ASU 2011-11 is not expected to have any effect for the Company.

 

Application of Critical Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

18

 

 

 

 

 
 

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.

 

From time to time, we may enter into collaborative arrangements with multiple deliverable elements including items such as licensing rights, development milestones and royalties from product sales. If we determine that such deliverables can be separated, the associated revenue is allocated among the separate units based on relative fair value. We recognize revenue as follows:

 

· OptiChem revenue is recognized upon shipping of the product to the customer or receipt of the applicable royalty.
· Deferred revenue is recognized upon receipt and the prepaid royalties recognized in the period in which they are earned based on sales reported by the customer.
· Technical development fees are recorded as received.

 

Deferred Taxes

 

We recognize deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities. We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences. As of July 31, 2012 and July 31, 2011, we have established a valuation allowance equal to our net deferred tax asset, as we have not been able to determine that we will generate sufficient future taxable income to allow us to realize the deferred tax asset.

 

Intangible Assets

 

We amortize our intangible assets over the period the asset is expected to contribute directly or indirectly to our future cash flows. We evaluate the remaining useful life of each intangible asset that is being amortized each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization.

 

We review our intangible assets for impairment each reporting period as discussed below under “Impairment of Long-Lived and Intangible Assets.” An impairment loss will be recognized if the carrying amount of an intangible asset is not recoverable and its carrying amount exceeds its fair value.

 

Impairment of Long-Lived and Intangible Assets

 

We assess the impairment of identifiable intangibles and long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could trigger an impairment review include the following:

 

· Significant under performance relative to expected historical or projected future operating results;
· Significant changes in the manner of our use of the acquired assets or the strategy for our overall business;
· Significant negative industry or economic trends;
  · Significant decline in our stock price for a sustained period; and 
  · Our market capitalization relative to net book value. 

 

When we determine that the carrying value of intangibles and long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we measure any impairment based on a projected discounted cash flow method using a discount rate determined by our management to be commensurate with the risk inherent in our current business model. Our judgments regarding the existence of impairment indicators are also based on legal factors, market conditions and expected future operational performance of related product lines of the identifiable intangible. Future events could cause us to conclude that impairment indicators exist and that our identifiable assets are impaired. We also evaluate the remaining estimated useful lives of each asset each reporting period and determine whether events or circumstances require revised useful lives.

 

19

 

 

 

 

 
 

 

During the fiscal year ended July 31, 2012, Management determined that certain amounts carried on our balance sheet are no longer recoverable or abandoned its plan to pursue marketability and accordingly reduced the amortized book values by $1,996,583 and recognized the loss in its reported loss from operations.

 

Research and Development

 

Research and development expenses are expensed as incurred. Research and development expenses include salaries and related expenses associated with the development of our technology and include compensation paid to engineering personnel and fees to consultants.

 

Contractual Obligations

 

The Company has certain contractual obligations and commercial commitments as disclosed in this Annual Report on Form 10-K and in the Company’s 2012 Proxy Statement that is incorporated herein by reference that existed as of July 31, 2012 that do not meet the definition of long term debt obligations, capital leases, operating leases or purchase obligations. Subsequent to July 31, 2012, the Company has subsequently entered into a Lease Agreement as described in Item 2. Properties above.

 

Item 7A. Qualitative and Quantitative Disclosures About Market Risk

 

Not applicable to smaller reporting companies.

 

Item 8. Financial Statements and Supplementary Data

 

Financial Statements of Accelr8 Technology Corporation

 

Report of Independent Registered Public Accounting Firm  
Balance Sheets as of July 31, 2012 and 2011  
Statements of Operations for the years ended July 31, 2012 and 2011  
Statements of Shareholders Equity for the years ended July 31, 2012 and 2011  
Statements of Cash Flow for the years ended July 31, 2012 and 2011  
Notes to Financial Statements  

 

 

 

20

 

 

 

 

 
 

 

 

Report of Independent Registered Public Accounting Firm

 

Board of Directors

Accelr8 Technology Corporation

Denver, Colorado

 

We have audited the accompanying balance sheets of Accelr8 Technology Corporation (a Colorado corporation) as of July 31, 2012 and 2011, and the related statements of operations, shareholders’ equity and cash flows for the years ended July 31, 2012 and 2011. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Accelr8 Technology Corporation as of July 31, 2012 and 2011, and the results of its operations and changes in its cash flows for the years ended July 31, 2012 and 2011, in conformity with U.S. generally accepted accounting principles.

 

Denver, Colorado

October 19 , 2012

 

/s/ COMISKEY & COMPANY

PROFESSIONAL CORPORATION

 

 

21

 

 

 

 

 
 

 

ACCELR8 TECHNOLOGY CORPORATION
BALANCE SHEETS
JULY 31, 2012 AND 2011
 
ASSETS
     

 

      2012       2011  
Current assets:                
Cash and cash equivalents   $ 14,263,248     $ 775,856  
Trade accounts receivable     750,947       596,128  
Inventory (Note 3)     10,263       30,278  
Prepaid expenses and other (Note 4)     17,928       20,577  
Total current assets     15,042,386       1,422,839  
Long term accounts receivable, net of current portion     —         745,440  
Property and equipment, net (Note 5)     3,956       3,528  
Investments, net (Note 10)     1,486,459       1,304,522  
Intellectual property, net (Note 6)     680,941       2,788,009  
Total Assets   $ 17,213,742     $ 6,264,338  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
                 
Current liabilities:                
Accounts payable   $ 63,029     $ 34,961  
Accrued compensation and other liabilities     1,243,342       24,582  
Deferred revenue (Note 11)     85,345       9,797  
Total current liabilities     1,391,716       69,340  
Long-term liabilities:                
Deferred compensation     986,459       1,379,522  
Total liabilities   $ 2,378,175     $ 1,448,862  
                 
Shareholders' equity (Notes 7):                
Common stock, no par value;                
45,000,000 shares authorized; 25,231,939 (2012) and 11,103,367 (2011) shares issued and outstanding     22,985,809       14,333,258  
Contributed capital     7,924,880       1,246,864  
Accumulated deficit     (15,801,522 )     (10,491,046 )
Shares held for employee benefit (1,129,110 shares at cost)     (273,600 )     (273,600 )
Total shareholders' equity     14,835,567       4,815,476  
Total liabilities and shareholders' equity   $ 17,213,742     $ 6,264,338  

 

 

See accompanying notes to financial statements.

 

 

22

 

 

 

 

 
 

 

ACCELR8 TECHNOLOGY CORPORATION
STATEMENTS OF OPERATIONS
FOR YEARS ENDED JULY 31, 2012 and 2011
         
Revenues (Note 9 and 11):     2012       2011  
Technical development fees   $ 140,000     $ 842,408  
OptiChem revenue     45,910       34,279  
License fees     50,000       —    
Qualified discovery therapeutic grant     —         244,479  
Total revenues   $ 235,910     $ 1,121,166  
                 
Costs and expenses:                
Research and development     431,906       454,997  
General and administrative     2,945,309       810,078  
Amortization (Note 6)     203,460       253,499  
Depreciation (Note 5)     2,097       2,396  
Marketing and sales     8,315       9,621  
Other expense, impairment of intangibles     1,996,583       —    
Total costs and expenses   $ 5,587,670     $ 1,530,591  
Income (Loss) from operations     (5,351,760 )     (409,425 )
Other (expense) income:                
Interest and dividend income     16,297       16,092  
Unrealized holding gain (loss) on investments (Note 10)     23,987       14,572  
Unrealized holding gain (loss) on asset sale     1,000       —    
Total other income     41,284       30,664  
Net income(loss)   $ (5,310,476 )   $ (378,761 )
Net income (loss) per share:  Basic and diluted net income(loss) per share   $ (0.43 )   $ (0.04 )
Weighted average shares outstanding     12,430,060       10,791,597  

 

See accompanying notes to financial statements.

 

 

 

23

 

 

 

 
 

 

ACCELR8 TECHNOLOGY CORPORATION
STATEMENTS OF SHAREHOLDER’S EQUITY
FOR YEARS ENDED JULY 31, 2012 AND 2011
                                                 
      Shares       Common Stock Amount       Contributed Capital       Accumulated Deficit       For Employee Benefit       Total
Shareholders’ Equity
 
                                                 
Balances, July 31, 2010     10,757,317     $ 14,138,820     $ 1,156,843     $ (10,112,285 )   $ (273,600 )   $ 4,909,778  
Net Loss     —         —         —         (378,761 )     —         (378,761 )
Exercise of Options and Warrants     346,050       194,438       —         —         —         194,438  
Equity Based Compensation     —         —         90,021       —         —         90,021  
Balances, July 31, 2011     11,103,367     $ 14,333,258     $ 1,246,864     $ (10,491,046 )   $ (273,600 )   $ 4,815,476  
Net Loss     —         —         —         (5,310,476 )     —         (5,310,476 )
Issuance of Common Stock and Warrants     14,000,000       8,523,982       5,896,018       —         —         14,420,000  
Exercise of Options and Warrants     128,572       128,569       —         —         —         128,569  
Equity Based Compensation     —         —         781,998       —         —         781,998  
Balances, July 31, 2012     25,231,939     $ 22,985,809     $ 7,924,880     $ (15,801,522 )   $ (273,600 )   $ 14,835,567  

 

 

 

 

 

 

 

See accompanying notes to financial statements.

 

 

24

 

 

 

 

 

 
 

 

ACCELR8 TECHNOLOGY CORPORATION
STATEMENTS OF CASH FLOWS
FOR YEARS ENDED JULY 31, 2012 and 2011
         
Cash flows from operating activities:     2012       2011  
    Net loss   $ (5,310,476 )   $ (378,761 )
    Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:                
      Depreciation     2,097       2,396  
      Amortization     203,460       253,499  
      Equity based compensation     781,998       90,021  
      Other expense, impairment loss     1,996,583       —    
      Unrealized gain on investments     (23,987 )     (14,572 )
      Realized (gain) loss on sale of investments, interest and                
       dividends reinvested     (7,944 )     (6,413 )
      (Increase) decrease in assets:                
         Accounts receivable     590,621       411,477  
         Inventory     20,015       2,342  
         Prepaid expense and other     2,649       (1,182 )
      Increase (decrease) in liabilities:                
         Accounts payable     28,068       2,826  
         Accrued liabilities     718,760       1,291  
         Deferred revenue     75,548       (10,428 )
         Deferred compensation     106,936       95,985  
      Net cash (used in)/provided by operating activities     (815,672 )     448,481  
                 
                 
Cash flows from investing activities:                
Purchase of equipment and patent costs     (95,505 )     (75,336 )
Contribution to deferred compensation trust     (150,000 )     (75,000 )
Net cash used in investing activities     (245,505 )     (150,336 )
                 
Cash flows from financing activities                
Exercise of Warrants and Options     128,569       194,438  
Issuance of Common Stock and warrants     14,420,000       —    
Net cash provided by financing activities     14,548,569       194,438  
Increase (decrease) in cash and cash equivalents     13,487,392       492,583  
Cash and cash equivalents, beginning of year     775,856       283,273  
Cash and cash equivalents, end of year   $ 14,263,248     $ 775,856  

 

See accompanying notes to financial statements.

 

 

25

 

 

 

 
 

ACCELR8 TECHNOLOGY CORPORATION

NOTES TO FINANCIAL STATEMENTS

 

NOTE 1 ORGANIZATION AND NATURE OF BUSINESS

 

Accelr8 Technology Corporation is a Colorado C-Corporation focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company’s BACcel TM platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity.

 

 

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, including receivables from major customers.

 

The Company periodically maintains cash balances at a commercial bank in excess of the Federal Deposit Insurance Corporation insurance limit of $250,000. At July 31, 2012 and 2011, the Company's uninsured cash balance was approximately $14,013,248 and $229,575, respectively.

 

The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company performs ongoing credit evaluations of its clients' financial condition.

 

Estimated Fair Value of Financial Instruments

 

The carrying amounts of cash and cash equivalents, investments and other long-term liabilities approximates fair value at July 31, 2012 and 2011.

 

The carrying value of all other financial instruments potentially subject to valuation risk, principally consisting of accounts receivable and accounts payable, also approximates fair value.

 

The following methods and assumptions were used to estimate the fair value of financial instruments:

 

Cash and Cash Equivalents - Generally, cash held by the Company is invested in US Treasury securities. The carrying amount approximates fair value. Investments - The carrying amount is based on quoted market prices plus cash. Long-Term Receivables - discounted future cash flows. Other Long-Term Liabilities - The carrying amount approximates fair value.

 

 

26

 

 

 

 

 
 

 

Cash and Cash Equivalents

 

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents.

 

Investments

 

The Company accounts for its investments in accordance with ASC 320. All investments are recorded as trading and reported at fair value with unrealized gains and losses reported with current earnings.

 

 

Inventory

 

Inventory is maintained by specific identification and valued at cost using the first-in first out method. Amounts of any particular inventory item are small and are used depending on particular characteristics.

 

Property and Equipment

 

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from five to seven years.

 

Research and Development

 

Research and development costs charged to operations for the years ended July 31, 2012 and 2011 were $431,906 and $454,997, respectively.

 

Intellectual Property

 

Intellectual property is amortized over the period the asset is expected to contribute directly or indirectly to the Company's future cash flows. The Company evaluates the remaining useful life of each intellectual property that is being amortized each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Included in intellectual property are patents, trademarks and technology. Intellectual properties are currently being amortized over their estimated useful lives of 20 years.

 

Long-lived Assets

 

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset. During the fiscal year ended July 31, 2012, Management determined that certain amounts carried on our balance sheet are no longer recoverable or abandoned its plan to pursue marketability and accordingly reduced the amortized book values by $1,996,583 and recognized the loss in its reported loss from operations. See Note 6 below.

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 605, "Revenue Recognition," when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.

 

From time to time, we may enter into collaborative arrangements with multiple deliverable elements including items such as licensing rights, development milestones and royalties from product sales. If we determine that such deliverables can be separated, the associated revenue is allocated among the separate units based on relative fair value.

 

27

 

 

 

 

 
 

 

Technical Development Fees

 

Technical development fee revenue was recorded as received.

 

OptiChem Revenues

 

Revenue is recognized when the Company ships the product to customers or upon the receipt of royalty payments from our licenses.

 

License Fees

 

The Company estimates its performance period used for recognition of licensing fees based on the specific terms of each agreement and the applicable facts and circumstances.

 

Sales Returns and Allowances

 

Allowances on accounts receivable and notes receivable are recorded when circumstances indicate collection is doubtful for particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for sales returns and allowances on a specific account basis.

 

Deferred Revenue

 

Deferred revenue represents amounts received but not yet earned under existing agreements.

 

Income Taxes

 

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

 

The Company follows the provisions of ASC 740, Income Taxes , to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company’s income tax liabilities. Interest and penalties, if any, would be recorded to general and administrative expenses.

 

Earnings Per Share

 

The Company follows ASC 260, "Earnings Per Share," which requires companies to present basic earnings per share and diluted earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity.

 

The Company's net income (loss) for the periods presented cause the inclusion of potential Common Stock instruments outstanding to be antidilutive. For the fiscal year ended July 31, 2012 and July 31,2011 there were Common Stock options and warrants exercisable for 17,151,430 and 950,000 shares of Common Stock which were not included in diluted loss per share as the effect was antidilutive.

 

28

 

 

 

 

 
 

 

 

Equity Based Compensation

 

The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period. The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company's expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. The estimated expected option life is based primarily on historical employee exercise patterns. The Company has not paid dividends in the past and does not have any plans to pay any dividends in the future. See Note 7 for further information.

 

Comprehensive Income (loss)

 

The Company follows ASC 220, "Reporting Comprehensive Income," which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company has no other items that would be included in comprehensive income (loss).

 

Recent Accounting Pronouncements

 

In May 2011, the FASB issued additional guidance on fair value disclosures. This guidance contains certain updates to the measurement guidance as well as enhanced disclosure requirements. The most significant change in disclosures is an expansion of the information required for Level 3 measurements including enhanced disclosure for: (1) the valuation processes used by the reporting entity; and (2) the sensitivity of the fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. The Company adoption on February 1, 2012 did not have a material effect on the Company's financial statements.

 

In June 2011, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2011-05, "Comprehensive Income (Topic 820)." This ASU seeks to improve comparability, consistency, and transparency of financial reporting with respect to comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholder's equity, among other amendments. The amendments of this ASU require all non-owner changes in stockholder's equity to be presented either in single continuous statement of comprehensive income or two separate but consecutive statements. This ASU is effective for fiscal years and interim periods beginning after December 15, 2011 and early adoption is permitted. The Company's adoption on February 1, 2012 did not have a material effect on the Company's financial statements.

 

In December 2011, the FASB issued ASU 2011-11, "Disclosures about Offsetting Assets and Liabilities (Topic 210). This ASU seeks to enhance current disclosures and increase the comparability of Balance Sheets prepared on the basis of U.S. generally accepted accounting principles and those prepared on the basis of International Financial Reporting Standards, by requiring all entities to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements, and reverse sale and repurchase agreements and securities borrowing and securities lending arrangements. This ASU is effective for fiscal years and interim periods beginning after January 1, 2013. The adoption of ASU 2011-11 is not expected to have any effect for the Company.

 

 

29

 

 

 

 
 

 

 

NOTE 3 INVENTORY

The Company purchases raw materials (custom chemicals and glass substrates) for producing OptiChem coated slides. Raw material on hand at the end of each reporting period is priced at cost based on the first-in first-out method. There was no work-in-process or finished goods inventory as of July 31, 2012 and July 31, 2011.

 

NOTE 4 PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets as of July 31, 2012 totaled $17,928 as compared to $20,577 as of July 31, 2011.

 

NOTE 5 PROPERTY AND EQUIPMENT

 

Property and equipment are recorded at cost
and consisted of the following at July 31:
 
      2012       2011  
Computer equipment   $ 22,551     $ 22,551  
Laboratory and scientific equipment     301,338       303,281  
Furniture and fixtures     16,601       16,601  
                 
Total property and equipment     340,490       342,433  
Accumulated depreciation                
      (336,534 )     (338,905 )
Net property and equipment                
    $ 3,956     $ 3,528  
                 

 

Depreciation expense for the years ended July 31, 2012 and 2011 was $2,097 and $2,396, respectively.

 

NOTE 6 INTELLECTUAL PROPERTY

 

Intellectual property consisted of the following at July 31:

     
      2012       2011  
                 
OptiChem Technologies   $ 192,954     $ 4,454,538  
Patents     697,767       604,792  
Trademarks     —         49,018  
      890,721       5,108,348  
Accumulated amortization     (209,780 )     (2,320,339 )
                 
    $ 680,941     $ 2,788,009  
                 

 

Future amortization expense for the intangible assets is estimated as follows:

 

Years Ending July 31,            
           
2013     $ 44,536  
2014       44,536  
2015       44,536  
2016       44,536  
Thereafter       502,797  
Total future amortization     $ 680,941  
           

 

30

 

 

 

 

 
 

 

Intellectual properties are recorded at cost and are being amortized on a straight-line basis over their estimated useful lives of 20 years, the patent and patent application life of the OptiChem Technologies. Amortization expense was $203,460 and $253,499 respectively, for the years ended July 31, 2012 and 2011. The Company routinely evaluates the recoverability of its long-lived assets based upon estimated future cash flows from and estimated fair value of such long-lived assets. If in management's judgment, the anticipated undiscounted cash flows or estimated fair value are insufficient to recover the carrying amount of the long-lived asset, the Company will determine the amount of the impairment and the value of the asset will be written down.

 

During the fiscal year ended July 31, 2012, Management determined that certain amounts carried on our balance sheet are no longer recoverable or abandoned its plan to pursue marketability and accordingly reduced the amortized book values by $1,996,583 and recognized the loss in its reported loss from operations.

 

NOTE 7 SHAREHOLDERS' EQUITY

 

Stock Purchase

 

On April 20, 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (“Abeja”), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of $1.03 per share for an aggregate purchase price of $14,420,000; (i) 14,000,000 shares of the Company’s Common Stock; (ii) a warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $1.03 per share; and (iii) another warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share, with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement. The purchase of Common Stock and warrants pursuant to the Investment qualified for equity treatment under Generally Accepted Accounting Principles. The respective values of the warrants and Common Stock were calculated using their relative fair values and classified both classified under Contributed Capital. The value therefore recorded for the warrants is $5,896,018 and for the Common Stock is $8,523,982.

 

Stock Option Plans

 

The Company has option agreements with key executives and three stock-based compensation plans, which are discussed below:

 

Option and Warrant Agreement With Director and Former Officer

 

In fiscal 1998, options for the purchase of 1,129,110 shares held by our then Chief Executive Officer ("Executive Options and Warrants") were exercised and placed into a "Rabbi" Trust. Such shares are issuable upon the occurrence of retirement, death or termination of such person’s employment over a ten-year period after such occurrence, unless the Board of Directors determines otherwise.

 

In accordance with generally accepted accounting principles, the Company has included the assets and liabilities of the "Rabbi" Trust in its financial statements, and the shares of the Company's Common Stock held by the "Rabbi" Trust have been treated as treasury stock for financial reporting purposes and have no voting rights.

 

Qualified Stock Option Plan

 

The Qualified Stock Option Plan (the “Qualified Plan”) is a shareholder approved plan that provides for stock option grants to employees, including executive officers. The exercise price of each option, which has a maximum ten-year life, is established by the Company's Compensation Committee on the date of grant.

 

As of July 31, 2012, there were 317,500 options exercised under the Qualified Plan, 375,000 that remain outstanding and 7,500 available for grant.

 

31

 

 

 

 

 
 

 

 

Non-qualified Stock Option Plan

 

The Non-Qualified Stock Option Plan (the “Non-Qualified Plan”) is a shareholder approved plan that provides for stock option grants to independent contractors, technical advisors and directors of the Company. The exercise price of each option, which has a maximum ten-year life, is established by the Company's Compensation Committee on the date of grant.

 

As of July 31, 2012, there were 185,000 options exercised under the Non-Qualified Plan, 90,000 that remain outstanding and 25,000 available for grant.

 

Omnibus Stock Option Plan

 

On December 14, 2004 the Company’s shareholders approved the Omnibus Stock Option Plan and reserved 500,000 shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company. The authorized shares in this plan were increased by 5,000,000 shares to an aggregate amount of 5,500,000 upon shareholder approval during the fiscal year ended July 31, 2012.

 

As of July 31, 2012, 5,000 options had been exercised pursuant to the Omnibus Plan, 2,715,000 that remain outstanding, leaving 2,780,000 available for grant.

 

Accounting for Employee Based Option Plans

 

As is discussed in Note 2, the Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended.

 

As of July 31, 2012 and 2011, total unrecognized share-based compensation cost related to unvested stock options was approximately $763,999 and $0. For the years ended July 31, 2012 and 2011, the Company recognized $781,998 and $29,177 in stock based compensation costs related to the issuance of options to employees under ASC 718.

 

The following weighted-average assumptions were used for grants for the year ended July 31, 2012: no dividend yield; risk free interest rate between 0.28% and 1.00%; expected life between 2 and 5 years; and expected volatility between 97% and 133%. The weighted average fair value of options granted during the fiscal year ended July 31, 2012 was $0.57 and during the fiscal year ended July 31, 2011 was $2.59. The weighted average remaining contractual life of options outstanding at July 31, 2012 was 7.8 years. The expected forfeiture rate used was 23%.

 

The following table summarizes information on stock option activity for the Omnibus Plan, the Qualified Plan and the Non-Qualified Plan.

 

      Number of Shares       Exercise Price Per Share       Weighted Average Exercise Price Per Share  
                         
Options Outstanding July 31, 2010     1,010,000       $0.73-4.5     $ 2.57  
Granted     —         —         —    
Exercised     260,000       $0.73-2.25       —    
Expired     —         —         —    
Options Outstanding July 31, 2011     750,000       $0.73-4.50       2.91  
Granted     2,510,000       $1.04-3.13     $ 1.17  
Cancelled     80,000       $2.50-2.69     $ 2.67  
Exercised     —         —         —    
Expired     —         —         —    
Options Outstanding July 31, 2012     3,180,000       $0.73-4.50     $ 1.56  
                         

  

 

32

 

 

 

 
 

 

 

As of July 31, 2012 and 2011, 1,530,000 and 985,000 options outstanding were currently exercisable and carried weighted average exercise prices of $2.08 and $4.05 respectively. The following table summarizes information about stock options outstanding and exercisable at July 31, 2012:

 

    Outstanding   Exercisable
Range of Exercise Price   Number   Weighted  Average Remaining Contractual Life   Weighted Average Exercise Price   Number   Weighted Average Exercise Price
                     
$0.00-1.00       10,000       7.4     $ 0.73       10,000     $ 0.73  
$1.01-2.00       2,305,000       9.7     $ 1.05       685,000     $ 1.06  
$2.01-3.00       632,500       2.6     $ 2.56       632,500     $ 2.56  
$3.01-4.50       232,500       4.1     $ 3.92       202,500     $ 4.04  
Total       3,180,000                     1,530,000          

 

 

NOTE 8 INCOME TAXES

 

The following comprises the components of the income tax provision (benefit) as of July 31:

 

Year Ended July 31,       2012       2011  
Current       —         —    
Deferred     $ (1,799,606 )   $ (140,000 )
Total     $ (1,779,606 )   $ (140,000 )

 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred income taxes are as follows:

 

July 31,     2012       2011  
Deferred tax assets:                
Intangible assets, definite lived   $ 184,262     $ (249,000 )
Property & equipment     97       —    
Deferred revenue     31,953       4,000  
Charitable contributions     6,000       6,000  
Stock options     219,888       206,000  
Officer’s compensation     259,000       —    
Deferred compensation     275,566       236,000  
General business credits     144,000       144,000  
Net operating loss carry-forward     4,381,715       3,367,000  
Valuation allowance     (5,502,481 )     (3,714,000 )
Net deferred tax asset:   $ —      $ —    
Deferred tax liabilities:                
Unrealized gain on investment   $ (8,875 )   $ —    
Valuation allowance     8,875       —    
Net Deferred Tax Liabilities   $ —      $ —    
Total net deferred taxes   $ —      $ —    

 

 

33

 

 

 

 
 

 

 

As of July 31, 2012, the Company has generated regular tax net operating losses of approximately $12,300,000. For federal and state purposes, net operating losses can be carried forward for up to 20 years. The Company’s net operating losses will begin to expire in 2019.

 

The net deferred tax asset valuation allowance is $5,493,606 as of July 31, 2012 compared to $3,714,000 as of July 31, 2011. The valuation allowance is based on management’s assessment that it is more likely than not that the net operating loss will not be realized in the foreseeable future. The Company’s ability to realization tax benefit from the net operating loss is also subject to annual limitation under Internal Revenue Code Section 382. Due to the change in control which occurred as a result of Abeja Ventures, LLC’s investment in the company on June 26, 2012, the Company estimates that the annual Section 382 limitation on utilization of net operating losses will be $500.000.

 

The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate is as follows:

 

Year Ended July 31,     2012       2011  
U.S. Federal statutory income tax rate     (34.0 )%     (34.0 )%
State taxes, net of federal tax benefit     (3.0 )     (3.0 )
Non-deductible equity and other compensation     5.19       (0.1 )
Prior period net operating loss correction     (1.70 )     —    
Valuation allowance     33.51       37.1  
      0 %     0 %

 

NOTE 9 MAJOR CUSTOMERS AND FOREIGN REVENUE

 

For the years ending July 31, 2012 and 2011, revenues were $235,910 and $1,121,166, respectively. Of the total revenues, revenues from one customer were $140,000 (59.3%) in the year ended July 31, 2012 and $842,408 (75.14%) for the year ended July 31, 2011.

 

Foreign Revenues were as follows for the fiscal years ended July 31:

 

Foreign Revenues     2012       2011  
OptiChem Revenues   $ 27,649     $ 23,073  
License Fees     —        —   
Technical Development Fees     —        —   
Consulting Fees     —        —   
         Total   $ 27,649     $ 23,073  

 

34

 

 

 

 

 
 

 

 

NOTE 10 COMMITMENTS

 

Investments and Deferred Compensation Arrangement

 

In January 1996, the Company established a deferred compensation plan for key employees. Contributions to the plan are provided for under the employment agreement with Thomas V. Geimer, which is detailed at the end of this note. For the fiscal year ended July 31, 2012, the Company contributed $75,000 to the plan.

 

The following information is provided related to the trust assets, which consist of cash and equity securities as of July 31, 2012 and 2011. These assets, which based upon the Company's intended use of the investments, have been classified as trading securities. Unrealized holding gains or loss on trading securities are included in other income (expense).

 

      2012       2011  
Cost basis   $ 1,462,472     $ 1,289,950  
Unrealized holding gain (loss)     23,987       14,572  
    Aggregate fair value   $ 1,486,459     $ 1,304,522  

 

Deferred compensation related to the Rabbi Trust was $1,486,459 and $1,304,522 as of July 31, 2012 and 2011, respectively.

 

Operating Lease

 

The Company is a party to a lease for its office and laboratory space that expires on September 30, 2012. Total rent expense including common area charges was approximately $73,965 and $68,330 during the years ended July 31, 2012 and 2011, respectively. Future minimum lease payments, of $3,339 per month plus the pro rata share of taxes, insurance and common facility charges are payable monthly through September 30, 2012. The lease was extended through February 2013 at similar terms. See Note 13 below.

 

Employment Agreement and Consulting Agreement

 

Effective December 1, 2007, we entered into an Employment Agreement with Mr. Geimer. The agreement provided for an annual base salary of $165,000 with annual deferred compensation of $75,000 and was to have expired on December 31, 2012. On June 26, 2012, Thomas V. Geimer resigned as the Company’s Chief Executive Officer, Chief Financial Officer and Secretary. In connection with his resignation, Mr. Geimer entered into an Amendment to Employment Agreement with the Company, as well as a new Consulting Agreement. Pursuant to the Amendment to Employment Agreement, Mr. Geimer and the Company agreed to stagger certain payments due to him such that $650,000 was paid to Mr. Geimer upon the closing of the Investment and $700,000 will be payable to him on July 1, 2013. Any payments due to Mr. Geimer under his Employment Agreement (as amended) but not timely paid by the Company will bear interest at a rate of 18% per annum. In addition, the $75,000 deferred compensation payment for the Company’s fiscal year ending July 31, 2012 was contributed prior to the closing of the Investment. Pursuant to the Consulting Agreement, Mr. Geimer agreed to provide certain transition and other services to the Company. In exchange, for the remainder of 2012, the Company will pay Mr. Geimer an amount equal to $24,000 per month. From January 1, 2013 through December 31, 2013, Mr. Geimer’s aggregate consulting fee will be $96,000 ($8,000 per month).

 

NOTE 11 DEFERRED REVENUE

 

Deferred revenue recognized was $85,345 and $9,797, respectively; for the fiscal years ended July 31, 2012 and 2011. Deferred revenue consists of prepaid royalty fees from Nanostring and SCHOTT. During the year ended July 31, 2012 an additional $100,000 was received from SCHOTT as prepaid royalties of which $3,903 was recognized during the fiscal year ended July 31, 2012 and $10,428 recognized during the fiscal year ended July 31, 2011 and are reflected as OptiChem revenues.

 

35

 

 

 

 
 

 

 

NOTE 12 FAIR VALUE MEASUREMENTS

 

The fair value hierarchy in ASC 820 prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as described in the following list.

 

Level 1 Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. A quoted price in an active market provides the most reliable evidence of fair value.

 

Level 2 Inputs other than quoted prices included within level 1 that are observable for the asset, either directly or indirectly. Level 2 inputs include:

  · Quoted prices for similar assets in active markets
· Quoted prices for identical or similar assets in markets that are not active, prices are not current, or price quotations vary substantially over time, or among markets for which little information is released publicly
· Inputs other than quoted prices that are observable for the asset
· Inputs that are derived principally from or corroborated by observable market data by correlation or other means

 

Level 3 Inputs are unobservable inputs for the asset. Unobservable inputs are used to measure fair value to the extent that observable inputs are not available. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset, including risk.

 

At July 31, 2012 and 2011, investments of $1,486,459 and $1,304,522 were carried at fair value, and were classified within Level 1 of the valuation hierarchy.

 

NOTE 13 Subsequent Events

 

Colorado Lease Amendment

 

On August 3, 2012, the Company entered into an extension of its lease for office and laboratory space in Denver, Colorado. The amended lease extended the term of the lease until February 1, 2013 on similar terms as its current lease.

 

Arizona Lease and Grant Agreement

 

On August 20, 2012, the Company entered into a Lease Agreement (“Lease”) with Pima County, a political subdivision of the State of Arizona (“Landlord”), pursuant to which the Company will lease approximately 15,096 square feet of office space located in Tucson, Arizona for a period of three years (the “Initial Term”), which may be extended by the Company for up to three additional one-year periods (each a “Renewal Term”). The Lease also provides that the Company has the option, with six months prior notice to Landlord, to lease either or both of two additional areas with an aggregate size of approximately 7,920 square feet.

 

Pursuant to the Lease, the Company agreed to: (i) pay rent equal to $9.25 per usable square foot per year (approximately $139,600 per year or approximately $11,600 per month) during the Initial Term and $19.80 per usable square foot per year (approximately $298,900 per year or approximately $24,900 per month) during any Renewal Term; (ii) relocate its corporate offices to the Tucson area and begin operations within 30 days of the date that the tenant improvements are substantially completed (the “Commencement Date”); and (iii) within 18 months of the Commencement Date, employ at least 30 individuals with a median salary of at least $70,000, which median salary must be maintained throughout the term of the Lease. If the Company fails to satisfy the condition described in clause (iii) of the preceding sentence, the rental rate under the Lease will be increased by a percentage that is twice the percentage by which the Company’s annual payroll has fallen short of the specified goal (subject to a cap equal to $19.80 per usable square foot per year). The Lease also provides that Landlord will pay for tenant improvements (up to a cap of $1,400,000) as well as certain repairs, utilities and insurance. When completed, the Company believes this facility will be adequate for its needs for the foreseeable future.

 

36

 

 

 

 

 
 

 

On August 22, 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority will provide certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1,000,000 (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:

· Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).
· Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).
· Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).
· Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4,520,000.

 

For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties.

 

  Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure Controls and Procedures

 

Based on an evaluation under the supervision and with the participation of the Company’s Management, the Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of July 31, 2012 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to the Company’s Management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company’s internal control over financial reporting includes those policies and procedures that:

 

· Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
· Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and
· Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

 

37

 

 

 

 

 
 

 

Management, including the Company’s Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of our internal control over financial reporting as of July 31, 2012. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. Based on that assessment, management concluded that, during the period covered by this report, such internal controls and procedures were effective as of July 31, 2012.

 

This Annual Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s assessment was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission.

 

Changes in Internal Control Over Financial Reporting

 

There was no changes in the Company's internal control over financial reporting during the Company's fiscal quarter ended July 31, 2012 that materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

 

Item 9B. Other Information

 

Not Applicable.

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The information required by this Item is set forth under the heading “Directors, Executive Officers and Corporate Governance” in the Company’s 2012 Proxy Statement to be filed with the U.S. Securities and Exchange Commission (“SEC”) in connection with the solicitation of proxies for the Company’s 2012 Annual Meeting of Shareholders (“2012 Proxy Statement”) and is incorporated herein by reference. Such Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this report relates.

 

Item 11. Executive Compensation.

 

The information required by this Item is set forth under the headings “Executive Compensation” in the Company’s 2012 Proxy Statement and is incorporated herein by reference.

 

38

 

 

 

 

 
 

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 

 

The information required by this Item is set forth under the headings “Security Ownership of Certain Beneficial Owners and Management” in the Company’s 2012 Proxy Statement and is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

The information required by this Item is set forth under the heading “Certain Relationships and Related Transactions, and Director Independence” in the Company’s 2012 Proxy Statement and is incorporated herein by reference. 

 

Item 14. Principal Accountant Fees and Services.

 

The information required by this Item is set forth under the heading “Fees Paid to Auditors” in the Company’s 2012 Proxy Statement and is incorporated herein by reference.

 

 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules

 

( a) Documents filed as part of this report

 

( 1) All financial statements

 

 

    Page
  Report of Independent Registered Public Accounting Firm 21
  Balance Sheets as of July 31, 2012 and 2011 22
  Statements of Operations for the years ended July 31, 2012 and 2011 23
  Statements of Shareholders Equity for the years ended July 31, 2012 and 2011 24
  Statements of Cash Flow for the years ended July 31, 2012 and 2011 25
  Notes to Financial Statements 26

 

 

 

( 2) Financial Statement Schedule s

 

All financial statement schedules have been omitted, since the required information is not applicable or because the information required is included in the financial statements and notes thereto.

 

( b) Exhibits required by Item 601 of Regulation S-K

 

The information required by this Item is set forth on the exhibit index that follows the signature page of this report.

 

 

39

 

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

  ACCELR8 TECHNOLOGY CORPORATION
     
October 26, 2012 By: /s/ Lawrence Mehren
(Date Signed)   Lawrence Mehren, President and Chief Executive Officer

 

Power of Attorney

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lawrence Mehren, as his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

 

Signature   Capacity   Date
         
/s/ Lawrence Mehren   President, Chief Executive Officer and Director   October 26, 2012
Lawrence Mehren        
         
/s/ Steve Reichling   Chief Financial Officer and Chief Accounting Officer   October 26, 2012
Steve Reichling        
         
/s/ John Patience   Chairman of the Board of Directors   October 26, 2012
John Patience        
         
/s/ Thomas V. Geimer   Director   October 26, 2012
Thomas V. Geimer        
         
/s/ Jack Schuler   Director   October 26, 2012
Jack Schuler        
         
/s/ Matthew W. Strobeck   Director   October 26, 2012
Matthew W. Strobeck, Ph.D.        

 

 

 

40

 

 

 

 

 
 

 

 

Exhibit Index

 

Exhibit No. Description Filing Information
   
3.1.1 Articles of Incorporation of Accerl8 Technology Corporation, as amended from time to time Filed herewith 
3.1.2 Amendment to Articles of Incorporation of Accerl8 Technology Corporation Incorporated by reference to Annex B of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on May 17, 2012
3.2 Bylaws of Accelr8 Technology Corporation Filed herewith 
4.1 Warrant No. 1 issued by Accelr8 Technology Corporation to Abeja Ventures, LLC on June 26, 2012 Filed herewith 
4.2 Warrant No. 2 issued by Accelr8 Technology Corporation to Abeja Ventures, LLC on June 26, 2012 Filed herewith 
10.1 Accelr8 Technology Corporation 2004 Omnibus Stock Option Plan* Incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on November 15, 2004
10.2 Amendment to the Accelr8 Technology Corporation 2004 Omnibus Stock Option Plan* Incorporated by reference to Annex C of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on May 17, 2012
10.3 Form of Stock Option Award Agreement* Incorporated by reference to Exhibit 4.4 filed with the Registrant’s Form S-8 Registration Statement (No. 333-182930) on July 30, 2012
10.4 Securities Purchase Agreement between Accelr8 Technology Corporation and Abeja Ventures, LLC, dated as of April 20, 2012 Incorporated by reference to Exhibit 10.1 filed with the Registrant’s Form 10-Q/A for the quarterly period ended April 30, 2012
10.5 Registration Rights Agreement between Accelr8 Technology Corporation and Abeja Ventures, LLC, dated as of June 26, 2012 Filed herewith 
10.6 Employment Agreement between Accelr8 Technology Corporation and Thomas V. Geimer* Filed herewith 
10.7 Amendment to Employment Agreement between Accelr8 Technology Corporation and Thomas V. Geimer* Filed herewith 
10.8 Consulting Agreement between Accelr8 Technology Corporation and Thomas V. Geimer* Filed herewith 
10.9 Offer Letter between Accelr8 Technology Corporation and Lawrence Mehren, dated as of June 24, 2012* Filed herewith 
10.10 CFO Offer Letter, dates as of August 8, 2012 Filed herewith 
10.11 Lease Agreement between Accelr8 Technology Corporation and Pima County, dated as of August 20, 2012 Filed herewith 
10.12 Grant Agreement between Accelr8 Technology Corporation and the Arizona Commerce Authority, dated as of August 22, 2012 Filed herewith 
23 Consent of Independent Registered Public Accounting Firm Filed herewith 
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith

 

 

41

 

 

 

 

 
 

 

 

31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith
32 Certificate of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Filed herewith
101** XBRL Instance Document  
101** XBRL Taxonomy Extension Schema Document  
101** XBRL Taxonomy Calculation Linkbase Document  
101** XBRL Taxonomy Extension Definition Linkbase Document  
101** XBRL Taxonomy Label Linkbase Document  
101** XBRL Taxonomy Presentation Linkbase Document  

 

 

 

42

 

 

 

 

Exhibit 3.1.1



Exhibit 3.2

 

EXHIBIT B

BY-LAWS

ACCELR8 TECHNOLOGY CORPORATION

(formerly known as HYDRO-SEEK. INC.)

ARTICLE I

Offices

1. Principal Office . The principal office of the Corporation shall be selected by the Board of Directors from time to time and may be within or without the State of Colorado.

2. Other Offices . The Corporation may have such other offices, within or without the State of Colorado, as the Board of Directors may, from time to time, determine.

3. Registered Office. The registered office of the Corporation required by the Colorado Corporation Act to be maintained in Colorado may be, but need not be, identical with the principal office if in Colorado, and the address of the registered office may be changed from time to time by the Board of Directors.

ARTICLE II

Stock and the Transfer Thereof

1. Stock Certificates . The shares of the Corporation's capital stock shall be represented by consecutively numbered certificates signed by the President or a Vice President and the Secretary or Assistant Secretary of the Corporation, and sealed with the seal of the Corporation, or a facsimile thereof. If certificates are signed by a transfer agent, acting in behalf of the Corporation, and a registrar, the signatures of the officers of the Corporation may be facsimile. In case any officer who has signed shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the date of its issue.

Each certificate representing shares shall state upon the

(a) that the Corporation is organized under the laws of the State of Colorado;

(b) the name of the person to whom issued;

(c) the number and class of shares which such certificate represents; and

(d) the par value, if any, of the shares represented by such certificate.

Each certificate also shall set forth restrictions upon transfer, if any, or a reference thereto,as shall be adopted by the Board of Directors or by the shareholders, or as may be contained in this Article II.

No certificate shall be issued for any share until such share is fully paid.

2. Consideration for Shares . Shares shall be issued for such consideration expressed in dollars as shall be fixed from time to time by the Board of Directors. Treasury shares may be disposed of by the Corporation for such consideration expressed in dollars as may be fixed from time to time by the Board of Directors. No shares shall be issued for less than the par value thereof. The consideration for the issuance of shares may be paid, in whole or in part, in money, in other property, tangible or intangible, or in labor or services actually performed for the Corporation. Neither promissory notes nor future services shall constitute payment or part payment for shares of the Corporation.

 

 

 
 

3. Lost Certificate . The Board of Directors may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, and the Board of Directors when authorizing such issue of a new certificate or certificates may in its discretion, and as a condition precedent to the issuance thereof, require the owner of such lost or destroyed certificate or certificates or his legal representative to advertise the same in such manner as it shall require, and/or furnish to the Corporation a bond in such sum as it may direct, as indemnity against any claim that may be made against the Corporation. Except as hereinabove in this section provided, no new certificate or certificates evidencing shares of stock shall be issued unless and until the old certificate or certificates, in lieu of which the new certificate or certificates are issued, shall be surrendered for cancellation.

4. Registered Holder as Owner . The Corporation shall be entitled to treat the holder of record of any share of stock as the owner thereof entitled to receive dividends and to vote such shares, and accordingly shall not be bound to recognize any equitable.or any other claim to or interest in such shares on the part of any other person, whether or not it shall have express or other notice thereof, except as may be required by a valid proxy or by the laws of the State of Colorado.

5. Return Certificate s. All certificates for shares changed or returned to the Corporation for transfer shall be marked by the Secretary "Cancelled", with the date of cancellation, and the transaction shall be immediately recorded in the certificate book opposite the memorandum of their issue. The returned certificate may be inserted in the certificate book.

6. Transfer of Shares . Upon surrender to the Corporation or to a transfer agent of the Corporation of a certificate of stock endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, and such documentary stamps as may be required by law, it shall be the duty of the Corporation to issue a new certificate. Each such transfer of stock shall be entered on the stock book of the corporation.

7. Transfer Agent . The Board of Directors shall have power to appoint one or more transfer agents and registrars for the transfer and registration of certificates of stock of any class, and may require that stock certificates shall be countersigned and registered by one or more of such transfer agents and registrars. Any powers or duties with respect to the transfer and registration of certificates may be delegated to the transfer agent and registrar.

ARTICLE III

Shareholders and Meetings Thereof

1. Annual Meeting . The annual meeting of the shareholders for the election of directors and the transaction of such other business as may properly come before the meeting shall be held on the third Tuesday of September of each year, but if such day be a holiday, then on the first business day thereafter which is not a holiday; provided, however, that the Board of Directors may, by resolution, postpone such meeting for a period of time not in excess of sixty (60) days. The place of the annual meeting shall be the principal office of the Corporation or such other place within or without the State of Colorado as the Board of Directors may determine.

 

Hydro-Seek, Inc. -2- By-laws

 

 

 
 

 

2. Special Meetings . Special meetings of the shareholders may be called by the President, a Vice President, the Board of Directors, or the holders of not less than one-tenth of all the shares entitled to vote at the meeting. Special meetings shall be held at the principal office of the Corporation, unless the Board of Directors determines otherwise.

3. Notice of Meetings . Written or printed notice stating the place, day, and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered not less than ten (10) nor more than fifty (50) days before the date of the meeting, either personally or by mail, by or at the direction of the President, the Secretary, or the officer or persons calling the meeting, to each shareholder of record entitled to vote at such meeting; except that (a) if the authorized capital stock is to be increased, or (b) in the case of a special meeting to be held at a place other than the principal office of the Corporation, then at least thirty (30) days' notice shall be given. If applicable statutes require a certain minimum notice for any particular business to be transacted, then at least that minimum notice shall be given. The notice shall be given to each shareholder of record in the manner above provided. No business other than that specified in the notice of special meeting shall be transacted at any such special meeting. The notice of special meeting may be waived by submitting a signed waiver or by attendance at the meeting.

4. Closing of Transfer Books and Fixing Record Date . For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, or entitled to receive payment of any dividend, or in order to make a determination of shareholders for any other proper purpose, the Board of Directors of the Corporation may provide that the stock transfer books shall be closed for a stated period not to exceed in any case fifty (50) days immediately preceding such meeting. In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than fifty (50) days, and in case of a meeting of share holders, not less than ten (10) days prior to the date on which the particular action, requiring such determination of shareholders, is to be taken. If the stock transfer books are not closed and no record date is fixed for the determination of shareholders entitled to notice of or to vote at a meeting of shareholders, or Shareholders entitled to receive payment of a dividend, the date on which notice of the meeting is mailed or the date on which the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of the shareholders. When a determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this Paragraph, such determination shall apply to any adjournment thereof.

5. Voting List . The officer or agent having charge of the stock transfer books for shares of the Corporation shall make, at least ten (10) days before each meeting of shareholders, a complete list of the shareholders entitled to vote at such meeting or any adjournment thereof, arranged in alphabetical order, with the address of and the number of shares held by each, which list, for a period of ten (10) days prior to such meeting, shall be kept on file at the principal office of the Corporation, and shall be subject to inspection by any shareholder at any time during usual business hours. Such list shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any shareholder during the whole time of the meeting. The original stock transfer books shall be prima facie evidence as to who are the shareholders entitled to examine such list or transfer books or to vote at any meeting of shareholders.

6. Quorum . A quorum at .any meeting of the shareholders shall consist of 33% of the shares entitled to vote represented in person or by proxy. If a quorum is present, the affirmative vote of the majority of the shares represented at the meeting entitled to vote on the subject matter shall be the act of the shareholders. If less than 33% of the shares entitled to vote be represented at a meeting, a majority of the shares so represented may adjourn the meeting from time to time to the same place without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at a meeting as originally notified. The shareholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.

 

Hydro-Seek, Inc. -3- By-laws

 

 

 
 

 

7. Proxie s. At all meetings of shareholders, a shareholder may vote by proxy, executed in writing by the shareholder or by his duly authorized attorney in fact. Such proxy shall be filed with the Secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven months from the date of its execution, unless otherwise provided in the proxy.

8. Voting of Shares . Each outstanding share shall be entitled to one vote and each fractional share shall be entitled to a corresponding fractional vote on each matter submitted to vote at a meeting of shareholders.

9. Voting of Shares by Certain Holders . Neither treasury shares, nor shares of its own stock held by the Corporation in a fiduciary capacity, nor shares held by another corporation if the majority of the shares entitled to vote for the election of directors of such other corporation is held by the Corporation, shall be voted at any meeting or counted in determining the total number of outstanding shares at any given time.

Shares standing in the name of another corporation, domestic or foreign, may be voted by such officer, agent, or proxy as the by-laws of such corporation may prescribe, or, in the absence of such provision, as the board of directors of such corporation may determine.

Shares held by an administrator, executor, personal representative, guardian, or conservator may be voted by him, either in person or by proxy, without a transfer of such shares into his name. Shares standing in the name of a trustee may be voted by him, either in person or by proxy, but no trustee shall be entitled to vote shares held by him without a transfer of such shares into his name.

Shares standing in the name of a receiver may be voted by such receiver, and shares held by or under th~ control of a receiver may be voted by such receiver without the transfer thereof into his name if authority so to do be contained in an appropriate order of the court by which such receiver was appointed.

A shareholder whose shares are pledged shall be entitled to vote such shares until the shares have been transferred into the name of the pledgee, and thereafter the pledgee shall. be entitled to vote the shares so transferred.

10. Chairman . The Chairman of the Board of Directors of the Corporation, if there is one, or in his absence, the President, shall act as chairman at all meetings of shareholders.

11. Oral vote . voting at any shareholders meeting shall be oral; provided, however, that voting shall be by written ballot if oral; provided, however, that voting shall be by written ballot if such demand is made by any shareholder present in person or by proxy and entitled to vote.

12. Informal Action by Shareholders. Any action required to be taken at a meeting of the shareholders, or any other action which may be taken at a meeting of the shareholders, may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by all of the shareholders entitled to vote with respect to the subject matter thereof. Such consent shall have the same force and effect as a unanimous vote of the shareholders, and may be stated as such in any articles or document filed with the Secretary of State of Colorado under the Colorado Corporation Act.

Hydro-Seek, Inc. -4- By-laws

 

 
 

 

13. Annual Report . The President of the Corporation shall prepare an annual report which will set forth a statement of affairs of the Corporation as of the end of its last fiscal year, including a balance sheet and an income statement, and present it at the Annual Meeting of Shareholders.

ARTICLE IV

Directors. Powers and Meetings

1. General Powers . The business and affairs of the Corporation shall be managed by its Board of Directors, except as otherwise provided in the Colorado Corporation Act or the Articles of Incorporation.

2. Number. Tenure and Qualifications . The number of directors of the Corporation shall be not less than three (3) nor more than seven (7). Directors shall be elected at each Annual Meeting of Shareholders. Each director shall hold office until the next Annual Meeting of Shareholders and thereafter until his successor shall have been elected and qualified. Directors need not be residents of Colorado or shareholders of the Corporation. Directors shall be removable in the manner provided by the statutes of Colorado.

3. Vacancies . Any director may resign at any time by giving written notice to the President or to the Secretary of the Corporation. Such resignation shall take effect at the time specified therein; and unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. Any vacancy occurring in the Board of Directors may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum. A director elected to fill a vacancy shall be elected for the unexpired term of his predecessor in office. Any directorship to be filled by reason of an increase in the number of directors shall be filled by the affirmative vote of a majority of the directors then in office or by all election at an annual meeting or at a special meeting of shareholders called for that purpose, and a director so chosen shall hold office for the term specified in Paragraph 2 of this Article.

4. Removal of Directors . Any director may be removed either with or without cause, at any time, by a vote of the shareholders holding a majority of the shares then issued and outstanding and who are entitled to vote for the election of directors, at any special meeting called for that purpose. In case any vacancy so created shall not be filled by the shareholders at such meeting, such vacancy may be filled by the Board of Directors as provided hereinafter.

5. Regular Meetings . A regular meeting of the Board of Directors shall be held without other notice than this By-Law immediately after and at the same place as the Annual Meeting of Shareholders. The Board of Directors may provide by resolution the time and place, either within or without the State of Colorado, for the holding of additional regular meetings without other notice than such resolution.

6. Special Meetings . Special meetings of the Board of Directors may be called by or at the request of the President, the Chairman of the Board, or any two directors. The person or persons authorized to call special meetings of the Board of Directors may fix any place, either within or without the State of Colorado, as the place for holding any special meeting of the Board of Directors called by them.

7. Notice. Notice of any special meeting shall be given at least seven (7) days previous thereto by written notice delivered personally or mailed to each director at his business address, or by notice given at least two (2) days prior to the meeting by telegraph or in person. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage thereon prepaid. If notice be given by telegram, such notice shall be deemed to bed elivered when the telegram is delivered to the telegraph company. Any director may waive notice of any meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.

 

Hydro-Seek, Inc. -5- By-laws

 

 
 

8. Ouorum. A majority of the number of directors fixed by these By-Laws shall constitute a quorum for the transaction of business. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

9. Compensation . By resolution of the Board of Directors, any director may be paid anyone or more of the following: his expenses, if any, of attendance at a meeting; a fixed sum for attendance at each meeting; or a stated salary as director. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.

10. Presumption of Assent . A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent to such action with the person acting as the Secretary of the meeting before the adjournment thereof, or shall forward such dissent by registered or certified mail to the Secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

11. Committees . The Board of Directors, by resolution adopted by a majority of the number of directors, may designate two (2) or more directors to constitute an Executive Committee which may exercise all of the authority of the Board of Directors in the management of the Corporation, during the period of time between meetings of the Board of Directors. The Board of Directors, by resolution adopted by a majority of the number of directors, may also designate two (2) or more directors to constitute a Compensation Committee to administer the Incentive Stock Option Plan and the Non-Qualified Stock Option Plan of the Corporation and to perform such other duties as may be delegated to it by the Board of Directors from time to time or an Audit Committee to perform such duties as may be delegated to it by the Board of Directors from time to time. However, the designation of any such committee and the delegation thereto of authority shall not operate to relieve the Board of Directors, or any member thereof, of any responsibility imposed upon it or him by law.

12. Action by Directors Without Meeting . Any action required to be taken at a meeting of the directors of the Corporation or any action which may be taken at such a meeting, may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by all of the directors entitled to vote with respect to the subject matter thereof. A consent shall be sufficient for this Paragraph if it is executed in counterparts, in which event all of such counterparts, when taken together, shall constitute one and the same consent.

13. Chairman of the Board . The Chairman of the Board, if such officer shall be chosen by the Board of Directors, shall preside at all meetings of the Board of Directors and meetings of shareholders at which he is present. He shall, subject to the direction of the Board of Directors, have general supervision over the affairs of the Corporation, and shall, from time to time, consult and advise with the President in the direction and management of the Corporation's business and affairs, and shall also do and perform such other duties as may, from time to time, be assigned to him by the Board of Directors.

14. Bank Accounts. etc . Anything herein to the contrary notwithstanding, the Board of Directors may, except as may otherwise be required by law, authorize any officer or officers, agent or agents, in the name of and on behalf of the Corporation, to sign checks, drafts, or other orders for the payment of money or notes or other evidences of indebtedness, to endorse for deposit, deposit to the credit of the Corporation at any bank or trust company or banking institution in which the Corporation may maintain an account or to cash checks, notes, drafts, or other bankable securities or instruments, and such authority may be general or confirmed to specific instances, as the Board of Directors may elect.

Hydro-Seek, Inc. -6- By-laws

 

 
 

  

ARTICLE V

Officers and Agents

1 . G eneral . The officers of the Corporation shall be a President, one or more Vice Presidents, a Secretary and a Treasurer. The Board of Directors may appoint such other officers, assistant officers, as they may consider necessary, who shall be chosen in such manner and hold their offices for such terms and have such authority and duties as from time to time may be determined by the Board of Directors. The salaries of all the officers of the Corporation shall be fixed by the Board of Directors. One person may hold any two offices, except that no person may simultaneously hold the offices of President and Secretary. In all cases where the duties of any officer, agent or employee are not prescribed by the By-Laws or by the Board of Directors, such officer, agent or employee shall follow the orders and instructions of the President.

2. Election and Term of Office . The officers of the Corporation shall be elected by the Board of Directors annually at the first meeting of the board held after each Annual Meeting of the Shareholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as conveniently may be. Each officer shall hold office until the first of the following to occur: Until his successor shall have been duly elected and shall have qualified; or until his death; or until he shall resign; or until he shall have been removed in the manner hereinafter provided.

3. Removal . Any officer or agent may be removed by the Board of Directors or by the Executive Committee whenever in its judgment the best interest of the Corporation will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of an officer or agent shall not in itself create contract rights.

4. Vacancies . A vacancy in any office, however occurring, may be filled by the Board of Directors for the unexpired portion of the term.

5. President . The President shall, subject to the direction and supervision of the Board of Directors, be the chief executive officer of the Corporation and shall have general and active control of its affairs and business and general supervision of its officers, agents and employees. He shall, unless otherwise directed by the Board of Directors, attend in person or by substitute appointed by him, shall execute in behalf of the Corporation written instruments appointing a proxy or proxies to represent the Corporation, at all meetings of the stockholders of any other corporation in which the Corporation shall hold any stock. He may, on behalf of the Corporation, in person or by substitute or by proxy, execute written waivers of notice and consents with respect to any such meetings. At all such meetings and otherwise, the President, in person or by substitute or proxy as aforesaid, may vote the stock so held by the Corporation and may execute written consent and other instruments with respect to such stock and may exercise any and all rights and powers incident to the ownership of said stock, subject however to the instructions, if any, of the Board of Directors. The President shall have custody of the Treasurer's bond, if any.

6. Vice Presidents . The Vice Presidents shall assist the President and shall perform such duties as may be assigned to them by the President or by the Board of Directors. In the absence of the President, the Vice President designated by the Board of Directors or (if there be no such designation) ,designated in writing by the President shall have the powers and perform the duties of the President. If no such designation shall be made all Vice Presidents may exercise such powers and perform such duties.

Hydro-Seek, Inc. -7- By-laws

 

 
 

  

7. Secretary . The Secretary shall: (a) Keep the minutes of the proceedings of the shareholders, executive committee and the Board of Directors; (b) See that all notices are duly given in accordance with the provisions of these By-Laws or as required by law; (c) Be custodian of the corporate records and of the seal of the Corporation and affix the seal to all documents when authorized by the Board of Directors; (d) Keep at its registered office or principal place of business within or outside Colorado a record containing the names and addresses of all shareholders and the number and class of shares held by each, unless such a record shall be kept at the office of the Corporation's transfer agent or registrar; (e) Sign with the President, or a Vice President, certificates for shares of the Corporation, the issuance of which shall have been authorized by resolution of the Board of Directors; (f) Have general charge of the stock transfer books of the Corporation, unless the Corporation has a transfer agent; and (g) In general, perform all duties incident to the office of Secretary and such other duties as from time to time may be assigned to him by the President or the Board of Directors. Assistant secretaries, if any, shall have the same duties and powers, subject to supervision by the Secretary.

8. Treasurer . The Treasurer shall be the principal financial officer of the Corporation and shall have the care and custody of all funds, securities, evidence of indebtedness and other personal property of the Corporation and shall deposit the same in accordance with the instructions of the Board of Directors. He shall receive and give receipts and acquittances for moneys paid in on account of the Corporation, and shall payout of the funds on hand all bills, payrolls and other just debts of the Corporation of whatever nature upon maturity. He shall perform all other duties incident to the office of the Treasurer and, upon request of the Board, shall make such reports to it as may be required at any time. He shall, if required by the Board, give the Corporation a bond in such sums, and with such sureties as shall be satisfactory to the Board, conditioned upon the faithful performance of his duties and for the restoration to the Corporation of all books, papers, vouchers, money and other property of whatever kind in his possession or under his control belonging to the Corporation. He shall have such other powers and perform such other duties as may be from time to time prescribed by the Board of Directors or the:President. The assistant treasurers, if any, shall have the same powers and duties, subject to the supervision of the Treasurer. '

The Treasurer shall also be the principal accounting officer of the Corporation. He shall prescribe and maintain the methods and systems of accounting to be followed, keep complete books and records of account, prepare and file all local, state and federal tax returns, prescribe and maintain an adequate system of internal audit, and prepare and furnish to the President and the Board of Directors statements of account showing the financial position of the Corporation and the results of its operations.

 

ARTICLE VI

Indemnification of Officers and Directors

Each Director and Officer of this Corporation, and each person who shall serve at its request as a Director or Officer of another corporation in which this Corporation owns shares of capital stock or of which it is a creditor, whether or not then in office, and his personal representatives, shall be indemnified by the Corporation against all costs and expenses actually and necessarily incurred by him in connection with the defense of any action, suit or proceeding in which he may be involved or to which he may be made a party by reason of his being or having been such Director or Officer, except in relation to matters as to which he shall be finally adjudged in such action, suit or proceeding to be liable for negligence of misconduct in the performance of duty.

 

Hydro-Seek, Inc. -8- By-laws

 

 
 

  

Such costs and expenses shall include amounts reasonably paid in settlement for the purpose of curtailing the costs of litigation, but only if the Corporation is advised in writing by its counsel that in his opinion the person indemnified did not commit such negligence or misconduct. The foregoing right of indemnification shall not be exclusive of other rights to which he may be entitled as a matter of law or by agreement

ARTICLE VII

Miscellaneous

1. Waivers of Notice . Whenever notice is required by law, by the Articles of Incorporation or by these By-Laws, a waiver thereof in writing signed by the director, shareholder or other person entitled to said notice, whether before, or after the time stated therein, or his appearance at such meeting in person or (in the case of a shareholders' meeting) by proxy, shall be equivalent to such notice.

2. Effective Date of Notice and Waiver . Whenever notice is required to be given to any shareholder or director under the provisions of the laws of the State of Colorado or under the provisions of the Articles of Incorporation or these By-Laws, such notice shall be deemed to be delivered when deposited in the United States mail, postage.prepaid, addressed to the person entitled to receipt thereof at his address as it appears from the records of the Corporation. Whenever such notice is required, a waiver thereof in writing signed at any time by the person entitled to such notice shall be equivalent to the giving of such notice. A waiver of such notice of any special meeting of shareholders shall state the purpose for which the meeting was called or the business to be transacted thereat

3. Declaration of Dividends . The Board of Directors at any regular or special meeting may declare dividends payable out of the surplus of the Corporation, whenever in the exercise of its discretion it may deem such declaration advisable and such is permitted by law. Such dividends may be paid in cash, property, or shares of that Corporation.

4. Benefit Program .. Directors shall have the power to install and authorize any pension, profit sharing, stock option, insurance, welfare, educational, bonus, health and accident or other benefit program which the Board deems to be in the interest of the Corporation, at the expense of the Corporation, and to amend or revoke any plan so adopted.

5. Seal . The corporate seal of the Corporation shall be circular in form and shall contain the name of the Corporation and the words " Seal , Colorado".  

6. Fiscal Year . The Board of Directors shall have the power to fix, and from time to time change, the fiscal year of the Corporation. Unless otherwise fixed by the Board, the fiscal year shall be from June 1st to May 31 st of each year.

7. Amendments . The Board of Directors shall have power to make, amend and repeal the By-Laws of the Corporation at any regular meeting of the Board or at any special meeting called for that purpose.

Hydro-Seek, Inc. -9- By-laws

 

 

Exhibit 4.2

 

 

NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE "SECURITIES"), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS.

ACCELR8 TECHNOLOGY CORPORATION

WARRANT

Warrant No. Abeja-1 Date of Issuance: June 26, 20 12

Accelr8 Technology Corporation, a Colorado corporation (the " Company "), hereby certifies that, for value received, Abeja Ventures, LLC, a Delaware limited liability company, or its registered assign (the " Holder "), is entitled to purchase from the Company 7,000,000 shares (as adjusted from time to time as provided in Section I I) of common stock, no par value per share, of the Company (the " Common Stock ") (each such share, a "Warrant Share" and all such shares, the "Warrant Shares"), at an exercise price determined pursuant to Section 3 (the " Exercise Price "), at any time and from time to time from and after the date hereof through and including the date that is five (5) years following the date of issuance set forth above (the " Expiration Date "), and subject to the following terms and conditions:

1. Purchase Agreement. This Warrant is one of two Warrants (collectively, the " Warrants ") issued by the Company in connection with that certain Securities Purchase Agreement, entered into on April 20, 2012 (the " Purchase Agreement "), by and among the Company and Holder, and is subject to, and the Company and the Holder shall be bound by, all the applicable terms, conditions and provisions of the Purchase Agreement.

2. Definitions . In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement.

 

3. Exercise Price . This Warrant may be exercised for a price per Warrant Share equal to $1.03, subject to adjustment from time to time pursuant to Section 11 .

 

4. Registration of Warrant . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "Warrant Register"), in the name of the record Holder hereof from time to time. The Company may deem and treat the Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

5. Registration of Transfers . Subject to the Holder's appropriate compliance with the restrictive legend on this Warrant, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment substantially in the form attached hereto as Attachment B duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a "New Warrant"), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

 

 

 

 
 

6. Exercise and Duration of Warrants . This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the date hereof to and including the Expiration Date. At 6:30 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The Company may not call or redeem all or any portion of this Warrant without the prior written consent of the Holder.

7. Delivery of Warrant Shares .

(a) To effect conversions hereunder, the Holder shall not be required to physically surrender this Warrant unless the aggregate number of Warrant Shares represented by this Warrant is being exercised. Upon delivery of an Exercise Notice substantially in the form attached hereto as Attachment A (an " Exercise Notice ") to the Company at its address for notice determined as set forth herein, and upon payment of the applicable Exercise Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder, the Company shall promptly (but in no event later than five (5) trading days after the Date of Exercise (as defined below)) issue and deliver, or cause its transfer agent to issue and deliver, to the Holder a certificate for the Warrant Shares issuable upon such exercise registered in the name of the Holder or its designee. A " Date of Exercise " means the date on which the Holder shall have delivered to the Company: (i) an Exercise Notice, appropriately completed and duly signed, and (ii) payment of the Exercise Price (by certified or official bank check, intra-bank account transfer or wire transfer) for the number of Warrant Shares so indicated by the Holder to be purchased.

 

(b) If by the fifth trading day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner required pursuant to Section 7(a) , the Holder will have the right to rescind such exercise.

 

(c) The Company's obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity, including a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

8. Charges, Taxes and Expenses. Issuance and delivery of certificated or uncertificated shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee, or other incidental tax or expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

-2-

 

 

 

 
 

 

9. Replacement of Warrant . If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a new warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a new warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver this mutilated Warrant to the Company as a condition precedent to the Company's obligation to issue the new warrant.

 

10. Reservation of Warrant Shares . The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from Liens or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 11). The Company covenants and warrants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable.

 

11. Certain Adjustments. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this Section 11 .

 

(a) Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of any Warrants), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company; then in each such case (A) the Exercise Price will be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which equals the number of shares of Common Stock outstanding immediately prior to such event (excluding treasury shares, if any), and the denominator of which equals the number of shares of Common Stock outstanding immediately after such event, and (B) the number of Warrant Shares issuable hereunder shall be concurrently adjusted by multiplying such number by the reciprocal of such fraction. Such adjustments will take effect (i) if a record date shall have been fixed for determining the stockholders or security holders, as applicable, of the Company entitled to receive such dividend, distribution or issuance by reclassification, as the case may be, immediately after such record date, (ii) otherwise, immediately after the effective date of such dividend, distribution, subdivision, combination, or issuance by reclassification, as the case may be.

 

(b) Fundamental Transaction . If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or a series of related transactions, (A) effects any merger or consolidation of the Company with or into another Person, (B) effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets, (C) effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share

 

 

 

-3-

 

 

 

 

 
 

 

exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (except for issuances by reclassification contemplated by Section Il(a)(iv)) or (D) consummates a stock or share purchase agreement or other business combination (including a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than fifty percent (50%) of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or group making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person or group of Persons) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property (each transaction or series of transactions referred to in clause (i) or (ii) above, a "Fundamental Transaction"); then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, (1) the number of shares of common stock of the successor or acquiring corporation or, if it is the surviving corporation, of the Company, and (2) any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock fqr which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount and components of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Board shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration (substituting the most appropriate market-based measure for the Trading Market in determining the daily VWAP from time to time for each component of the Alternate Consideration or, if no market-based measure is reasonably available for any such component, fixing the daily VWAP of such component at the value determined by such apportionment, but subject to further adjustment as provided in this Section 11 ). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant of like tenor to this Warrant but adjusted to be consistent with the foregoing provisions and evidencing the Holder's right to exercise such warrant for the appropriate number of shares of capital stock and Alternate Consideration, if any, in exchange for this Warrant. The Company shall ensure that the terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 11(b) and ensuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction or series of related transactions analogous to a Fundamental Transaction. " VWAP " means, for any date, the price determined by the first of the following clauses that applies: (A) if the Common Stock is then listed or quoted on a trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the principal trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (B) if prices for the Common Stock are then reported in the "Pink Sheets" published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported during trading hours, or (C) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Company's Board of Directors and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.

-4-

 

 

 

 
 

 

(c) Payment of Exercise Price . The Holder may pay the Exercise Price by certified or official bank check, by intra-bank account transfer or by wire transfer of same-day funds.

12. No Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay the Holder an amount of cash equal to the product of such fraction multiplied by the closing price of one share of Common Stock as reported on the principal trading market for the Common Stock on the Date of Exercise.

 

13. Notices . Any and all notices or other communications or deliveries hereunder (including any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number pursuant to this Section 13 prior to 6:30 p.m. (New York City time) on a trading day, (ii) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified pursuant to this Section 13 on a day that is not a trading day or later than 6:30 p.m. (New York City time) on any trading day, (iii) the trading day following the date of mailing, if sent by nationally recognized overnight courier service to the street address specified pursuant to this Section 13, or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be as follows:

   

(a) if to the Company, to
   
  Accelr8 Technology Corporation
   

7000 North Broadway, Building 3-307

  Denver, Colorado 80221
  Attn: Chief Executive Officer
  Facsimile: (303) 863-1218
   
  with a copy to (which shall not constitute notice to the Company):
   
  Schlueter & Associates, P.C.
  1050 17th Street, Suite 1750
  Attn: Henry Schlueter, Esq. and David Stefanski, Esq.
  Facsimile: (303) 296-8880
   

(b) if to the Holder, to the address, facsimile number or email or street address appearing on the Warrant Register (which shall initially be the facsimile number and email and street address set forth for the initial Holder in the Purchase Agreement);

or to such other address, facsimile number or email address as the Company or the Holder may provide to the other in accordance with this Section 13 .

14. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder's last address as shown on the Warrant Register.

 

-5-

 

 

 

 
 

15. Miscellaneous .

(a) Assignment. Subject to the restrictions on transfer described herein, the rights and obligations of the Company and the Holder shall be binding upon, and inure to the benefit of, the successors, assigns, heirs, administrators and transferees of the parties. The Company shall not have the right directly or indirectly to assign or transfer this Warrant without the prior written consent of the Holder, which may be withheld in the Holder's sole discretion, or as part of a Fundamental Transaction.

 

(b) No Third Party Beneficiaries . Nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.

 

(c) Amendments; Waiver. This Warrant may be amended only in writing signed by the Company and the Holder, and any amendment so effected shall amend each Warrant issued pursuant to the Purchase Agreement and be binding upon each holder of such Warrants (provided, however, that any such amendment that adversely affects any holder or class of holders of such Warrants in a manner that does not apply uniformly to all holders of such Warrants, as applicable, shall require the written consent of such adversely affected holders or class). Any provision of this Warrant may be waived, but only if in writing by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Warrant shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(d) Governing Law . This Warrant shall be governed by and construed in accordance with the laws of the State of Colorado, without regard to principles of conflict of laws.

 

(e) Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law in any respect, such provision shall be excluded from this Warrant and the balance of this Warrant shall be construed and interpreted as if such provision were so excluded and shall be enforceable in accordance with its remaining terms.

 

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

-6-

 

 
 

 

IN WTINESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as ofthe date fIrst indicated above.  

  ACCELR8 TECHNOLOGY CORPORATION
  a Colorado corporation
   
  By: /s/ Thomas Geimer
  Name: Thomas Geimer
  Its: Chief Executive Officer

 

 

(Signature Page - Warrant No. Abeja-1)

 

 

 

 
 

 

ATTACHMENT A

EXERCISE NOTICE

To Accelr8 Technology Corporation:

The undersigned hereby irrevocably elects to purchase shares (the " Shares ") of common stock, no par value per share (" Common Stock "), of Accelr8 Technology Corporation, a Colorado corporation, pursuant to Warrant No. __, originally issued on , 2012 (the " Warrant "). The undersigned elects to utilize the following manner of exercise:

Shares:      
  _____________   Full Exercise of Warrants
  _____________   Partial Exercise of Warrants (in the amount of __________ Shares)
       
Exercise Price: $_____________  
       
Manner of Exercise:  
      Certified of Official Bank Check
      Intra-Bank Account Transfer
      Wire Transfer

 

[Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of the [undersigned]/[the undersigned's nominee as is specified below].]

 

Date:  
   
Full Name of Holder*:  
   
Signature of Holder or Authorized Representative:  
   
Name and Title of Authorized Representative†:  
   
Additional Signature of Holder (if jointly held):  
   
Social Security or Tax Identification Number:  
   
Address of Holder:  
   
   
   
Full Name of Nominee of Holder†:  
   
Address of Nominee of Holder†:  
   

 

* Must conform in all respects to name of holder as specified on the face of the Warrant.

† If applicable. 

 

 

 
 

ATTACHMENT B

FORM OF ASSIGNMENT

[To be completed and signed only upon transfer of Warrant]

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers untothe right represented by the attached Warrant to purchase _____ shares of Common Stock of Accelr8 Technology Corporation, a Colorado corporation (the "Company"), to which the Warrant relates and appoints as attorney to transfer said right on the books of the Company with full power of substitution in the premises.

Date:  
   
Full Name of Holder*:  
   
Signature of Holder or Authorized Representative:  
   
Name and Title of Authorized Representative†:  
   
Additional Signature of Holder (if jointly held):  
   
Social Security or Tax Identification Number:  
   
Address of Holder:  
   
   
   
Full Name of Transferee:  
   
Address of Transferee:  
   

 

In the presence of:

______________________________________________

 

* Must conform in all respects to name of holder as specified on the face of the Warrant.

† If applicable. 

 

Exhibit 4.2

 

 

NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE "SECURITIES"), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS.

ACCELR8 TECHNOLOGY CORPORATION

WARRANT

Warrant No. Abeja-2 Date of Issuance: June 26, 20 12

Accelr8 Technology Corporation, a Colorado corporation (the " Company "), hereby certifies that, for value received, Abeja Ventures, LLC, a Delaware limited liability company, or its registered assign (the " Holder "), is entitled to purchase from the Company 7,000,000 shares (as adjusted from time to time as provided in Section I I) of common stock, no par value per share, of the Company (the " Common Stock ") (each such share, a "Warrant Share" and all such shares, the "Warrant Shares"), at an exercise price determined pursuant to Section 3 (the " Exercise Price "), at any time and from time to time from and after the date hereof through and including the date that is five (5) years following the date of issuance set forth above (the " Expiration Date "), and subject to the following terms and conditions:

1. Purchase Agreement. This Warrant is one of two Warrants (collectively, the " Warrants ") issued by the Company in connection with that certain Securities Purchase Agreement, entered into on April 20, 2012 (the " Purchase Agreement "), by and among the Company and Holder, and is subject to, and the Company and the Holder shall be bound by, all the applicable terms, conditions and provisions of the Purchase Agreement.

2. Definitions . In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement.

 

3. Exercise Price . This Warrant may be exercised for a price per Warrant Share equal to $2.00, subject to adjustment from time to time pursuant to Section 11 .

 

4. Registration of Warrant . The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "Warrant Register"), in the name of the record Holder hereof from time to time. The Company may deem and treat the Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

5. Registration of Transfers . Subject to the Holder's appropriate compliance with the restrictive legend on this Warrant, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment substantially in the form attached hereto as Attachment B duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a "New Warrant"), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

 

 

 

 
 

6. Exercise and Duration of Warrants . This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the date hereof to and including the Expiration Date. At 6:30 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The Company may not call or redeem all or any portion of this Warrant without the prior written consent of the Holder.

7. Delivery of Warrant Shares .

(a) To effect conversions hereunder, the Holder shall not be required to physically surrender this Warrant unless the aggregate number of Warrant Shares represented by this Warrant is being exercised. Upon delivery of an Exercise Notice substantially in the form attached hereto as Attachment A (an " Exercise Notice ") to the Company at its address for notice determined as set forth herein, and upon payment of the applicable Exercise Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder, the Company shall promptly (but in no event later than five (5) trading days after the Date of Exercise (as defined below)) issue and deliver, or cause its transfer agent to issue and deliver, to the Holder a certificate for the Warrant Shares issuable upon such exercise registered in the name of the Holder or its designee. A " Date of Exercise " means the date on which the Holder shall have delivered to the Company: (i) an Exercise Notice, appropriately completed and duly signed, and (ii) payment of the Exercise Price (by certified or official bank check, intra-bank account transfer or wire transfer) for the number of Warrant Shares so indicated by the Holder to be purchased.

 

(b) If by the fifth trading day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner required pursuant to Section 7(a) , the Holder will have the right to rescind such exercise.

 

(c) The Company's obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity, including a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

8. Charges, Taxes and Expenses. Issuance and delivery of certificated or uncertificated shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee, or other incidental tax or expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

-2-

 

 

 

 
 

 

9. Replacement of Warrant . If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a new warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a new warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver this mutilated Warrant to the Company as a condition precedent to the Company's obligation to issue the new warrant.

 

10. Reservation of Warrant Shares . The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from Liens or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 11). The Company covenants and warrants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable.

 

11. Certain Adjustments. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this Section 11 .

 

(a) Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of any Warrants), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company; then in each such case (A) the Exercise Price will be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which equals the number of shares of Common Stock outstanding immediately prior to such event (excluding treasury shares, if any), and the denominator of which equals the number of shares of Common Stock outstanding immediately after such event, and (B) the number of Warrant Shares issuable hereunder shall be concurrently adjusted by multiplying such number by the reciprocal of such fraction. Such adjustments will take effect (i) if a record date shall have been fixed for determining the stockholders or security holders, as applicable, of the Company entitled to receive such dividend, distribution or issuance by reclassification, as the case may be, immediately after such record date, (ii) otherwise, immediately after the effective date of such dividend, distribution, subdivision, combination, or issuance by reclassification, as the case may be.

 

(b) Fundamental Transaction . If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or a series of related transactions, (A) effects any merger or consolidation of the Company with or into another Person, (B) effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets, (C) effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share

 

 

 

-3-

 

 

 

 

 
 

 

exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (except for issuances by reclassification contemplated by Section Il(a)(iv)) or (D) consummates a stock or share purchase agreement or other business combination (including a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than fifty percent (50%) of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or group making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person or group of Persons) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property (each transaction or series of transactions referred to in clause (i) or (ii) above, a "Fundamental Transaction"); then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, (1) the number of shares of common stock of the successor or acquiring corporation or, if it is the surviving corporation, of the Company, and (2) any additional consideration (the "Alternate Consideration") receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock fqr which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount and components of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Board shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration (substituting the most appropriate market-based measure for the Trading Market in determining the daily VWAP from time to time for each component of the Alternate Consideration or, if no market-based measure is reasonably available for any such component, fixing the daily VWAP of such component at the value determined by such apportionment, but subject to further adjustment as provided in this Section 11 ). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant of like tenor to this Warrant but adjusted to be consistent with the foregoing provisions and evidencing the Holder's right to exercise such warrant for the appropriate number of shares of capital stock and Alternate Consideration, if any, in exchange for this Warrant. The Company shall ensure that the terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 11(b) and ensuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction or series of related transactions analogous to a Fundamental Transaction. " VWAP " means, for any date, the price determined by the first of the following clauses that applies: (A) if the Common Stock is then listed or quoted on a trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the principal trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (B) if prices for the Common Stock are then reported in the "Pink Sheets" published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported during trading hours, or (C) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Company's Board of Directors and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.

-4-

 

 

 

 
 

 

(c) Payment of Exercise Price . The Holder may pay the Exercise Price by certified or official bank check, by intra-bank account transfer or by wire transfer of same-day funds.

12. No Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay the Holder an amount of cash equal to the product of such fraction multiplied by the closing price of one share of Common Stock as reported on the principal trading market for the Common Stock on the Date of Exercise.

 

13. Notices . Any and all notices or other communications or deliveries hereunder (including any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number pursuant to this Section 13 prior to 6:30 p.m. (New York City time) on a trading day, (ii) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified pursuant to this Section 13 on a day that is not a trading day or later than 6:30 p.m. (New York City time) on any trading day, (iii) the trading day following the date of mailing, if sent by nationally recognized overnight courier service to the street address specified pursuant to this Section 13, or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be as follows:

   

(a) if to the Company, to
   
  Accelr8 Technology Corporation
   

7000 North Broadway, Building 3-307

  Denver, Colorado 80221
  Attn: Chief Executive Officer
  Facsimile: (303) 863-1218
   
  with a copy to (which shall not constitute notice to the Company):
   
  Schlueter & Associates, P.C.
  1050 17th Street, Suite 1750
  Attn: Henry Schlueter, Esq. and David Stefanski, Esq.
  Facsimile: (303) 296-8880
   

(b) if to the Holder, to the address, facsimile number or email or street address appearing on the Warrant Register (which shall initially be the facsimile number and email and street address set forth for the initial Holder in the Purchase Agreement);

or to such other address, facsimile number or email address as the Company or the Holder may provide to the other in accordance with this Section 13 .

14. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder's last address as shown on the Warrant Register.

 

-5-

 

 

 

 
 

15. Miscellaneous .

(a) Assignment. Subject to the restrictions on transfer described herein, the rights and obligations of the Company and the Holder shall be binding upon, and inure to the benefit of, the successors, assigns, heirs, administrators and transferees of the parties. The Company shall not have the right directly or indirectly to assign or transfer this Warrant without the prior written consent of the Holder, which may be withheld in the Holder's sole discretion, or as part of a Fundamental Transaction.

 

(b) No Third Party Beneficiaries . Nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.

 

(c) Amendments; Waiver. This Warrant may be amended only in writing signed by the Company and the Holder, and any amendment so effected shall amend each Warrant issued pursuant to the Purchase Agreement and be binding upon each holder of such Warrants (provided, however, that any such amendment that adversely affects any holder or class of holders of such Warrants in a manner that does not apply uniformly to all holders of such Warrants, as applicable, shall require the written consent of such adversely affected holders or class). Any provision of this Warrant may be waived, but only if in writing by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Warrant shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(d) Governing Law . This Warrant shall be governed by and construed in accordance with the laws of the State of Colorado, without regard to principles of conflict of laws.

 

(e) Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law in any respect, such provision shall be excluded from this Warrant and the balance of this Warrant shall be construed and interpreted as if such provision were so excluded and shall be enforceable in accordance with its remaining terms.

 

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

-6-

 

 
 

 

IN WTINESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as ofthe date fIrst indicated above.  

  ACCELR8 TECHNOLOGY CORPORATION
  a Colorado corporation
   
  By: /s/ Thomas Geimer
  Name: Thomas Geimer
  Its” Chief Executive Officer

 

 

(Signature Page - Warrant No. Abeja-2)

 

 

 

 
 

 

ATTACHMENT A

EXERCISE NOTICE

To Accelr8 Technology Corporation:

The undersigned hereby irrevocably elects to purchase shares (the " Shares ") of common stock, no par value per share (" Common Stock "), of Accelr8 Technology Corporation, a Colorado corporation, pursuant to Warrant No. __, originally issued on , 2012 (the " Warrant "). The undersigned elects to utilize the following manner of exercise:

Shares:      
  _____________   Full Exercise of Warrants
  _____________   Partial Exercise of Warrants (in the amount of __________ Shares)
       
Exercise Price: $_____________  
       
Manner of Exercise:  
      Certified of Official Bank Check
      Intra-Bank Account Transfer
      Wire Transfer

 

[Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of the [undersigned]/[the undersigned's nominee as is specified below].]

 

Date:  
   
Full Name of Holder*:  
   
Signature of Holder or Authorized Representative:  
   
Name and Title of Authorized Representative†:  
   
Additional Signature of Holder (if jointly held):  
   
Social Security or Tax Identification Number:  
   
Address of Holder:  
   
   
   
Full Name of Nominee of Holder†:  
   
Address of Nominee of Holder†:  
   

 

* Must conform in all respects to name of holder as specified on the face of the Warrant.

† If applicable. 

 

 

 
 

ATTACHMENT B

FORM OF ASSIGNMENT

[To be completed and signed only upon transfer of Warrant]

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers untothe right represented by the attached Warrant to purchase _____ shares of Common Stock of Accelr8 Technology Corporation, a Colorado corporation (the "Company"), to which the Warrant relates and appoints as attorney to transfer said right on the books of the Company with full power of substitution in the premises.

Date:  
   
Full Name of Holder*:  
   
Signature of Holder or Authorized Representative:  
   
Name and Title of Authorized Representative†:  
   
Additional Signature of Holder (if jointly held):  
   
Social Security or Tax Identification Number:  
   
Address of Holder:  
   
   
   
Full Name of Transferee:  
   
Address of Transferee:  
   

 

In the presence of:

______________________________________________

 

* Must conform in all respects to name of holder as specified on the face of the Warrant.

† If applicable. 

Exhibit 10.5 

 

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made and entered into as of June 26, 2012, by and among Accelr8 Technology Corporation, a Colorado corporation (the "Company"), and Abeja Ventures, LLC, a Delaware limited liability company (the "Purchaser").

 

RECITALS

 

WHEREAS, the Company and the Purchaser are parties to a Securities Purchase Agreement, dated as of April 20, 2012 (the " Purchase Agreement '), pursuant to which the Purchaser is purchasing 14,000,000 shares of common stock, no par value per share (" Common Stock "), of the Company; and

 

WHEREAS, in connection with the consummation of the transactions contemplated by the Purchase Agreement, and pursuant to the terms of the Purchase Agreement, the parties desire to enter into this Agreement in order to grant certain registration rights to the Purchaser as set forth below.

 

AGREEMENT

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser, intending to be legally bound, hereby agree as follows:

 

1. Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings assigned to such terms in the Purchase Agreement. For all purposes of this Agreement, the following terms shall have the meanings set forth below:

 

" Commission " means the United States Securities and Exchange Commission.

 

" Effective Date " means the date that the Registration Statement is first declared effective by the Commission.

 

" Effectiveness Date " means the earlier of (a) the 90th day following the Request Date, and (b) the fifth Trading Day following the date on which the Company is notified by the Commission that the Registration Statement will not be reviewed or is no longer subject to further review and comments.

 

" Effectiveness Period " means the period from the Effective Date until the Termination Date.

 

" Filing Date " means the 30th day following the Request Date; provided, however, that this date may be tolled for as long as any Holder of Registrable Securities whose Registrable Securities are to be included in the registration statement has failed to provide the Company with reasonably and customarily requested information.

 

" Holder " means a holder from time to time of Registrable Securities.

 

" Necessary Holders " means, at any time of determination, any combination of Holders then holding a majority of the outstanding Registrable Securities that were originally purchased pursuant to the Purchase Agreement.

 

" Original Purchaser " means with respect to the Securities held by any Holder, the Purchaser (which may be the Holder) which purchased the Shares held by such Holder from the Company on the Closing Date.

 

 

-1-

 

 

 

 
 

 

 

" Prospectus " means the prospectus included in a Registration Statement (including a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

 

" Registrable Securities " means (i) the Securities, (ii) all shares of Common Stock held or beneficially owned by Thomas V. Geimer as of the date hereof (including shares of Common Stock underlying the Accelr8 Technology Corporation Deferred Compensation Plan Trust Agreement dated May 15, 1996), (iii) all shares of Common Stock (including shares of Common Stock issuable pursuant to warrants) that were not sold pursuant to the Purchase Agreement but that have attendant registration rights as of the date of the Purchase Agreement and for which disclosure has been publicly made in the Company's filings with the Commission, and (iii) any shares of Common Stock or other securities issued upon any stock split or similar event in respect of, or as a dividend or other distribution upon, any of the foregoing Securities, until such time as such securities (1) have been sold to the public pursuant to a registration statement or other means such that they are no longer "restricted securities" under the Securities Act, or (2) have become Rule 415 Cutback Securities.

 

" Registration Statement " means the registration statement required to be filed hereunder in accordance with Section 2(a), including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus (including pre-and post-effective amendments), all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.

 

" Request Date " means the date one or more Holders holding in the aggregate not less than 25% of all Registrable Securities requests the Company in writing to register any of its Registrable Securities pursuant to this Agreement; provided that such Holders may make a demand for such registration under this Agreement more than three times.

 

" Rule 415 " means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

" Rule 424 " means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

" Special Counsel " means such attorney or law firm as shall be designated by one or more Holders holding no less than a majority of the outstanding Registrable Securities. If no Special Counsel is designated, then the obligations of the Company associated with Special Counsel shall not apply.

 

" Termination Date " means the earlier to occur of (I) the date which is five years after the date that the Registration Statement is declared effective by the Commission, and (ii) the date when all Registrable Securities which are (or pursuant to Section 2(a) may be) covered by the Registration Statement have been sold or may be sold by all Holders without volume or manner of sale limitations pursuant to Rule 144, as determined by the counsel to the Company; provided that if requested by the Company's transfer agent, such determination shall be made, at the Company's expense, pursuant to a written opinion letter to such effect, addressed and acceptable to such transfer agent.

 

-2-

 

 

 

 

 
 

 

2. Registration .

 

(a) Filing of Registration Statement . On or prior to the Filing Date, the Company shall prepare and file with the Commission a registration statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register the Registrable Securities on Form S-3 for resale, in which case such registration shall be on another appropriate form in accordance herewith) and shall contain (except if otherwise agreed by the Holders) the "Plan of Distribution" attached hereto as Appendix A. The Company shall cause the Registration Statement to be declared effective under the Securities Act as soon as possible but, in any event, not later than the Effectiveness Date, and shall use its best efforts to keep the Registration Statement continuously effective under the Securities Act until the Termination Date. The Company shall not be obligated to enter into any underwriting agreement for the sale of any of the Registrable Securities.

 

(b) Cutback Securities . Notwithstanding the provisions of this Section 2 , if (i) after the Effective Date, the Registration Statement ceases to be effective and available to the Holders as to all of the Registrable Securities (whether upon the delivery of a notice pursuant to Section 6(d) or otherwise) at any time prior to the Termination Date without becoming available to the Holders as to all of the Registrable Securities within 20 Trading Days pursuant to the delivery of an Advice, or (ii) at the time of effectiveness of the Registration Statement, such Registration Statement is not available to the Holders as to all of the Registrable Securities; in either case, caused by the assertion by the Commission that the number of shares proposed to be registered under the Registration Statement constitutes an offering by or on behalf of the Company not at a fixed price, the Company shall use its best efforts to register the maximum number of shares permissible by the Commission to retain the status of the offering as a secondary offering under Rule 415. In reducing the number of shares to be registered under the Registration Statement, the Company shall omit Registrable Securities (such omitted Registrable Securities, the " Rule 415 Cutback Securitie s") pro rata per Holder based on the number of Shares held by the respective Holders. Except as provided in the sentence next preceding, the Company shall not be liable to any Holder for any damages in respect of its failure to register Rule 415 Cutback Securities for resale under the Securities Act or any state securities or "blue sky" laws.

 

(c) Registration Statement Questionnaire . In connection with a registration request made by a Holder pursuant to Section 2(a) and from time to time thereafter, the Company may require a selling Holder to furnish to the Company a Registration Statement Questionnaire in form and substance reasonably acceptable to the Company based on information required by the Commission. Each Holder shall furnish the information required in a Registration Statement Questionnaire within five Trading Days of the Company's request.

 

(d) Piggy-Back Registrations . If at any time prior to the Termination Date an effective Registration Statement is not available for the resale of all Registrable Securities, and the Company determines to prepare and file with the Commission a registration statement under the Securities Act relating to an offering for its own account or the account of others of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to each Holder written notice of such determination and, if within 15 days after the date of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement all or any part of the Registrable Securities such Holder requests to be registered, subject to customary underwriter cutbacks applicable to all holders of registration rights.

 

-3-

 

 

 

 

 
 

 

3. Registration Procedures . In connection with the Company's registration obligations hereunder, the Company shall:

 

(a) Holder Review . Not less than two Trading Days prior to the filing of the Registration Statement or any related Prospectus or any amendment or supplement thereto (other than a supplement which attaches a previously filed SEC Report), the Company shall furnish to the Holders and the Special Counsel (if any has been designated) copies of all such documents proposed to be filed, which documents will be subject to the review of such Holders and such Special Counsel. The Company shall not file the Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities or the Special Counsel shall reasonably object in good faith.

 

(b) Filing; Compliance . (i) Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable, and in any event within 15 days, to any comments received from the Commission with respect to the Registration Statement or any amendment thereto and, as promptly as reasonably practicable provide the Holders true and complete copies of all correspondence from and to the Commission relating to the Registration Statement (except, with respect to any Holder who does not waive this parenthetical, to the extent such correspondence would disclose material non-public information to a Holder); and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by the Registration Statement during the applicable period in accordance with the intended methods of disposition by the Holders thereof set forth in the Registration Statement as so amended or in such Prospectus as so supplemented. Notwithstanding the foregoing, the Company shall not be in breach of its obligations under this Section in the event the delay or inability in filing with the Commission is due to the failure of any Holder of Registrable Securities whose Registrable Securities are to be included in a filing to respond or provide information that is requested in a reasonable and customary fashion.

 

(c) Notices . Notify the Holders of Registrable Securities to be sold and the Special Counsel as promptly as reasonably possible (and, in the case of clause (i)(A) next below, not less than three Trading Days prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than two Trading Days following the day (i)(A) when a Prospectus or any Prospectus supplement (other than a supplement which attaches a previously filed SEC Report) or post-effective amendment to the Registration Statement is proposed to be filed; (B) when the Commission notifies the Company whether there will be a "review" of such Registration Statement and whenever the Commission comments in writing on such Registration Statement (the Company shall provide true and complete copies thereof and all written responses thereto to each of the Holders, except, with respect to any Holder who does not waive this parenthetical, to the extent such correspondence would disclose material nonpublic information); and (C) with respect to the Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any request by the Commission or any other Governmental Authority during the period of effectiveness of the Registration Statement for amendments or supplements to the Registration Statement or Prospectus or for additional information; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence of any event or passage of time that makes the financial statements included in the Registration Statement ineligible for inclusion therein or any statement made in the Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to the Registration Statement, Prospectus or other documents so that, in the case of the Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

-4-

 

 

 

 
 

 

 

(d) Stop Orders . Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal as promptly as reasonably practicable of, (i) any order suspending the effectiveness of the Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction.

 

(e) Copy of Registration Statement . Furnish to each Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission.

 

(f) Copies of Prospectus . Promptly deliver to each Holder, without charge, as many copies of the Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request. The Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 1(c) to discontinue disposition of Registrable Securities pursuant to the Registration Statement.

 

(g) Blue Sky Laws . Prior to any public offering of Registrable Securities, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of all jurisdictions within the United States as any Holder reasonably requests in writing, to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by the Registration Statement; provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.

 

(h) Share Certificates . Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may request in writing a reasonable period of time prior to any sale of Registrable Securities.

 

-5-

 

 

 

 

 
 

 

(i) Updates . Upon the occurrence of any event contemplated by Section 1(c)(v ), as promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(j) Commission Rules . Comply in all material respects with all applicable rules and regulations of the Commission.

 

4. Registration Expenses . All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to the Registration Statement. The fees and expenses referred to in the foregoing sentence shall include (i) all registration and filing fees (including fees and expenses (A) with respect to filings required to be made with any Trading Market, and (B) in compliance with applicable state securities or Blue Sky laws), (ii) printing expenses (including expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested by the Holders of a majority of the Registrable Securities included in the applicable Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) reasonable fees and disbursements of counsel for the Company and lip to $5,000 of the fees and disbursements of Special Counsel (but only if a Special Counsel is designated), (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required under this Agreement or the Purchase Agreement. In no event shall the Company be responsible for any broker or similar commissions, or, except to the extent provided for in the preceding sentence, any legal fees or other costs of the Holders.

 

5. Indemnification .

 

(a) Indemnification by the Company . The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, agents, employees, and investment advisors of each Holder, each Person who controls (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) any Holder, and the officers, directors, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (1) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder's proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved Appendix A for this purpose) or (2) in the case of an occurrence of an event of the type specified in Section l(c)(ii)-(v) , the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated by Section 6(d) . The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is aware in connection with the transactions contemplated by this Agreement.

 

-6-

 

 

 

 

 
 

 

(b) Indemnification by Holders . Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its officers, directors, agents and employees, each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) the Company, and the officers, directors, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon (x) such Holder's failure to comply with the prospectus delivery requirements of the Securities Act, or (y) any untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising solely out of or based solely upon any omission of a material fact required to be stated therein or necessary to make the statements therein not misleading to the extent, but only to the extent, that (I) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder's proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration Statement (it being understood that each Holder has approved Appendix A for this purpose), such Prospectus or such form of Prospectus or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the type specified in Section l(c)(ii)-(v) , the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of the Advice contemplated by Section 6(d) ; provided , however , that in no event shall the liability of any Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c) Conduct of Indemnification Proceedings .

 

(i) Notice . If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an " Indemnified Party "), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the " Indemnifying Party ") in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with the defense thereof; provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.

 

(ii) Separate Counsel . An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties, unless (I) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of one separate counsel shall be at the expense of the Indemnifying Party).

 

-7-

 

 

 

 

 
 

 

(iii) Settlement . The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

 

(iv) Fees and Expenses . All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 5) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder).

 

(k) Contribution .

 

(i) Relative Fault . If a claim for indemnification under Section 5(a) or Section 5(b) is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact required to be stated or necessary to make the statements not misleading, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 5(c) , any reasonable attorneys' or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section 5 were available to such party in accordance with its terms. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 1(k) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph.

 

(ii) Limitations . Notwithstanding the provisions of this Section (k) . no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, except in the case of fraud by such Holder.

 

-8-

 

 

 

 

 
 

 

(iii) Non-Exclusive . The indemnity and contribution agreements contained in this Section (k) are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.

 

6. Miscellaneous .

 

(a) Remedies . In the event of a breach by the Company or by any Holder of any of its respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. Notwithstanding the foregoing, the Holders shall have no right to take any action to restrain, enjoin or otherwise delay any registration statement filed by or proposed to be filed by the Company as a result of any controversy that may arise with respect to the interpretation or implementation of this Agreement.

 

(b) No Piggyback on Registrations . The Company represents and warrants to, and agrees with, the Holders that (i) neither the Company nor any of its security holders may include securities of the Company in the Registration Statement, other than the Registrable Securities, and the Company shall not after the date hereof enter into any agreement providing any such right to any of its security holders without the written consent of the Necessary Holders, and (ii) except as disclosed in or attached to the Company's filings with the Commission, the Company has not previously entered into any agreement granting any registration rights with respect to any of its securities to any Person which have not been fully satisfied.

 

(c) Compliance . Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

(d) Discontinued Disposition . Each Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section l (c) , such Holder will forthwith discontinue disposition of such Registrable Securities under the Registration Statement until such Holder's receipt of the copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing (the " Advice ") by the Company that the use of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company may provide appropriate stop orders to enforce the provisions of this Section 6(d) .

 

(e) Regulation M . Each Holder agrees not to take any action with respect to any distribution deemed to be made pursuant to any Registration Statement which would constitute a violation of Regulation M under the Exchange Act or any other applicable rule, regulation or law.

 

-9-

 

 

 

 

 
 

 

(f) Amendments and Waivers . No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and Necessary Holders (provided, however, that any such amendment that adversely affects any Holder or class of Holders in a manner that does not apply uniformly to all Holders, Shares, or Registrable Securities, as applicable, shall require the written consent of such adversely affected Holders or class) or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought; provided, however, that a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of certain Holders or Registrable Securities and that does not directly or indirectly affect the rights of other Holders or Registrable Securities must be given by all Holders or all Holders of such Registrable Securities, as the case may be, to which such waiver or consent relates; and, provided, further, that the provisions of the proviso next preceding may be amended, modified, or supplemented only with the consent of all Holders. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(g) Notices . Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via email at the email address specified pursuant to this Section 6(g) prior to 6:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via email at the email address specified pursuant to this Section 6(g) on a day that is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service for overnight delivery to the street address specified pursuant to this Section 6(g) , or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

 

If to the Company: Accelr8 Technology Corporation
  7000 North Broadway, Building 3-307
  Denver, Colorado 80221
  Facsimile: (303) 863-1218
   
with a copy to (which copy shall not constitute notice to the Company):
   
  Schlueter & Associates, P.C.
  1050 17th Street, Suite 1750
  Denver, Colorado 80265
  Attn: Henry Schlueter, Esq. and David Stefanski, Esq.
  Facsimile: (303) 296-8880
   
If to a Holder: To the address of such Holder as it appears in the stock transfer books of the Company;
   

 

 

or such other facsimile number or email or street address as may be designated in writing hereafter, in the same manner, by such Person.

 

(h) Successors and Assigns . This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign its rights or obligations hereunder except (I) with the prior written consent of each Holder, (2) to its successors. Each Holder may assign their respective rights hereunder in the manner and to the Persons permitted under the Purchase Agreement.

 

-10-

 

 

 

 

 
 

 

(i) Execution and Counterparts . This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile or electronic transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic signature page were an original thereof.

 

(j) Governing Law . All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Arizona, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates, employees or agents) may be commenced, and to the extent permitted by applicable law shall be commenced exclusively, in the state and federal courts sitting in Maricopa County, Arizona. Each party hereto hereby irrevocably submits to the jurisdiction of the Maricopa County, Arizona courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such Maricopa County, Arizona court, or that such Proceeding has been commenced in an improper or inconvenient forum. To the extent permitted by applicable law, each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such patty at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any party shall commence a Proceeding to enforce any provisions of this Agreement, then the prevailing party in such Proceeding shall be reimbursed by the other party for its attorney's fees and other costs and expenses actually incurred with the investigation, preparation and prosecution of such Proceeding.

 

(k) Cumulative Remedies . The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

 

(l) Severability . If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(m) Construction . The rules of construction set forth in Section 1.2 of the Purchase Agreement shall apply to this Agreement.

 

 

-11-

 

 

 

 

 
 

 

(n) End of Effectiveness Period . At the end of the Effectiveness Period the Holders shall discontinue sales of Shares pursuant to such Registration Statement upon receipt of notice from the Company of its intention to remove from registration the shares covered by such Registration Statement which remain unsold.

 

(o) Independent Nature of Holders' Obligations and Rights . The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders constitute a "group" or are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Holder shall be entitled to protect and enforce its rights, including the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE FOR COMPANY FOLLOWS]

 

 

-12-

 

 

 

 

 
 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Registration Rights Agreement to be duly executed by its authorized signatory as of the date first indicated above.

 

 

Accelr8 Technology Corporation, a Colorado corporation

   
  By: /s/ Thomas V. Geimer
  Thomas V. Geimer
  Chief Executive Officer

 

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE FOR HOLDER FOLLOWS]

 

 

 

 

 

 

 

 

 
 

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Registration Rights Agreement to be duly executed by its authorized signatory as of the date first indicated above.

 

  Abeja Ventures, LLC, a Delaware limited liability company
   
  By: /s/ Lawrence Mehren
  Lawrence Mehren
  Manager

 

 

 

 

 

 

 

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[END OF SIGNATURE PAGES]

 

 

 

 

 

 
 

 

 

APPENDIX A

 

Plan of Distribution

 

The selling stockholder may, from time to time, sell any or all of its shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholder may use anyone or more of the following methods when selling shares:

 

$ ordinary brokerage transactions and transactions In which the broker-dealer solicits purchasers;

 

$ block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

$ purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

$ exchange distribution in accordance with the rules of the applicable exchange;

 

$ privately negotiated transactions;

 

$ short sales;

 

$ through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

$ broker-dealers may agree with the selling stockholder to sell a specified number of such shares at a stipulated price per share;

 

$ a combination of any such methods of sale; and

 

$ any other method permitted pursuant to applicable law.

 

The selling stockholder may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

 

The selling stockholder may also engage in short sales against the box, puts and calls and other transactions in our securities or derivatives of our securities and may sell or deliver shares in connection with these trades.

 

Broker-dealers engaged by the selling stockholder may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholder (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholder does not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by the selling stockholder. The selling stockholder may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities Act.

 

 

 

 

 

 

 
 

 

In connection with the sale of our common stock or interests therein, the selling stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholder may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The selling stockholder may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling stockholder to include the pledgee, transferee or other successors in interest as selling stockholder under this prospectus.

 

The selling stockholder also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling stockholder to include the pledgee, transferee or other successors in interest as selling stockholder under this prospectus.

 

The selling stockholder and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

 

We are required to pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

The selling stockholder has advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by the selling stockholder. If we are notified by the selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus. If the selling stockholder uses this prospectus for any sale of the shares of common stock, it will be subject to the prospectus delivery requirements of the Securities Act.

 

The anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholder.

 

Exhibit 10.6  

 

ACCELR8 TECHNOLOGY CORPORATION

 

EMPLOYMENT AGREEMENT

WITH THOMAS V. GEIMER

 

This Employment Agreement is made and entered into effective the 1st day of January 2008, by and between Accelr8 Technology Corporation, a Colorado corporation (the “Company”), and Thomas V. Geimer, an individual (“Executive”).

 

RECITALS

 

A. The Company desires to be assured of the association and services of Executive for the Company.

 

B. Executive is willing and desires to be employed by the Company, and the Company is willing to employ Executive, upon the terms, covenants and conditions hereinafter set forth.

 

AGREEMENT

 

NOW, THEREFORE , in consideration of the mutual terms, covenants and conditions hereinafter set forth, the parties hereto agree as follows:

 

1. Employment. The Company hereby employs Executive as its Chairman of the Board of Directors, Chief Executive Officer, Chief Financial Officer, and Secretary.

 

2. Term. The term of this Agreement shall be for a period of five (5) years effective as of January 1, 2008, and ending on December 31, 2012 (the "Initial Term"), unless terminated earlier pursuant to Section 7 below; provided, however, that Executive's obligations in Sections 6 and 8 below shall continue in effect after such termination. This Agreement shall be automatically renewed for successive one year periods (the "Renewal Term") unless, at least 90 days prior to the expiration of the Initial Term or any Renewal Term, either party gives written notice to the other party specifically electing to terminate this Agreement at the end of the Initial Term or any such Renewal Term.

 

3. Compensation; Reimbursement.

 

3.1 Base Salary. For all services rendered by Executive under this Agreement, the Company shall pay Executive a base salary of One Hundred Sixty Five Thousand Dollars ($165,000) per year (the "Base Salary"). The Base Salary shall be payable in equal, consecutive monthly installments. Payment of the Base Salary shall be subject to the customary withholding tax and other employment taxes as required with respect to compensation paid by a corporation to an employee. It is expressly understood and agreed that the Base Salary may be increased upon the approval of the Company's Compensation Committee (if such a committee exists) or a subcommittee of the Board of Directors consisting only of members of the Board who are not employees of the Company (if a Compensation Committee does not exist).

 

 

 

 
 

 

 

3.2 Deferred Compensation. In addition to Executive’s Base Salary provided for in Section 3.1, the Company shall contribute Seventy Five Thousand Dollars ($75,000) per year to the Company's deferred compensation plan for Executive (“Deferred Compensation”). It is expressly understood and agreed that the Deferred Compensation may be increased upon the approval of the Company's Compensation Committee (if such a committee exists) or a subcommittee of the Board of Directors consisting only of members of the Board who are not employees of the Company (if a Compensation Committee does not exist).

 

3.3 Deferred Salary. The Company's Compensation Committee (if such a committee exists) or a subcommittee of the Board of Directors consisting only of members of the Board who are not employees of the Company (if a Compensation Committee does not exist) may, upon 30 days written notice to the Executive, defer for up to six months up to 50% of the Executive's Base Salary and up to 50% of the Executive's Deferred Compensation (collectively the "Deferred Salary"), if it determines, in its sole and absolute discretion that the Company has insufficient cash assets and cash flow to continue to pay the full amount of the Base Salary and Deferred Compensation. The Deferred Salary shall be immediately due and payable in full, along with interest at a rate of 10% per annum on the Deferred Salary on the earlier of (i) the end of the Initial Term or any such Renewal Term of the Agreement, unless terminated earlier pursuant to Section 7 below, or (ii) at such time as the Company's Compensation Committee (if such a committee exists) or a subcommittee of the Board of Directors consisting only of members of the Board who are not employees of the Company (if a Compensation Committee does not exist) determine, in its sole and absolute discretion that the Company has sufficient cash assets and cash flow to pay the Deferred Salary.

 

3.4 Bonus. In addition to the Base Salary and the Deferred Compensation, the Company shall pay Executive such Bonus or Bonuses as the Company's Compensation Committee (if such a committee exists) or a subcommittee of the Board of Directors consisting only of members of the Board who are not employees of the Company (if a Compensation Committee does not exist) shall determine in their sole discretion.

 

3.5 Long-term Incentive Compensation. On December 11, 2007, the date this Agreement was approved by the Compensation Committee of the Company, Executive was granted 100,000 options to acquire shares of the Company’s $0.001 par value common stock at a price of $3.60 per share pursuant to the Company’s 2004 Omnibus Stock Option Plan (the “Stock Options”). The Stock Options shall expire at 5:00 p.m. on December 11, 2017. The Company and Executive shall enter into a separate stock option agreement to evidence the stock option grant, attached hereto as Exhibit A.

 

3.6 Key Man Life Insurance. In addition to the Base Salary, the Deferred Compensation, and any Bonuses, the Company shall carry key man life insurance in the amount of five million dollars ($5,000,000) on Executive’s life (the “Key Man Life Insurance”). Pursuant to a resolution passed by the Compensation Committee effective November 30, 2007, Executive shall designate a beneficiary who shall be entitled to one-half of the proceeds of the Key Man Life Insurance.

 

-2-

 

 

 

 

 
 

 

3.7 Additional Benefits. In addition to the Base Salary, Deferred Compensation, any Deferred Salary, Bonuses and the Key Man Life Insurance, Executive shall be entitled to all other benefits of employment provided to the employees of the Company.

 

3.8 Reimbursement. Executive shall be reimbursed for all reasonable “out-of-pocket” business expenses for business travel and business entertainment incurred in connection with the performance of his duties under this Agreement (1) so long as such expenses constitute business deductions from taxable income for the Company and are excludable from taxable income to Executive under the governing laws and regulations of the Internal Revenue Code (provided, however, that Executive shall be entitled to full reimbursement in any case where the Internal Revenue Service may, under Section 274(n) of the Internal Revenue Code, disallow to the Company some percentage of meals and entertainment expenses); and (2) to the extent such expenses do not exceed the amounts allocable for such expenses in budgets that are approved from time to time by the Company. The reimbursement of Executive's business expenses shall be upon monthly presentation to and approval by the Company of valid receipts and other appropriate documentation for such expenses.

 

4. Scope of Duties.

 

4.1 Assignment of Duties. Executive shall have such duties as may be assigned to him from time to time by the Company's Board of Directors commensurate with his experience and responsibilities in the positions for which he is employed pursuant to Section 1 above. Such duties shall be exercised subject to the control and supervision of the Board of Directors of the Company.

 

4.2 General Specification of Duties. Executive's duties shall include, but not be limited to those duties that are generally associated with the positions of Chairman of the Board of Directors, Chief Executive Officer, Chief Financial Officer and Secretary of a company similarly situated to the Company, and as such duties and responsibilities are more particularly described in the Company’s Bylaws.

 

The foregoing specifications are not intended as a complete itemization of the duties which Executive shall perform and undertake on behalf of the Company in satisfaction of his employment obligations under this Agreement.

 

4.3 Executive's Devotion of Time. Executive hereby agrees to devote his full time abilities and energy to the faithful performance of the duties assigned to him and to the promotion and forwarding of the business affairs of the Company, and not to divert any business opportunities from the Company to himself or to any other person or business entity.

 

4.4 Conflicting Activities.

 

(a) Executive may, during the Initial Term or any Renewal Term of this Agreement, be engaged in other business activities without the prior consent of the Board of Directors of the Company; provided, however, that Executive may not compete directly with the Company. Further, nothing in this Agreement shall be construed as preventing Executive from investing his personal assets in passive investments in business entities which are not in competition with the Company or its affiliates, or from pursuing business opportunities as permitted by Section 4.4(b).

 

-3-

 

 

 

 
 

 

 

(b) Executive hereby agrees to promote and develop all business opportunities that come to his attention relating to current or anticipated future business of the Company, in a manner consistent with the best interests of the Company and with his duties under this Agreement. Should Executive discover a business opportunity that does not relate to the current or anticipated future business of the Company, he shall first offer such opportunity to the Company. Should the Board of Directors of the Company not exercise its right to pursue this business opportunity within a reasonable period of time, not to exceed sixty (60) days, then Executive may develop the business opportunity for himself; provided, however, that such development may in no way conflict or interfere with the duties owed by Executive to the Company under this Agreement. Further, Executive may develop such business opportunities only on his own time, and may not use any service, personnel, equipment, supplies, facility or trade secrets of the Company in their development. As used herein, the term "business opportunity" shall not include business opportunities involving investment in publicly traded stocks, bonds or other securities, or other investments of a personal nature.

 

5. Change of Control. If any time during the Initial Term or any Renewal Term of this Agreement there is a change of control of the Company, as defined below, and Executive's employment is terminated by the Company under Section 7.1(a), (b), (d) or (e) within the greater of one (1) year following the change of control or the remaining term of this Agreement (the “Change of Control Date”), the Company shall pay to Executive (a) the balance of all amounts due from the Change of Control Date until the end of the Initial Term or such Renewal Term, including Deferred Compensation and any Deferred Salary due under this Agreement plus (b) an amount equal to five times the sum of (i) his annual Base Salary as in effect on the date of termination plus (ii) the amount of $75,000 in recognition of Deferred Compensation payments made on behalf of Executive, and (c) any other amounts due to Executive under any other provision of this Agreement. This amount shall be paid to Executive in one lump sum as soon as practicable, but in no event later than one hundred twenty (120) days, after the date that Executive's employment is terminated. In addition to the lump sum payment referenced in the preceding sentence, the Company shall pay to Executive any accrued and unpaid Bonuses as provided for in Section 3.4 at the same time as the lump sum payment is made. For example, if the Change of Control Date was January 1, 2008, the amount paid to would be equal to $2,400,000 ([$165,000 (Base Salary) + $75,000 (Deferred Compensation) X 5 (years remaining on contract)] + [$165,000 (base salary) + $75,000 (deferred compensation) X 5]).

 

For purposes of this subsection, a change of control shall mean the occurrence of one or more of the following three events:

 

(1) After the effective date of this Agreement, any person becomes a beneficial owner (as such term is defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) directly or indirectly of securities representing 33% or more of the total number of votes that may be cast for the election of directors of the Company;

 

(2) Within two years after a merger, consolidation, liquidation or sale of assets involving the Company, or a contested election of a Company director, or any combination of the foregoing, the individuals who were directors of the Company immediately prior thereto shall cease to constitute a majority of the Board; or

 

-4-

 

 

 

 

 
 

 

 

(3) Within two years after a tender offer or exchange offer for voting securities of the Company, the individuals who were directors of the Company immediately prior thereto shall cease to constitute a majority of the Board.

 

6. Confidentiality of Trade Secrets and Other Materials.

 

6.1 Executive acknowledges that in his employment hereunder, he will be making use of, acquiring and adding to the Company's trade secrets and its confidential and proprietary information of a special and unique nature and value relating to such matters as, but not limited to, the Company's business operations, manufacturing processes, manufacturing techniques, manufacturing methods, manufacturing technology, internal structure, financial affairs, programs, software, systems, procedures, manuals, confidential reports, lists of clients and prospective clients and sales and marketing methods, as well as the amount, nature and type of services, equipment and methods used and preferred by the Company's clients and the fees paid by such clients, all of which shall be deemed to be confidential information. Executive acknowledges that such confidential information has been and will continue to be of central importance to the business of the Company and that disclosure of it to or its use by others could cause substantial loss to the Company. In consideration of employment by the Company, Executive agrees that during the term of this Agreement and any renewal or extension of his employment by the Company and upon and after leaving the employ of the Company for any reason whatsoever, Executive shall not, for any purpose whatsoever, directly or indirectly, divulge or disclose to any person or entity any of such confidential information which was obtained by the Executive as a result of Executive's employment with the Company or any trade secrets of the Company, but shall hold all of the same confidential and inviolate.

 

6.2 All contracts, agreements, financial books, records, instruments and documents; client lists; memoranda; data; reports; programs; software; tapes; rolodexes; telephone and address books; letters; research; card decks; listings; programming; and any other instruments, records or documents relating or pertaining to clients serviced by the Company or the Executive, the services rendered by the Executive, or the business of the Company (collectively, the "Records") shall at all times be and remain the property of the Company. Upon termination of this Agreement and the Executive's employment under this Agreement for any reason whatsoever, Executive shall return to the Company all Records (whether furnished by the Company or prepared by the Executive), and Executive shall neither make nor retain any copies of any of such Records after such termination.

 

6.3 All inventions and other creations, whether or not patentable or copyrightable, made or conceived in whole or in part by Executive while employed by the Company and within eighteen months thereafter, which relate directly to the business, existing or proposed, of the Company or any other business or research or development effort in which the Company or any of its subsidiaries or affiliates engages during Executive's employment by the Company will be disclosed promptly by Executive to the Company and shall be the sole and exclusive property of the Company. All copyrightable works created by Executive and covered by this Section 6.3 shall be deemed to be works for hire. Executive shall cooperate with the Company in patenting or copyrighting all such inventions and other creative works, shall execute, acknowledge, seal and deliver all documents tendered by the Company to evidence its ownership thereof throughout the world, and shall cooperate with the Company in obtaining, defending, and enforcing its rights therein.

 

-5-

 

 

 

 

 
 

 

7. Termination.

 

7.1 Bases for Termination.

 

(a) Executive's employment hereunder may be terminated at any time by mutual agreement of the parties.

 

(b) This Agreement shall automatically terminate on the last day of the month in which Executive dies or becomes permanently incapacitated. "Permanent incapacity" as used herein shall mean mental or physical incapacity, or both, reasonably determined by the Company's Board of Directors based upon a certification of such incapacity by, in the discretion of the Company's Board of Directors, either Executive's regularly attending physician or a duly licensed physician selected by the Company's Board of Directors, rendering Executive unable to perform substantially all of his duties hereunder and which appears reasonably certain to continue for at least six consecutive months without substantial improvement. Executive shall be deemed to have "become permanently incapacitated" on the date the Company's Board of Directors has determined that Executive is permanently incapacitated and so notifies Executive.

 

(c) Executive's employment may be terminated by the Company "with cause," effective upon delivery of written notice to Executive given at any time (without any necessity for prior notice) if any of the following shall occur:

 

(1) any action by Executive which would be grounds for termination under applicable law (currently covering any willful breach of duty, and habitual neglect of duty);

 

(2) any material breach of Executive's obligations in Sections 4 or 6 above, other than any such breach resulting from “Permanent incapacity”; or

 

(3) any material acts or events which inhibit Executive from fully performing his responsibilities to the Company in good faith, such as (i) a felony criminal conviction; (ii) any other criminal conviction involving Executive's lack of honesty or Executive's moral turpitude; (iii) drug or alcohol abuse; or (iv) acts of dishonesty, gross carelessness or gross misconduct.

 

(d) Executive's employment may be terminated by the Company "without cause" (for any reason or no reason at all) at any time by giving Executive 60 days prior written notice of termination, which termination shall be effective on the 60th day following such notice. If Executive's employment under this Agreement is so terminated, the Company shall (i) make a lump sum cash payment to Executive within 10 days after termination is effective of an amount equal to (1) Executive's Base Salary accrued to the date of termination; (2) unreimbursed expenses accrued to the date of termination; (3) an amount equal to the greater of (a) Executive's annual Base Salary (i.e., 12 months of Base Salary), or (b) amounts remaining due to Executive as Base Salary (assuming that payments under this Agreement were made until expiration of the Initial Term or if applicable the Renewal Term), and (4) any other amounts due to Executive under any other provision of this Agreement. For purposes of this provision, Executive's annual Base Salary and the remaining portion of the term of the Agreement shall be calculated as of the termination date. After the Company's termination of Executive under this provision, the Company shall not be obligated to provide the benefits to Executive described in Section 3 (except as may be required by law). In addition to the lump sum payment referenced in the preceding sentence, the Company shall pay to Executive the Bonus provided for in Section 3.4 based upon the number of days in the year that Executive was employed by the Company, within one hundred five days after the end of the fiscal year in which Executive was terminated.

 

-6-

 

 

 

 

 
 

 

(e) Executive may terminate his employment hereunder by giving the Company 60 days prior written notice, which termination shall be effective on the 60th day following such notice.

 

7.2 Payment Upon Termination. Upon termination under Sections 7.1(a), (b), (c) or (e), the Company shall pay to Executive within 10 days after termination an amount equal to the sum of (1) Executive's Base Salary accrued to the date of termination; (2) unreimbursed expenses accrued to the date of termination, and (3) any other amounts due to Executive under any other provision of this Agreement. Except for the foregoing compensation then due and owing and the compensation provided for in Section 8.1(d), the Company shall not be obligated to compensate Executive, his estate or representatives after any such termination. Further, Executive shall not be entitled to any of the benefits described in Section 3 (except as provided by law) after such termination.

 

7.3 Dismissal from Premises. At the Company's option, Executive shall immediately leave the Company's premises on the date notice of termination is given by either Executive or the Company.

 

8. Restrictive Covenants .

 

8.1 The Company and Executive acknowledge and agree that Executive’s services are of a special and unusual character which have a unique value to the Company, the loss of which cannot be adequately compensated by damages in an action at law and if used in competition with the Company could cause serious harm to the Company. Further, Executive and the Company also recognize that an important part of Executive's duties will be to develop good will for the Company through his personal contact with customers, agents and others having business relationships with the Company, and that there is a danger that this good will, a proprietary asset of the Company, may follow Executive if and when his relationship with the Company is terminated. Accordingly, Executive covenants that for a period of eighteen months after Executive ceases to be employed by the Company for any reason whatsoever, Executive shall not, within the United States of America, without the prior written consent of the Company, directly or indirectly:

 

(a) Offer to render any services or solicit the rendition of any services which were rendered by the Company during the two year period immediately preceding such cessation of Executive’s employment with the Company to any clients, customers or accounts of the Company who were such at any time during such two year period to or for the benefit or account of Executive or to or for the benefit or account of any other person or entity.

 

-7-

 

 

 

 

 
 

 

(b) Render or attempt to render any services which were rendered by the Company during the two year period immediately preceding such cessation of Executive’s employment with the Company to any clients, customers or accounts of the Company who were such at any time during such two year period to or for the benefit or account of Executive or to or for the benefit or account of any other person or entity.

 

(c) Solicit for employment or employ to or for the benefit or account of Executive or to or for the benefit or account of any other person or entity any employee of the Company, nor shall Executive urge, directly or indirectly, any client or referrer of clients, customers, or accounts of the Company to discontinue, in whole or in part, business with the Company or not to do business with the Company. For purposes of this Section 8.1(c) of this Agreement, the term “referrer of clients” shall mean any person or entity who or which referred a client, customer or account to the Company at any time prior to such cessation of Executive's employment with the Company.

 

(d) Engage, either as a consultant, independent contractor, proprietor, stockholder, partner, officer, director, employee or otherwise, in any business which (i) designs, sells, or competes in the surface chemistry and quantitative instruments industry, or the DNA/RNA assays, protein-based assays and biosensors industries, (ii) is developing and/or commercializing a diagnostic product intended for rapid diagnosis in life-threatening bacterial infections, or (iii) any business that otherwise competes with the Company in any state of the United States or in any foreign country, in each such case where the Company sold, licensed or otherwise its products or related services at any time during the two year period immediately preceding such cessation of Executive’s employment with the Company. The Company and the Executive agree that the Company may elect to either enforce or waive this Section 8.1(d); provided however, that if the Company elects to enforce this Section 8.1(d), then subject to the provisions of the immediately following sentence, the Company agrees to pay Executive on a monthly basis an amount equal to his monthly Base Salary at the time of termination for each month that the Company elects to keep this provision in effect. It is expressly understood and agreed that if Executive is paid any amounts pursuant to Section 7.1(d), then the provisions of this Section 8.1(d) shall remain in full force and effect without the Company being obligated to make the additional payments contemplated in the immediately preceding sentence.

 

8.2 The parties hereto agree that to the extent that any provision or portion of Section 8.1 of this Agreement shall be held, found or deemed to be unreasonable, unlawful or unenforceable by a court of competent jurisdiction, then any such provision or portion thereof shall be deemed to be modified to the extent necessary in order that any such provision or portion thereof shall be legally enforceable to the fullest extent permitted by applicable law; and the parties hereto do further agree that any court of competent jurisdiction shall, and the parties hereto do hereby expressly authorize, request and empower any court of competent jurisdiction to, enforce any such provision or portion thereof or to modify any such provision or portion thereof in order that any such provision or portion thereof shall be enforced by such court to the fullest extent permitted by applicable law.

 

-8-

 

 

 

 

 
 

 

8.3 The provisions of Sections 8.1(a), 8.1(b), 8.1(c) and 8.1(d) of this Agreement are cumulative. Compliance with Sections 8.1(a), 8.1(b), 8.1(c) and 8.1(d) of this Agreement is a condition precedent to the Company's obligation to make any payments of any nature to Executive, whether under this Agreement or otherwise. Nothing in this Agreement shall be construed as prohibiting the Company from pursuing any other remedies available to it for a breach or threatened breach of Sections 6 and 8 of this Agreement.

 

8.4 As used in this Section 8, “clients”, “customers” and “accounts” shall include any person or entity that, directly or indirectly, through one or more intermediaries, controls or is controlled by, or is under common control with, any such “clients”, “customers” or “accounts.”

 

9 Injunctive Relief. The Company and Executive hereby acknowledge and agree that any violation of the provisions of Sections 6 or 8 hereunder will cause irreparable injury to the Company and there is no adequate remedy at law for such violation. Accordingly, in addition to any other relief to which the Company may be entitled, the Company shall be entitled to such injunctive relief as may be ordered by any court of competent jurisdiction including, but not limited to, an injunction restraining any violation of Sections 6 or 8 above without the proof of actual damages.

 

10. Miscellaneous.

 

10.1 Transfer and Assignment. This Agreement is personal as to Executive and shall not be assigned or transferred by Executive without the prior written consent of the Company. This Agreement shall be binding upon and inure to the benefit of all of the parties hereto and their respective permitted heirs, personal representatives, successors and assigns.

 

10.2 Severability. Nothing contained herein shall be construed to require the commission of any act contrary to law. Should there be any conflict between any provisions hereof and any present or future statute, law, ordinance, regulation or other pronouncement having the force of law, the latter shall prevail, but the provision of this Agreement affected thereby shall be curtailed and limited only to the extent necessary to bring it within the requirements of the law, and the remaining provisions of this Agreement shall remain in full force and effect.

 

10.3 Governing Law. This Agreement is made under and shall be construed pursuant to the laws of the State of Colorado.

 

10.4 Counterparts. This Agreement may be executed in several counterparts and all documents so executed shall constitute one agreement, binding on all of the parties hereto, notwithstanding that all of the parties did not sign the original or the same counterparts. Facsimile signatures shall be deemed valid and binding.

 

10.5 Entire Agreement. This Agreement constitutes the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements, arrangements and understandings with respect thereto. No representation, promise, inducement, statement or intention has been made by any party hereto that is not embodied herein, and no party shall be bound by or liable for any alleged representation, promise, inducement or statement not so set forth herein.

 

-9-

 

 

 

 

 
 

 

10.6 Modification. This Agreement may be modified, amended, superseded or cancelled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the party or parties to be bound by any such modification, amendment, supersession, cancellation or waiver.

 

10.7 Attorneys' Fees and Costs. In the event of any dispute arising out of the subject matter of this Agreement, the prevailing party shall recover, in addition to any other damages assessed, its attorneys’ fees and court costs incurred in litigating or otherwise settling or resolving such dispute whether or not an action is brought or prosecuted to judgment. In construing this Agreement, none of the parties hereto shall have any term or provision construed against such party solely by reason of such party having drafted the same.

 

10.8 Waiver. The waiver by either of the parties, express or implied, of any right under this Agreement or any failure to perform under this Agreement by the other party, shall not constitute or be deemed as a waiver of any other right under this Agreement or of any other failure to perform under this Agreement by the other party, whether of a similar or dissimilar nature.

 

10.9 Cumulative Remedies. Each and all of the several rights and remedies provided in this Agreement, or by law or in equity, shall be cumulative, and no one of them shall be exclusive of any other right or remedy, and the exercise of any one or such rights or remedies shall not be deemed a waiver of, or an election to exercise, any other such right or remedy.

 

10.10 Headings. The section and other headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning and interpretation of this Agreement.

 

10.11 Notices. Any notice under this Agreement must be in writing, may be telecopied provided that evidence of the transmission and receipt is created at the time of transmission, sent by express 24-hour guaranteed courier, or hand-delivered, or may be served by depositing the same in the United States mail, addressed to the party to be notified, postage-prepaid and registered or certified with a return receipt requested. The addresses of the parties for the receipt of notice shall be as follows:

 

If to the Company: Accelr8 Technology Corporation
  7000 North Broadway, Building 3-307
  Denver, CO 80221
   
If to Executive: Thomas V. Geimer
  7000 North Broadway, Building 3-307
  Denver, CO 80221
   

 

Each notice given by registered or certified mail shall be deemed delivered and effective on the date of delivery as shown on the return receipt, and each notice delivered in any other manner shall be deemed to be effective as of the time of actual delivery thereof. Each party may change its address for notice by giving notice thereof in the manner provided above.

 

-10-

 

 

 

 

 
 

 

 

10.12 Survival. Any provision of this Agreement which imposes an obligation after termination or expiration of this Agreement shall survive the termination or expiration of this Agreement and be binding on Executive and the Company.

 

10.13 Withholdings. Not withstanding any other provision of this Agreement, the Company may withhold from any amounts payable or benefits provided to Executive under this Agreement any Federal, state or local taxes as shall be required to be withheld pursuant to any applicable law or regulation.

 

10.14 Effective Date. This Agreement shall become effective as of the date set forth on page 1 when signed by Executive and the Company.

 

 

 

[REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY]

 

 

 

 

 

 

 

 

 

 

 

-11-

 

 

 

 

 
 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Employment Agreement to be executed as of the date first set forth above.

 

 

 

    THOMAS V. GEIMER   ACCELR8 TECHNOLOGY CORPORATION
     
    By: ________________________________________
    A. Alexander Arnold III, Director and Member of the Compensation Committee
     
     
    By:  _______________________________________
    Charles E. Gerretson, Director and Member of the Compensation Committee

 

 

-12-

 

 

 

 

 
 

 

 

 

EXHIBIT A

 

STOCK OPTION AGREEMENT

 

 

 

 

 

 

-13-

Exhibit 10.7

AMENDMENT TO EMPLOYMENT AGREEMENT
WITH THOMAS V. GEIMER

This Amendment (the " Amendment ") to the Employment Agreement with Thomas V. Geimer dated January 1, 2008 (the "Agreement") by and among Accelr8 Technology Corporation, a Colorado corporation (" Company ") and Thomas V. Geimer (" Executive ") is hereby adopted as of June 26, 2012.

RECITALS

A. Pursuant to Section 10.6 of the Agreement, the Agreement may be amended by a writing signed by each of the parties to the Agreement.

B. The parties wish to amend the Agreement to incorporate various changes.

AMENDMENT TO THE AGREEMENT

In exchange for valuable consideration, the parties hereby amend the Agreement as follows:

1. Section 3.2 of the Agreement is hereby amended by adding the following sentence to the end of the existing paragraph:

Notwithstanding the foregoing or anything in this Agreement to the contrary, the Company's obligations under this Section 3.2 shall terminate upon the consummation of change of control (as defined in Section 5).

2. Section 5 of the Agreement is hereby amended by amending and restating the first paragraph as follows:

If any time during the Initial Term or any Renewal Term of the Agreement there is a change of control of the Company, as defined below, and Executive's employment is terminated by the Company under Section 7.l(a), (b), (d), or (e) with the greater of one (l) year following the change of control or the remaining term of this Agreement (the "Change of Control Date"), the Company shall pay to Executive the sum of $1,350,000 payable in accordance with Schedule 1 attached hereto. If the Company, or any successor, does not make timely payments pursuant to the schedule set forth on Schedule 1 following written notice to the Company (or successor) and a five day opportunity to cure, such unpaid amounts shall accrue interest at a rate of 18% per annum until paid in full. The foregoing payments made pursuant to this Section 5 shall fully satisfy all payment obligations of the Company or its affiliates owed to Executive and the Company shall have no further obligations with respect thereto (including pursuant to Section 3.2), other than payments to be made (i) pursuant to Section 7.1 (d)(l), (2) and (4) and (ii) to Executive out of the Deferred Compensation agreement dated March 4, 1996 in accordance with the terms thereof. This agreement will be deemed terminated in accordance with Section 7 immediately upon the consummation of a change of control pursuant to which Executive becomes entitled to the payments hereunder.

 

 

 
 

  

3. Section 7.1(d) ofthe Agreement is hereby amended by adding thefollowing sentence at the end thereof:

If the Executive is entitled to change of control payments pursuant to Section 5 above, the Executive shall not also be eligible to receive severance benefits set forth in (d)(3) above, but shall be entitled to receive other payments as specified in (d)(I), (2) and (4) above.

4. Section 10. 7 of the Agreement is hereby amended by adding the following sentence at the end thereof:

Notwithstanding the above, if Executive employs counsel to enforce his rights to collect any amounts due under this Agreement, the Company shall pay reasonable attorney's fees incurred by Executive, including costs incurred in connection therewith, plus interest thereon at the rate of 18% per annum.

5. Section 10.9 of the Agreement is hereby amended by adding the following sentence at the end thereof:

Notwithstanding anything in this Agreement to the contrary, amounts due to Executive under this Agreement shall not be subject to any right of offset.

6. The remaining provisions ofthe Agreement are unchanged by this Amendment.

7. To the extent that there is any conflict between the terms and conditions of this Amendment and the Agreement, the terms and conditions of this Amendment shall control and be binding upon the parties.

*****

 

 

 

 

 

2

 

 

 
 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of June 26, 2012.

 

  ACCELLR8 TECHNOLOGY CORPORATION
  a Colorado corporation
   
  By: /s/ David C. Howson
  President
   
   
  /s/ Thomas V. Geimer
  Thomas V. Geimer

 

 

 

 

 

 

 

(Signature Page to Amendment to Geimer Employment Agreement)

 

  

 
 

  

Schedule 1   

$650,000 shall be payable on closing of the change of control transaction (the parties specifically characterize and allocate this lump sum payment as follows: $594,000 for the covenant not to compete set forth in Executive's Employment Agreement; $56,000 as a change of control payment; and

$700,000 shall be payable on July 1, 2013 (the. parties specifically characterize this entire lump sum payment as a change in control payment).

Exhibit 10.8

 

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this " Agreement ") is made as of June 27, 2012 (the " Effective Date "), by and between Accelr8 Technology Corporation, a Colorado corporation (the " Company "), and Thomas V. Geimer (the " Consultant "). The Company and the Consultant are each a "party" and are together "parties" to this Agreement.

 

RECITALS

 

WHEREAS, Abeja Ventures, LLC, a Delaware limited liability company (the " Purchaser "), has made a significant equity investment in the Company pursuant to that certain Securities Purchase Agreement dated April 20, 2012, by and among the Purchaser and the Company (the " Purchase Agreement ");

 

WHEREAS, the Consultant wishes to render certain services to the Company in connection with the integration of the Company, its customers and its employees with the Purchaser (the " Services ") in accordance with the terms and conditions contained in this Agreement;

 

WHEREAS, the Company wishes to engage the Consultant to render the Services in accordance with the terms and conditions contained in this Agreement; and

 

WHEREAS, the Purchase Agreement requires that this Agreement be executed and delivered by the Consultant as a condition to the consummation of the transactions contemplated by the Purchase Agreement.

 

AGREEMENT

 

NOW THEREFORE, the parties, intending to be legally bound, agree as follows:

 

1.             Definitions.   Capitalized terms in this Agreement shall have the meanings ascribed to them below:

 

" Agreement " means this instrument and all Exhibits attached hereto and made a part hereof.

 

" Company " is defined in the Preamble.

 

" Confidential Information " means any and all:

 

(a) trade secrets concerning the business and affairs of the Company or any of its affiliates, including each past, current and planned manufacturing, production or distribution method or process, customer or supplier list, customer requirements list, price list, market study, business plan, computer program (including object code and source code), software or database technology, system, structure, architecture, product specification, data know-how, process, design, photograph, specification, sample, invention, idea, and any other information, however documented, of the Company or any of its affiliates that is a Trade Secret;

 

1

 

 

 

 
 

 

 

(b) information, regardless of whether a Trade Secret, concerning the business and affairs of the Company or any of its affiliates (which includes historical financial statements, financial projections and budgets, historical and projected sales, capital spending budgets and plans, the names and backgrounds of key personnel, personnel training techniques and materials, customer lists and terms of arrangements with customers and suppliers), however documented; and

 

(c) notes, analyses, compilations, studies, summaries and other material prepared by or for the Company or any of its affiliates containing or based, in whole or in part, on any information included in clauses (a) or (b) above.

 

" Consultant " is defined in the Preamble.

 

" Effective Date " is defined in the Preamble.

 

"Intellectual Property" is defined in Section 7.2.

 

" Purchase Agreement " is defined in the Recitals.

 

" Purchaser " is defined in the Recitals.

 

" Services " is defined in the Recitals and shall include any and all obligations, duties and responsibilities necessary to the successful completion of any project assigned to or undertaken by the Consultant under this Agreement; provided, however, that such Services shall not be inconsistent with the services provided by the Consultant to the Company prior to the closing of the transactions contemplated by the Purchase Agreement.

 

" Taxes " is defined in Section 5.3.

 

" Term " is defined in Section 2.

 

" Trade Secrets " means information, including the whole or any portion or phrase of any scientific or technical information, design, process, procedure, formula, pattern, compilation, program, device, method, technique, or improvement, or any business information or plans, financial information, or listing of names, addresses, or telephone numbers, that derive independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use.

 

2.             Term. This Agreement shall take effect on the Effective Date and shall terminate on December 31, 2013 (the " Term "). The Term may be extended for a period of time to be mutually agreed upon by the parties.

 

3.             Consultant's Undertakings.

 

3.1 Skill Level . The Consultant will provide the Services contemplated by this Agreement using efficient and effective levels of skill, it being understood that the Services will be provided at times as mutually agreed by the parties.

 

 

2

 

 

 

 
 

 

 

3.2 Scope of the Services . During the Term, and subject to the time limitations identified in Section 3.1, the Consultant will perform the Services and any activities related to the Services.

 

3.3 Location of the Services . During the Term, the Consultant shall perform the Services at the Company's or the Purchaser's place of business or at locations of customers of the Company, in person or via telephone or other communications method as mutually agreed by the parties.

 

4.               Termination .

 

4.1 Termination . This Agreement and the Services described under Section 3 will terminate:

 

(a) at the end of the Term;

 

(b) upon the death of the Consultant; or

 

(c) upon the Disability (as defined in Section 4.2) of the Consultant immediately upon notice from either party to the other.

 

4.2 Definition of Disability . For purposes hereof, the term "Disability" shall mean any physical or mental disability or incapacity that renders the Consultant incapable of performing the Services via the Consultant for a period of one (1) month or for shorter periods aggregating to two (2) months during the Tenn.

 

5.             Compensation and Expenses.

 

5.1 Compensation . For and in consideration of the performance of the Services by the Consultant and subject to the terms and conditions of this Agreement:

 

(a) From the date of this Agreement until December 31, 2012, the Company shall pay the Consultant a monthly consulting fee payable on the first day of each month beginning on July 1, 2012 equal to $24,000 (a portion of which is intended to serve as a gross up for additional taxes owed as a result of converting from an employee to a consultant);

 

(b) For the period from January 1,2013 to December 31, 2013, a monthly consulting fee payable on the first day of each month beginning on December 1, 2013 equal to $8,000;

 

(c) If during the period from the date of this Agreement until December 31, 2012, Consultant should die or be deemed Disabled, the full amount of compensation that would have been paid to Consultant under this Agreement during such period shall be due and payable within 15 days;

 

(d) If the Company shall terminate this Agreement prior to December 31, 2013 for any reason whatsoever, such Termination shall have no impact on the Company's obligation to pay Consultant the full amounts due to Consultant until December 31, 2013 under this Section 5;

 

 

3

 

 

 

 

 
 

 

(e) All payments due under this Agreement shall be paid to Consultant by means of ACH transfer to Consultant's bank account, attached hereto as Exhibit A.

 

5.2 Expenses . The Company shall reimburse Consultant for all reasonable direct out-of-pocket expenses (on a fully accountable basis) incurred by Consultant in connection with the services rendered hereunder; provided, however, that any expenses in excess of $1,000 shall require advance written (e-mail acceptable) approval by the Company.

 

5.3 Tax Responsibility . Each party shall be responsible for the payment of its own taxes, licenses and fees (" Taxes ") in connection with this Agreement. Neither party shall be responsible or liable for the other party's Taxes assessed in connection with this Agreement.

 

5.4 No Benefits . The Consultant agrees that it shall not be entitled to participate in or receive benefits under any Company programs maintained for Company employees, including, without limitation, life, medical and disability benefits, pension, profit sharing or other retirement plans or other fringe benefits. Additionally, all compensation earned in connection with the subject matter of this Agreement, including provision for employment taxes such as, but not limited to, income and SECA will be the responsibility of the Consultant.

 

6.              Relationship of the Parties . The relationship of the Consultant to the Company at all times during the term of this Agreement shall be that of an independent contractor. At no time during the Term will the Consultant be considered an employee of the Company, but rather at all times will remain an independent contractor. Accordingly, the Consultant has the sole right to manage, control and direct the method, manner and means by which the Services are executed as long as the manner of execution is consistent with the terms and conditions in this Agreement.

 

7.              Ownership of Property .

 

7.1 Title to Tangible Property . All tangible materials (whether original or duplicates) including, without limitation, file or data base materials in whatever form, books, manuals, sales literature, correspondence, documents, contracts, orders, messages, memoranda, notes, agreements, invoices, receipts, lists, software listings or printouts shall be the sole property of the Company. At any time upon request of the Company, and in any event promptly upon expiration or termination of this Agreement, the Consultant shall deliver all such materials to the Company.

 

7.2 Title to Certain Intangible Property. The Consultant shall immediately disclose and assign to the Company all rights, title and interest in any patents, copyrights and trade secrets or other proprietary rights arising from or relating to the performance of the Services or processes or products of the Company that the Consultant conceives or acquires during the performance of the Services hereunder for the Company or that the Consultant may conceive or acquire, during the six month period following the termination of this Agreement that is based upon knowledge acquired during the performance of the Services for the Company (the "Intellectual Property'). The Consultant shall execute all documents and instruments and perform all acts necessary to evidence the Company's ownership of the Intellectual Property.

 

8.               Confidential Information.

 

8.1 Protection . The following provisions shall apply to Confidential Information:

 

 

4

 

 

 

 

 
 

 

(a) Any Confidential Information received by the Consultant may be used only for the purposes intended by this Agreement;

 

(b) During and following the Term, the Consultant will hold in confidence the Confidential Information and will not disclose it to any person except with the specific prior written consent of the Company or except as otherwise expressly permitted by the terms of this Agreement;

 

(c) During and following the Term, the Consultant will not use for its own account or for the benefit of any third party any Confidential Information, without the prior written consent of the Company, except in the performance of the Services hereunder for or on behalf of the Company;

 

(d) During and following the Term, the Consultant agrees to take all actions necessary to protect the Confidential Information against any unauthorized disclosure, publication or use;

 

(e) Confidential Information may not be copied or reproduced without the Company's prior written consent; and

 

(f) All Confidential Information made available to the Consultant, including copies, shall be returned to the Company or destroyed upon the latest to occur of (I) fulfillment of the Consultant's need for access, (ii) completion of the Services or (iii) termination or expiration of this Agreement.

 

8.2 Disclosure . As part of the performance under this Agreement, the Consultant will promptly notify the Company of the happening of any of the following events:

 

(a) Any unauthorized disclosure or use of the Confidential Information;

 

(b) Any request by a third party to examine, inspect or copy any of the Confidential Information; and

 

(c) Any attempt to serve, or the actual service of, a court or administrative order, subpoena or summons that requires the production of any Confidential Information. The Consultant will surrender the Confidential Information to any third party only with the Company's consent or the final order of a court having jurisdiction over the matter.

 

9.              Injunctive Relief and Additional Remedy . The Consultant acknowledges that the injury that would be suffered by the Company as a result of a breach of the provisions of this Agreement (including any provision of Section 8) would be irreparable and that an award of monetary damages to the Company for such a breach would be an inadequate remedy. Consequently, the Company will have the right, in addition to any other rights it may have, to obtain injunctive relief to restrain any breach or threatened breach or otherwise to specifically enforce any provision of this Agreement and the Company will not be obligated to post bond or other security in seeking such relief.

 

 

5

 

 

 

 
 

  

 

10.             Covenants of Section 8 are Essential and Independent Covenants . The covenants made by the Consultant in Section 8 are essential elements of this Agreement and, without the Consultant's agreement to comply with such covenants, the Company would not have entered into this Agreement or the Purchase Agreement or engaged or continued the engagement of the Consultant. The Company and the Consultant have independently consulted with their respective counsel and have been advised in all respects concerning the reasonableness and propriety of such covenants, with specific regard to the nature of the business conducted by the Company. If the Consultant's engagement hereunder expires or is terminated, this Agreement will continue in full force and effect as is necessary or appropriate to enforce the covenants and agreements of the Consultant in Section 8.

 

11.             Representations and Warranties by the Consultant . The Consultant represents and warrants to the Company that the execution and delivery by the Consultant of this Agreement do not, and the performance by the Consultant of the Consultant's obligations hereunder will not, with or without the giving of notice or the passage of time, or both: (a) violate any judgment, writ, injunction or order of any court, arbitrator or governmental agency applicable to the Consultant; or (b) conflict with, result in the breach of any provisions of or the Termination of, or constitute a default under, any agreement to which the Consultant is a party or by which the Consultant is or may be bound. The Consultant has carefully considered the nature and extent of the restrictions upon the Consultant and the rights and remedies conferred upon the Company under this Agreement and hereby acknowledges and agrees that the same are reasonable in time arid territory, are designed to eliminate unfair business practices that otherwise would be unfair to the Company, are fully required to protect the legitimate interests of the Company and do not confer a benefit upon the Company disproportionate to the detriment imposed upon the Consultant. The Consultant acknowledges and agrees that the restrictions of Section 8 will not unreasonably interfere with his ability to find alternative employment or to earn a living.

 

12.             LIMITATION OF LIABILITY.

 

(A) IN NO EVENT SHALL THE COMPANY BE LIABLE TO THE CONSULTANT FOR ANY DAMAGES, INCLUDING, WITHOUT LIMITATION, LIABILITY ARISING OUT OF CONTRACT, NEGLIGENCE, STRICT LIABILITY AND TORT OR ANY CONSEQUENTIAL, INCIDENTAL OR PUNITIVE LOSS, DAMAGES OR EXPENSES (INCLUDING LOST PROFITS OR SAVINGS), AS A RESULT OF THIS AGREEMENT OR THE SERVICES, WITH THE EXCEPTION OF COMPENSATION AND EXPENSES THE COMPANY HAS AGREED TO PAY HEREUNDER AND DAMAGES DUE TO NEGLIGENCE OR INTENTIONAL WRONGDOING OF THE COMPANY.

 

 

(B) WITH REGARD TO THE SERVICES TO BE PERFORMED BY THE CONSULTANT PURSUANT TO THE TERMS OF THIS AGREEMENT, THE CONSULTANT SHALL NOT BE LIABLE TO THE COMPANY, OR TO ANYONE WHO MAY CLAIM ANY RIGHT DUE TO ANY RELATIONSHIP WITH THE COMPANY, FOR ANY ACTS OR OMISSIONS IN THE PERFORMANCE OF SERVICES ON THE PART OF THE CONSULTANT, EXCEPT WHEN SAID ACTS OR OMISSIONS OF THE CONSULTANT ARE DUE TO WILLFUL MISCONDUCT OR GROSS NEGLIGENCE. THE COMPANY SHALL HOLD THE CONSULTANT FREE AND HARMLESS FROM ANY OBLIGATIONS, COSTS, CLAIMS, JUDGMENTS, ATTORNEYS' FEES, AND ATTACHMENTS ARISING FROM OR GROWING OUT OF THE SERVICES RENDERED TO THE COMPANY PURSUANT TO THE TERMS OF THIS AGREEMENT OR IN ANY WAY CONNECTED WITH THE RENDERING OF SERVICES, EXCEPT WHEN THE SAME SHALL ARISE DUE TO THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF THE CONSULTANT AND THE CONSULTANT IS ADJUDGED TO BE GUILTY OF WILLFUL MISCONDUCT OR GROSS NEGLIGENCE BY A COURT OF COMPETENT JURISDICTION.

 

13.             Notice . Any notice, request, demand or other communication required or permitted hereunder shall be in writing and shall be deemed to have been given if personally delivered or sent by facsimile transmission, upon receipt, or if sent by registered or certified mail, upon the sooner of the date on which receipt is acknowledged or the expiration of three days after deposit in United States post office facilities properly addressed with postage prepaid. All notices to a party will be sent to the addresses set forth below or to such other address or person as such party may designate by notice to each other party hereunder:

 

If to the Company:

 

Accelr8 Technology Corporation

7000 North Broadway, Building 3-307

Denver, Colorado 80221

Attn: Chief Executive Officer

Facsimile: (303) 863-1218

 

If to the Consultant:

 

Thomas V. Geimer

400 S. Steele Street #19

Denver, Colorado 80209

 

14.             Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement and supersedes all prior written and oral agreements and understandings between the parties with respect to the subject matter of this Agreement. This Agreement may not be amended except by a written agreement executed by both parties.

 

15.             Amendment and Waiver . This Agreement may be amended, superseded, canceled, renewed or extended, and the terms hereof may be waived, only by a written instrument signed by the parties or, in the case of a waiver, by the party waiving compliance. The failure of a party to insist upon strict performance of any provision of this Agreement shall not constitute a waiver of, or estoppel against asserting, the right to require performance in the future. A waiver or estoppel in anyone instance shall not constitute a waiver or estoppel with respect to a later breach.

 

 

7

 

 

 

 

 
 

 

 

16.              Severability . If any of the terms and conditions of this Agreement are held by any court of competent jurisdiction to contravene, or to be invalid under, the laws of any political body having jurisdiction over this subject matter, that contravention or invalidity shall not invalidate the entire Agreement. Instead, this Agreement shall be construed as reformed to the extent necessary to render valid the particular provision or provisions held to be invalid, consistent with the original intent of that provision and the rights and obligations of the parties shall be construed and enforced accordingly, and this Agreement shall remain in full force and effect as reformed.

 

17.              Governing Law; Waiver of Jury Trial . This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Colorado without regard to the principles thereof relating to conflict of laws. Each of the parties hereto hereby waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement. Each of the parties hereto hereby (a) certifies that no representative, agent or attorney of the other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (b) acknowledges that it has been induced to enter into this Agreement by, among other things, the mutual waivers and certifications in this Section 17.

 

18.             Construction . The headings in this Agreement are inserted for convenience and identification only and are not intended to describe, interpret, define or limit the scope, extent or intent of this Agreement.

 

19.             Counterpart Execution . This Agreement may be executed and delivered (including by facsimile, pdf or similar electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

 

20.              Successors and Assigns . The Consultant may not assign any of its rights, interests or obligations under this Agreement without the prior written consent of the Company. Subject to the preceding sentence, this Agreement will apply to, be binding in all respects upon, and inure to the benefit of the successors and permitted assigns of the parties. The Company may assign any or all of its rights, interests and obligations hereunder (a) to one or more of its affiliates, (b) for collateral security purposes to any lender providing financing to the Company or its affiliates and any such lender may exercise all of the rights and remedies of the Company hereunder, and ©) to any subsequent purchaser of the Company or any material portion of its respective assets (whether such sale is structured as a sale of equity, a sale of assets, a merger or otherwise).

 

21.              Drafting Party . This Agreement expresses the mutual intent of the parties to this Agreement. Accordingly, regardless of the party preparing any document, the rule of construction against the drafting party shall have no application to this Agreement.

 

22.              Legal Fees . If any legal action is brought by either of the parties hereto, it is expressly agreed that the party in whose favor final judgment shall be entered shall be entitled to recover from the other party reasonable attorney's fees in addition to any other relief which may be awarded, including attorneys fees on appeal.

 

 

8

 

 

 

 

 
 

 

23.             No Partnership or Joint Venture. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or other entity or combination among the parties and each party shall remain solely responsible for the actions of its own employees and representatives.

 

24.             Publicity. No party shall publicize the existence of this Agreement or involvement in the undertakings and transactions contemplated in this Agreement without the prior written approval of the other parties, unless required by law.

 

25.             Survival of Covenants. The covenants, representations and agreements of Sections 5.4, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, and 25 are of a continuing nature and shall survive the expiration, termination or cancellation of this Agreement regardless of reason.

 

*****

 

 

 

 

 

 

 

 

9

 

 

 

 
 

 

 

 

IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first written above.

 

 

  COMPANY:
  ACCELR8 TECHNOLOGY CORPORATION
   
   
  By: /s/ Lawrence Mehren
  Chief Executive Officer
   
   
  CONSULTANT:
   
  THOMAS V. GEIMER
   
   
  Thomas V. Geimer

 

 

 

[ Signature Page to Geimer Consulting Agreement ]

 

 

 

 

 

 

 

 

 
 

IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first written above.

 

 

  COMPANY:
  ACCELR8 TECHNOLOGY CORPORATION
   
   
  By:
  Chief Executive Officer
   
   
  CONSULTANT:
   
  THOMAS V. GEIMER
   
  /s/ Thomas V. Geimer
  Thomas V. Geimer

 

 

 

 

 

[ Signature Page to Geimer Consulting Agreement ]

 

 

 

 

 
 

 

 

 

EXHIBIT A

 

ACH

 

 

 

Exhibit 10.9

 

 

[ACCELR8 LETTERHEAD]

 

 

 

 

Lawrence Mehren

[Address]

[Address]

 

Dear Larry,

 

Welcome to the Accelr8 Technologies team! We are excited that you are part of our organization. Your role as an Accelr8 employee is critical in the success of our company. We are ready to support you in your role at Accelr8 and hope that you will contact us with any questions or concerns you may have.

 

The purpose of this letter is to confirm certain new terms relating to your position, responsibilities, compensation, and benefits at Accelr8. If any of the terms outlined in this letter differ from terms discussed orally or in other correspondence, the terms outlined in this letter will supersede any prior terms.

 

In addition to the insurance benefits outlined below, you will be eligible for insurance coverage as may be offered from time to time by Accelr8 to other similarly-situated employees.  The specifics of such insurance coverage shall be governed by the applicable plan documents.

 

The following is designed to provide a brief description of certain aspects of your employment:

 

   
 • Position : President and Chief Executive Officer reporting to the Accelr8 Board of Directors. Until such time as the company hires a Chief Financial Officer you shall also serve as the company’s Chief Financial Officer.
 • Base Salary : Your pay will be at an annual rate of $300,000, paid in accordance with the company’s normal payroll practices and procedures.
 • Cash Bonus . As you are aware, Accelr8 has determined not to pay cash bonuses until the company is profitable or until such time as the Accelr8 Board of Directors determines that such bonuses are in the best interests of the company and its stockholders. You will be eligible for cash bonuses if and when the Accelr8 Board introduces such a plan.
 • Health Insurance : You will be eligible for participation in the Accelr8 Technologies’ Group Health Plan when the company makes such a plan available to employees.
 • Other Benefits : You will be eligible to participate in other benefit programs offered by Accelr8 to its employees generally from time to time.
 • PTO : In addition to the company’s standard paid holidays, you will receive vacation days in accordance with the company’s policies.
 • Business Expenses . The company will reimburse you for customary and reasonable expenses which you incur on behalf of the company, provided that you provide the company with receipts to substantiate the business expense in accordance with the company’s policies. The foregoing shall include reimbursement for the reasonable and documented costs and expenses you incur in connection with commuting between Tucson, Arizona and the Denver/Boulder, Co metropolitan areas on behalf of the company.
 • At-will Employment: Your employment with Accelr8 is at-will. Accordingly, the company may terminate you as an employee without advance notice and you will not be entitled to any severance payments.
 • Policies and Confidentiality: You will be required to execute and deliver to the company the Accelr8 Technologies’ form Employee Confidentiality and Intellectual Property Assignment Agreement an agree to the standard terms contained in the Accelr8 Employee Handbook.

 

 

 

 

 

 
 

  

 

This offer is not intended to be an employment contract, nor should it be construed as a guarantee that employment or any benefit program or other term or condition of employment will be continued for any period of time. Any wage figures are not intended to create an employment contract for any specific period of time and thus your employment is at-will; either you or Accelr8 Technologies can terminate it at any time with or without Cause.

 

We are excited for you to join our team and look forward to you growing with our company.

 

You will be required to adhere to all of Accelr8’s policies and procedures as may be in effect from time to time. In addition, as a condition of your employment with Accelr8, you will be required to sign the Company’s standard Confidentiality and Intellectual Property Assignment Agreement. As a further condition of employment with Accelr8, you will be required to submit to a background check at some point during the next approximate 60 days and your employment will be subject to termination at Accelr8’s option if the results of the background check are unacceptable. At the time the background check will be conducted, you will be provided the appropriate paperwork.

 

We are pleased to confirm the terms of your employment with Accelr8 and would ask you to confirm your acceptance of these terms of employment by signing below and returning a signed copy to us at your earliest convenience.

 

If you have any questions please do not hesitate to contact us.

 

 

Sincerely,

 

 

 

 

John Patience

Director

 

 

 

I, _______________________________ accept the terms of employment outlined above.

 

 

 

Acceptance:    
     
     
Signature   Date
     

 

 

 

 

Exhibit 10.10

Accelr8
Technology Corporation
 
 
 
July 22,2012
 
 
Steve Reichling
Via Email:
stevendreichling@gmail.com
 
Dear Steve,
 
C ongratulations! It is with great pleasure that I confirm our employment offer, in the position of Chief Financial Officer, reporting to Lawrence Mehren, CEO of Accelr8. The tentative start date for your new position is September l0th, 2012.
 
Your starting annual base salary will be $170,000 paid on a semi-monthly basis. As you are aware, Accelr8 has determined not to pay cash bonuses until the company is profitable or until such time as the Accelr8 Board of Directors determines that such bonuses are in the best interests of the company and its stockholders. You will be eligible for cash bonuses if and when the Accelr8 Board introduces such a plan.
 
Once you have accepted the offer, I will recommend to the Accelr8 Board of Directors, a New Hire stock option grant of 200,000 shares, with a five-year vesting schedule, 40% cliff after two years and monthly thereafter. Further, you will be eligible for annual performance based stock grants, the amount of which will be determined by the Board.
 
In addition to the above compensation, we will provide you a budget of$70,000 to be used toward relocation and temporary living arrangements. You will agree to relocate to the Tucson area no later than the completion date of the new company headquarters in Tucson Arizona which will be communicated to you once finalized. Until then you understand that your role will require you to commute to the current corporate headquarters in Denver.
 
You will be eligible to participate in Accelr8's benefit package which includes health care, life and disability insurance. Your benefits will be effective on the first of the month following your date of hire.
 
This offer is not intended to be an employment contract, nor should it be construed as a guarantee that employment or any benefit program or other term or condition of employment will be continued for any period of time. Any wage figures are not intended to create an employment contract for any specific period of time and thus your employment is at-will; either you or Accelr8 Technologies can terminate it at any time with or without Cause.

 

 

 

 

 

 
 

 

 

 

 
We are excited for you to join our team and look forward to you growing with our company.
 
You will be required to adhere to all of Accelr8's policies and procedures as may be in effect from time to time. In addition, as a condition of your employment with Accelr8, you will be required to sign the Company's standard Confidentiality and Intellectual Property Assignment Agreement. As a further condition of employment with Accelr8, you will be required to submit to a background check at some point during the next 60 days and your employment will be subject to termination at Accelr8's option if the results of the background check are unacceptable.
 
We are pleased to confirm the terms of your employment with Accelr8 and would ask you to confirm your acceptance of these terms of employment by signing below and returning a signed copy to us at your earliest convenience.
 
If you have any questions please do not hesitate to contact us.
 
 
Sincerely,
 
 
 
John Patience Chairman of the Board
Chairman of the Board

 

 

 

Accepted on 8/8/2012

 

 

/s/ Steve Reichling

Steve Reichling

 

Exhibit 10.11

 

(Graphic Omitted - Pima County Logo)

Facilities Management
150 WEST CONGRESS, 3rd FLOOR
TUCSON, ARIZONA 85701

 

REID H. SPAULDING, Director   PH: (520) 740-3703 * FAX: (520) 740-3900
     

August 28, 2012

HAND DELIVERED

 

Snell & Wilmer, L.L.P.
Jill Casson Owen
One South Church Avenue
Tucson, AZ 85701

 

 

RE: Acceler8 Lease -Abrams Public Health Building

Jill:


I have enclosed an original fully executed Lease for the above tenant and location for your file.


Please call me at 724-8230 if you have any questions regarding this matter.

 

Sincerely,

 

/s/ Melissa Loeschen

Melissa Loeschen
Program Manager -Senior

Enclosure

cc: Regina Nassen, Esquire -Pima County Attorney's Office -via e-mail

 

 

 

 
 

 

  CONTRACT
  No. CTN-FM-13000000000000000055
  AMENDMENT NO _______________
  This number must appear on all invoices, correspondence and documents pertaining to this contract.

LEASE AGREEMENT

This Lease Agreement (this " Lease "), dated August 20,2012 for reference purposes, is made and entered by and between ACCELR8 TECHNOLOGY CORPORATION, a Colorado corporation (hereinafter " Accelr8 " or " Tenant "), and PIMA COUNTY, a political subdivision of the State of Arizona (hereinafter " County " or " Landlord ").

RECITALS

A. County owns a building (the " Building ") located at 3950 S. Country Club Road in Tucson, Arizona, on the Kino public health campus, as shown on Exhibit A . The Building is adjacent to the University of Arizona Medical Center -South Campus.

B. County has authority, pursuant to A.R.S. § 11-254.04, to "spend public monies for and in connection with economic development activities," which includes "assistance, ... including ... improvement, leasing or conveyance of real ... property ... , that the board of supervisors has found and determined will assist in the creation or retention of jobs or will otherwise improve or enhance the economic welfare of the inhabitants of the county."

C. Tucson Regional Economic Opportunities, Inc. ("TREO") is an Arizona nonprofit corporation formed to serve as the lead economic development agency for the greater Tucson area and its surrounding regional partners. TREO's mission is to foster the creation of new businesses, the expansion of existing businesses within the region, and the attraction of companies that offer high wage jobs, in order to accelerate economic prosperity throughout Southern Arizona.

D. The Board of Supervisors has determined that the attraction of health sciences and bio-tech companies to Pima County will result in the creation of high-paying jobs for County residents, as well as other economic benefits, and that making space in the Building available to such companies at below-market rates will encourage such companies to relocate to or expand within the community.

E. TREO has identified and worked with Accelr8 in order to induce it to move to Tucson. Accelr8 has indicated that it is willing to relocate to Tucson in exchange for being permitted to lease space within the Building at a below-market rate.

 

AGREEMENT

1) LEASE/PREMISES. In consideration of rent monies and all terms, conditions, covenants, and agreements contained herein, Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the space within the Building identified on the attached Exhibit B (the " Premises "). The Premises is approximately 15,096 square feet in size and is located on the 4 th floor of the Building.

 

Page 1 of 22

 

 
 

 

a) Common Areas . The Building has, associated with it, certain interior and exterior areas for the common use of all occupants of the Building, including (but not limited to) streets, sidewalks, canopies, driveways, loading platforms, entryways, lobbies, auditoriums, conference rooms, stairways, elevators, hallways, washrooms, shelters, ramps, landscaped areas and related common areas (the "Common Areas"). Tenant shall have the right to use the Common Areas on a non-exclusive basis together with other occupants of the Building.

b) Parking. Tenant shall be entitled to use the number of parking spaces required for the Premises by applicable zoning based upon Tenant's use. One space, per full time employee working for Tenant at the Premises, will be reserved for Tenant's exclusive use, through posted signage provided by Landlord. Landlord will not police the parking to ensure that Tenant's spaces are not used by others. If, during the Term, Landlord builds a parking garage on the Kino public health campus, Landlord may require Tenant's employees to utilize that parking garage. There will be no charge for use of the garage by Tenant's employees during the Initial Term. During the Extension Terms, Tenant will pay a monthly parking fee of $50.00 per space in such parking garage.

c) Expansion Space . At all times during the Term of this Lease, Tenant shall have the option, with six months prior written notice to Landlord, to lease either or both of two additional areas, approximately 7,920 total square feet in size, on the 4 th floor of the Building, as shown on Exhibit B , at the then-current rate per usable square foot annually. Any build-out of this area must be done at Tenant's expense. If Tenant exercises the option to lease this space, it will be deemed to be a part of the "Premises" under this Lease. Tenant acknowledges that Landlord will, until such time as this option is exercised, continue to utilize this space for County purposes, but County will not lease the space to another tenant.

2)        ECONOMIC BENEFITS.

a) Additional Consideration . Tenant acknowledges that this Lease is being entered into by Landlord at a below-market rate, as part of an economic development program. As part of the consideration for this favorable Lease rate, Tenant agrees to (i) relocate to the Tucson Area and begin operations at the Premises within thirty days after the Commencement Date; and (ii) within eighteen months of the Commencement Date, employ at least thirty individuals at the Premises, with a median salary level of at least $70,000 ($70,000 x 30 =$2,100,000 annual payroll), and maintain that level of employment throughout the rest of the Term. Tenant will, at the time the employment goal is reached, notify Landlord and deliver a sworn statement, signed by Tenant's President, that the required employment levels have been met. Landlord will have the right to audit Tenant's records, from time to time, from and after delivery of that notice, and upon at least two business days advance notice to Tenant, to confirm that the goal has been met and is continuing to be met.

  

Page 2 of 22

 

 
 

 

b) Enforcement . If Tenant fails to meet condition (i) above, Landlord may terminate this Lease. If Tenant fails to satisfy condition (ii) above, then from and after the date of non-compliance until the Term ends or the condition is met, the Rent rate set forth below will be increased by a percentage that is twice the percentage by which Tenant's annual payroll has fallen short of the goal, except that in no event will the rental rate exceed $19.80 per usable square foot per year. Failure to satisfy condition (ii) shall not be a default under Section 11) below. Notwithstanding Section 11), the sole remedy for failure to meet condition (ii) above is as set forth in this subsection 2)b).

3)         TERM.

a) Initial Term . The initial term of this Lease is a period of three (3) years beginning on the Commencement Date as defined in Section 4) below and ending on the third anniversary of the Commencement Date (the "Initial Term").

b) Extension Terms . Tenant has the right to extend the Initial Term of this Lease for up to three additional one-year periods (each, an "Extension Term") if Tenant is in material compliance with all terms and conditions of this Lease at the time Tenant submits written notice to the Landlord of its intent to so extend the Lease. Each option must be exercised by Tenant not more than twelve (12) months nor less than six (6) months prior to the end of the Initial Term or preceding Extension Term. "Term" as used in this Lease includes the Initial Term and any Extension Terms that are utilized.

4)        TENANT IMPROVEMENTS; COMMENCEMENT DATE.

a) Tenant Improvements . Landlord shall build out, equip, and furnish the Premises substantially as illustrated on Exhibit C (the "Tenant Improvements"). Fixtures and equipment will be new and unused and of a quality meeting Landlord standards. Furnishings will be a combination of new and existing product as appropriate to promote a collaborative and high-tech environment while seeking to reuse existing County furnishings to the extent consistent with such environment.

i) Plans . Tenant will provide Landlord with all plans and specifications necessary for bidding, permitting and constructing the Tenant Improvements (the "Plans"). Final plans and specifications are subject to Landlord review and approval and must comply with all applicable building and other codes and regulations. Landlord has the right to make reasonable adjustments to the design to lower the cost of the Tenant Improvements, subject to Tenant's approval, which cannot be unreasonably withheld. Tenant will be responsible for any costs associated with changes to the Plans requested by Tenant after approval.

ii) Construction . Landlord shall construct the Tenant Improvements in a good and workmanlike manner, according to Plans. The build out will be at Landlord's expense except that Tenant will reimburse Landlord for any amount by which the total cost of the Tenant Improvements exceeds $1,400,000.00, payable within thirty (30) days after the Commencement Date. Landlord shall expedite the work to the extent reasonably possible working within existing applicable State and local statutes, policies and procedures. Landlord will not approve any changes to the Plans or issue any change orders during construction that will result in an increase in the cost in excess of $1,400,000.00 without Tenant's approval, which will not be unreasonably withheld.

iii) Value Engineering . After receiving the Plans, Landlord will obtain an estimate for total cost of the Tenant Improvements from its contractor. If the total cost exceeds $1,400,000.00, Tenant has the right to make reasonable adjustments to the design to lower the cost of the Tenant Improvements, subject to Landlord's approval, which cannot be unreasonably withheld.

iv) Rooftop . The existing rooftop solar array will need to be adjusted to accommodate roof penetrations necessary for the Tenant Improvements. Landlord acknowledges that roof-top exhaust stacks may be 10-12 feet above existing parapet, if required by good engineering practices, and if consistent with all building codes, zoning, and other applicable laws or regulations. Roof-top exhaust stacks and other roof-top equipment may require structural reinforcement of the roof. Any roof-top reinforcement will be done as part of the Tenant Improvements, according to the Plans.

a) Move-In . Landlord shall notify Tenant when the Tenant Improvements are substantially complete, subject only to minor "punch list" items, such that Tenant can begin moving into the Premises. The date of the substantial completion notice shall be the " Commencement Date ." Landlord shall also, in this notice, advise Tenant of the total usable square footage of the Premises and the annual rental amount as provided in Section 6)b ) below. Tenant shall be responsible for moving its personal property (including furnishings, phone, computer and office or medical/lab equipment) into the Premises, and bearing all expenses associated with move-in. Tenant shall coordinate its move-in with other Building occupants so that any disruption is minimized as much as reasonably possible.

5)        USE.

a) Permitted Uses : The Premises may be used by Tenant for all lawful purposes, including laboratory operations and associated use of fluids/flammables and other materials typical to engineering and biological labs, and any other uses reasonably related thereto, provided that all applicable laws and regulations regarding such uses (including zoning), and the storage and use of such materials, are followed. Tenant

 

Page 4 of 22

 
 

 

b) Solar Panels . tenant’s use of the premises may result in exhaust particles or condensation landing on roof-top solar panels. The impacts of such exhaust particles and condensation will be determined during the planning and design of the Tenant Improvements. If this exhaust degrades the panels more than the mutually agreed-upon estimated impacts based on the approved Plans, Tenant will indemnify County from and against any liability to third parties incurred as a result of the degradation.

c ) Prohibited Activities : Tenant shall not permit any unlawful activities on the Premises or any activities that unduly interfere with activities of the other occupants of the Building or neighboring property owners/ occupants.

d) Hazardous Materials Prohibited; Clean Air Act . Tenant shall not cause or permit any hazardous or toxic materials or substances to be brought upon, kept, or used in or about the Premises by Tenant, its agents, employees, contractors or invitees, without the prior written consent of Landlord, other than such hazardous or toxic materials or substances that are necessary or useful to Tenant’s business and will be used, kept and stored in a manner that complies with all laws regulating any such materials or substances. Tenant’s operations on the Premises shall comply with all applicable provisions of environmental laws and regulations, including the Clean Air Act, 42 U.S.C. 7401 et seq., and Arizona Revised Statutes, Title 49, Chapter 3. Tenant shall remediate and clean up, at its sole cost and expense, any contamination of the Premises occurring during the Term of this Lease.

e) Biological Waster & Material Disposal . Tenant shall properly dispose of any medical or biological waste-including but not limited to syringes, vials, prescriptions and any materials containing blood or other biological material used or generated on the Premises. Tenant’s disposal may include using appropriate medical waste containers and/or contracting with a third party medical waste disposal company. Tenant shall never dispose of any medical or biological supplies or waste outside of the Premises in the Building’s Common areas. Tenant shall indemnify and defend Landlord from and against any liability incurred by Landlord as a result of any disposal of such materials in violation of this Agreement or in violation of applicable law.

f) Common Areas . the Common Areas shall at all times be subject to the control and management of Landlord and Landlord shall have the right from time to time to change the area, level, location, appearance and furnishing or landscaping of the Common Areas provided that such activity does not materially interfere with Tenant’s operations. Landlord shall have the right an any time to temporarily close any portion of the Common Areas for the purpose of making repairs, changes or additions thereto and Landlord may enter into agreements with adjacent owners for cross-easements for parking, ingress or egress.

Page 5 of 22

 

 
 

g) Rules and Regulations . Tenant and its employees, agents, contractors and invitees shall abide by rules and regulations for the Building shown in Exhibit D that are established from time to time by Landlord concerning, among other things, sanitation, handling of trash and debris, loading and unloading of trucks and other vehicles, safety and security, after hours use and procedures and use of Common Areas. Such rules and regulations shall be applied in a non-discriminatory manner and shall not unduly limit or impair Tenant's permitted use of the Premises.

Notwithstanding Item 9 in the rules and regulations, Landlord agrees that Tenant is permitted to use flammable, combustible fluids and materials as set forth in Section 5)a) herein.

h) Use of Other Areas of the Building. It is Landlord's intent to utilize the Building for public health offices and related purposes, and may lease space within the Building to other organizations and agencies for such use. Landlord shall, however, have the right to make any legal use of the Building or portions thereof.

6)        RENT.

a) Rental Rate . Subject to Sections 1)c) and 2)b) above, the rental rate for the Rent during the Initial Term will be $9.25 per usable square foot per year and the Rent during any extension or renewal of the Lease beyond the Initial Term will be $19.80 per usable square foot per year.

b) Calculation of Usable Square Footage . Currently, the usable square footage of the Premises is estimated to be 15,096 usable square feet. The actual usable square footage shall be determined by Landlord at the conclusion of construction of the Tenant Improvements. Landlord shall, in the notice of substantial completion as described in Section 4) above, inform Tenant of the final usable square footage and the annual Rent amount, which shall be calculated by multiplying the actual usable square footage as determined by Landlord by the rental rate set forth above.

c) GPLET. Tenant will also be responsible for paying any government property lease excise taxes due under Title 42, Chapter 6, Article 5 of the Arizona Revised Statutes, and the City of Tucson transaction privilege tax. Within 30 days after execution of this Lease, the parties will execute and the County will record a memorandum of this Lease in compliance with A.R.S. § 42-6202(C)(1), and the County will provide the County Treasurer with a copy of this Lease as required by A.R.S. § 42-6202(C)(2).

d) Payment of Rent. Tenant shall pay Rent in advance, in equal monthly installments of 1/12 the annual Rent amount, on or before the Rent Commencement Date and the first day of each month thereafter during the Term, except that the first month's Rent shall be prorated if necessary to reflect a partial month. Rent Commencement Date shall be defined as ten (10) days after the Commencement Date. Rent shall be delivered to Pima County Government, Finance-Revenue Management Division, 33 N. Stone, 6 th Floor, Mail Stop DT-BAB6-404, Tucson, Arizona 85701. Tenant shall pay interest (simple interest, not compounded) on any late payments of Rent, or any other sum due under this Lease, at the rate of 8% per annum from the date due until paid.

 

Page 6 of 22

 
 

 

7)        REPAIRS, SERVICES & UTILITIES.

a) Repairs . Subject to Section 17) of this Lease concerning damage resulting from a casualty, and subsection f) of this section 7), Landlord shall make all repairs in and to the Building and Premises, except as provided below. This shall include the roof, structural portions of the Building, and major Building systems such as air conditioning motors or compressors, major plumbing requirements (in-wall plumbing), heating units, in-wall electrical connections, and fixtures and systems furniture installed as part of the Tenant Improvements.

b) Notification to Landlord . In the event of a breakdown or needed repairs to the Premises or equipment associated therewith, Tenant shall notify Landlord or its agent of such breakdowns or needed repairs, and Landlord shall cause such repairs and/or replacements as are necessary to correct such condition to be done within a reasonable period of time.

c) Janitorial . Tenant is responsible for providing and paying for janitorial services to the Premises. Landlord is responsible for providing janitorial services for all other areas, including the Common Areas of the Building. Tenant's janitorial contractor must obtain and maintain, during the entire period that it is performing work in the Premises, general liability and worker's compensation of $lM each, and must cause Landlord to be named as an additional insured on the liability policy. Tenant must provide proof of this insurance to Landlord prior to the janitorial contractor performing any work in the Premises. The janitorial contractor may only obtain water from, and dispose of water in, the mop sink in the janitorial closet provided as part of the fourth floor common area, and must use that storage area for storage of janitorial supplies. Tenant must provide a list of the names of each janitorial contractor employee who will be working in the Premises to Landlord so a key card can be issued. Tenant will incur charges as stated in section 7)d) below for each key card that is lost, damaged or stolen by any janitorial employee.

d) Security . Tenant shall comply with Landlord's building security system, which may include checking in and out of the Building after hours, or key cards issued by Landlord. Tenant shall pay to Landlord a standard charge (currently $50) for each key card that is lost, stolen or damaged and must be replaced by Landlord. Tenant is responsible for providing and paying for any security personnel that will be assigned exclusively to the Premises. Landlord is responsible for providing the security personnel for all other areas of the Building, including the front lobby. Landlord shall provide building security personnel 6 a.m. to 10 p.m. Monday through Friday, except on holidays, and on Saturday mornings that the County’s WIC office in the Building is open.

 

Page 7 of 22

 
 

 

e) Equipment . Tenant shall maintain, repair and replace all equipment including but not limited to security cameras, office and medical machines, and laboratory and scientific equipment provided and installed by Tenant.

f) Tenant Damage . Tenant shall promptly repair any damage done to the Premises, the Common Area, or the Building caused by any employee, agent, contractor or invitee of Tenant.

g) Access to the Premises . Tenant shall permit Landlord and Landlord’s authorized representatives to enter the Premises at times convenient to tenant for purposes of inspection, making any repairs and performing any work therein as may be necessary for Landlord to comply with the provisions of this Section 7) Landlord, in the performance of any such work, shall cause as little inconvenience, annoyance, disturbance, or damage to Tenant as may reasonably be possible under the circumstances.

h) Utilities . Landlord shall provide all utilities to the Premises and the Common Areas, including electricity, gas, water, sewer, and trash collection.

i Back-Up Generators . Tenant will be entitled to use one of the Landlord’s existing generators located at the Building on or adjacent property owned by Landlord for backup power to Tenant’s freezers and refrigerator only. In the event the existing generators cannot accommodate Tenant’s backup power needs, Tenant will have the right to install a small emergency generator in the yard immediately north of the Building. If Tenant installs a generator, Tenant will be responsible for testing, permitting, maintaining and repairing it.

ii) Chiller . Landlord will permit Tenant to use existing chillers serving the Building should there be sufficient capacity. If, in Landlord’s reasonable judgment, the existing chillers are insufficient to meet Tenant’s needs, Landlord shall provide an additional stand-alone, self-contained chiller sized to support Tenant’s laboratory cooling needs, to be located in the yard immediately north of the building. This separate chiller wil lbe separately metered, and Tenant will pay for the electricity used to run the chiller.

iii) HVAC . Heating, ventilation and air conditioning services (“HVAC”) will be provided to the Premises from 6 a.m. to 6 p.m. Monday through Friday, and from 6 a.m. to noon on Saturdays. If Tenants required hearing, ventilation or air conditioning services at any time other than those hours, Tenant must submit a request for service to Pima County’s Director of Facilities Management or his designee, at least 24 hours in advance of the desired date. The request may be oral. Tenant will pay Landlord an hourly fee for this additional service. The amount of the fee wil be based on actual energy costs incurred to provide the additional HVAC< and it may be adjusted by Landlord from time to time during the Term.
   

Page 8 of 22

 

 
 

i) Telephone/Internet . Tenant may use Landlord's internal local area network and associated telephone system at $35.00 per port (including provided handsets) plus all associated long distance charges, or Tenant may install its own system at its own expense. Any equipment installed by Tenant shall remain the property of Tenant and may be removed upon termination or expiration of the Lease. Tenant shall be responsible for supplying, installing and paying for its telephone equipment, service and internet/data service.

Tenant is responsible for obtaining a network connection from a local ISP and for supplying its own ISP connection hardware; Landlord will provide entry point for ISP into the building and a location for the ISP's network hardware to make the external connection; Landlord will provide a data connection to move Tenant internet traffic from the building entry point up to Tenant closet on 4th floor; Landlord will permit escorted access to Tenant network hardware located outside of Tenant's secured space during normal business hours; Landlord and Tenant will work together to create and implement a wireless network channel allocation plan that prevents network interference. Tenant is responsible for securing Tenant's networks against intrusion through use of encrypted/password-protected wireless connections. Tenant may use Landlord's conduit and fiber, provided that Tenant's use is not higher than would normally be expected for an operation of its type.

8) LICENSURE and REGISTRATION. Tenant will apply for and obtain any license, registration or permit that is required during the Term of this Agreement and will maintain such license, registration or permit in good standing throughout the Term of this Agreement. Tenant shall immediately notify County, in writing, if the license, registration or permit is denied or terminated. In the event of such denial or termination, County may, in its sole discretion, terminate this Agreement with no further obligation to Tenant.

9) TAXES. Tenant shall be responsible for all taxes related to this Lease and Tenant's personal property.

10) INSURANCE. Landlord shall be responsible for fire and other property insurance for the Building, and may self-insure for such losses. Tenant shall be responsible for insuring its personal property brought to the Premises. Tenant shall provide commercial general liability insurance or its equivalent in the amount of $2,000,000.00 for each occurrence. The policy shall be endorsed to include Landlord as an additional insured. Tenant's Worker's Compensation coverage shall contain a waiver of subrogation against Landlord. Tenant must provide Landlord with evidence of insurance prior to moving into the Premises. The Tenant's insurance shall be primary insurance and non-contributory with respect to all other available sources.

 

Page 9 of 22

 

 

 
 

11)      DEFAULT.

a) Tenant Default. The occurrence of anyone or more of the following events shall constitute a default and breach of this Lease by Tenant for which Landlord may terminate this Lease:

i) Monetary Obligations. The failure by Tenant to make any payment required to be made by Tenant hereunder, as and when due, where such failure shall continue for a period of ten (10) calendar days after notice from Landlord that such payment is due.

ii) Violation ofLaw. Use of the Premises for any unlawful or illegal purpose and such use continuing for a period of three (3) days after written notice from Landlord, provided that Tenant shall not be entitled to the benefit of more than one (1) such grace period of three (3) days under this subparagraph ii) during the Term of this Lease.

iii) Health and Safety Violation. Any action or omission by Tenant that, in the Landlord's reasonable judgment, causes a threat to the health or safety of the general public or the users of the Building and such use continuing for a period of two (2) days after written notice from Landlord. Tenant's failure to obtain and maintain any required license and/or registration for its operations at the Premises is considered a violation under this paragraph.

iv) Other Covenants. The failure by Tenant to observe or perform any other of the covenants, conditions or provisions of this Lease to be observed or performed by Tenant, where such failure continues for a period of thirty (30) days after written notice thereof by Landlord to Tenant; provided, however, that if the nature of Tenant's default is such that more than thirty (30) days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said thirty (30) day period and thereafter diligently prosecutes such cure to completion provided such cure is completed within one hundred and twenty (120) days of the notice by Landlord.

b) Landlord Default . Landlord shall be deemed to be in default hereunder if Landlord fails to perform any covenant or condition of this Lease to be performed by Landlord and such failure continues for thirty (30) days after written notice and demand from Tenant (unless the failure is of such a character as to require more than thirty (30) days to cure, in which event Landlord shall be in default only if it fails to initiate the cure within thirty (30) days, and thereafter diligently pursue the same to completion).

c) Remedies . Either party may pursue any remedies provided by law and in equity for the breach of this Lease, including termination of the Lease.

 

Page 10 of 22

 

 

 
 

12) NOTICES. All notices to be given under this Lease shall be in writing and shall be either served personally or sent by certified or registered mail, return receipt requested, to the parties as indicated below or to such other persons or addressees as either party may designate in writing to the other party:

TENANT:   Acceler8 Technology Corporation
    Attn: Lawrence Mehren
    3950 S. Country Club Rd, 4 lh Floor
    Tucson, AZ 85714
   
LANDLORD:   Clerk of the Board of Supervisors
    130 W. Congress St.
    Tucson, Arizona 85701
     
With a copy to:  
    Director, Pima County Facilities Management
    150 W. Congress Street, 3rd Floor
    Tucson, Arizona 85701

13) SUBLEASE AND ASSIGNMENT. Tenant may not assign its interest in this Lease, or sublet any portion of the Premises, without Landlord's prior written consent. Because this Lease is being entered into as part of the County's economic development program, that consent may be withheld by the County if the proposed subtenant or assignee is not, in the County's reasonable judgment, likely to provide the same level of economic benefits anticipated from Tenant's operations (based on economic impact analyses prepared by TREO). In addition, Tenant may not charge any additional sums for any assignment or sublease. Any assignment of this Lease or subletting of the Premises, if permitted, does not constitute a release of any obligations of the Tenant due under this Lease. The Landlord agrees that should it desire to sell the Building, it shall do so only subject to the terms and conditions of this Lease and further agrees to give at least thirty (30) days' notice of any such intent to the Tenant.

14) MODIFICATIONS. Tenant shall make no modifications to the Premises without written approval of Landlord, which shall not be unreasonably withheld.

15) FURNISHINGS. Tenant shall not remove from the Premises any fixtures, furnishings or equipment provided by the Landlord. Tenant may remove any furnishings, fixtures, or equipment paid for and installed by Tenant and shall restore the Premises to its condition prior to the installation of said furnishings, fixtures, or equipment. With Landlord's advance approval, Tenant may leave said items in place and they shall become the property of the Landlord. Tenant shall maintain, repair and replace all furnishings provided and installed by Tenant.

 

Page 11 of 22

 

 

 
 

16) NO LIENS OR INTERFERENCE. Tenant agrees not to incur, or if incurred to promptly remove, any obligations, judgments or other actions which result in a lien or encumbrance on the demised Premises.

17) DESTRUCTION OF PREMISES. If at any time during the Term of the Lease or any extension hereof, the Premises becomes partially or totally destroyed by reason of any damage by fire, flood, hurricane, windstorm or other casualty or act of God and the Landlord cannot or does not fully repair the Premises within ninety (90) days through no fault of the Tenant, the Tenant shall be relieved of any further obligation, duty or liability under this Lease. Ifthe Premises can be and are repaired fully in ninety (90) days, then the Lease shall continue in full force and effect while the repairs are being made, and the Tenant's Rent shall be abated by the percentage of the total space which is unavailable or not reasonably useful to the Tenant.

18) PERSONAL PROPERTY. All personal property placed or moved in the Premises shall be at the risk of the party placing such property on the Premises or moving such property in the Premises.

19) INSPECTION. Landlord shall be given access to Premises to view and inspect its condition and state of repair upon reasonable notice to Tenant.

20)      CONDEMNATION.

a) Complete Taking. Ifthe whole of the Premises is taken or condemned for any public or quasi-public use or purpose, by right of eminent domain or by purchase in lieu thereof, or if a substantial portion of the Premises is so taken or condemned that the portion or portions remaining is or are not sufficient and suitable, in the mutual reasonable judgment of Landlord and Tenant, for the continued operation of the business contemplated by this Lease to be conducted thereon, therein or therefrom so as to effectively render the Premises untenantable, then this Lease and the Term hereby granted shall cease and terminate as of the date on which Tenant is required to vacate the Premises as a result of the condemning authority taking possession and all Rent shall be paid by Tenant to Landlord up to that date or refunded by Landlord to Tenant if Rent has previously been paid by Tenant beyond that date.

b) Partial Taking. If a portion of the Premises is taken, and the portion or portions remaining can, in the mutual reasonable judgment of Landlord and Tenant, be adapted and used for the conduct of Tenant's business operation, then the Landlord shall promptly restore the remaining portion or portions thereof to a condition comparable to their condition at the time of such taking or condemnation, less the portion or portions lost by the taking, and this Lease shall continue in full force and effect except that the Rent payable hereunder shall, if necessary, be equitably adjusted to take into account the portion or portions of the Premises lost by the taking.

Page 12 of 22

 

 
 

21) DAMAGE TO PROPERTY. The Tenant covenants that it will permit no waste or damage to the lease property; that it will keep all improvements placed upon the Premises in reasonably good order and reasonably good state of repair, subject to Section 7) with respect to repair obligations.

22) QUIET ENJOYMENT. Landlord warrants that Landlord is seized of the Premises and has the full right to make this Lease. Landlord further covenants that Tenant shall have quiet and peaceful possession of the Premises during the entire Term as against lawful acts of third parties and as against the acts of all parties claiming title to, or a right to possess, the Premises.

23) EXPENSES ADVANCED BY TENANT. If Landlord fails within thirty (30) days (or such lesser time as is appropriate if there is a threat to health or safety) after requested by Tenant to make such repairs or perform such other act as may be required of Landlord under this Lease, Tenant may cause such repairs to be made or such acts to be performed at the expense of Landlord. Tenant may apply such claims against any subsequent installment of Rent.

24) SIGNS. Tenant may, upon obtaining any necessary permits from governmental authorities, and the advance written approval of Landlord, erect, maintain and repair at Tenant's own expense signs of such dimensions and materials as it may desire. Tenant is responsible for all costs associated with the design, manufacture and connecting any utilities necessary for any signage on the exterior of the Building or in the Premises. Landlord's consent shall not be unreasonably withheld, but Tenant acknowledges that nothing may be mounted on wood doors or other finished wood surfaces.

25) CHANGE IN OWNERSHIP. If ownership of the Premises or the name or address of the party entitled to Rent shall be changed, Tenant may, until receipt of written notice of such change, continue to pay Rent to the party to whom and in the manner in which the last preceding installment of Rent was paid. Tenant shall not be subject to double liability for any Rent so paid.

26) SURRENDER/HOLDING OVER. On termination of Tenant's occupancy, Tenant shall surrender the Premises in the condition in which Tenant is required to maintain them under this Lease. If Tenant for any reason and with written consent of Landlord remains in possession after the expiration of this Lease (including any optional extension), or after the date specified in any notice of termination given by either party, such possession shall be as a month to month Tenant, subject to all conditions of this Lease other than the Term hereof, at the current monthly Rent on the Lease expiration date, except that if Tenant holds over after the Initial Term without having exercised its extension options, the Rent will increase to $19.80 per square foot per year.

27) INTERPRETATION OF LEASE. The parties acknowledge that each has had the opportunity to review this Lease with counsel of its or their choice. This Lease shall not be construed most strongly in favor nor most strongly against either of the parties but shall be interpreted fairly and equitably to effectuate the intent of the parties. All provisions contained in this Lease shall bind and inure to the benefit of the parties hereto, their successors and assigns.

 

Page 13 of 22

 

 
 

28) ENTIRE AGREEMENT. This agreement contains the entire agreement between the parties and all previous agreements, negotiations, or understandings are superseded by and merged in this Lease. This Lease may be modified by the parties only by writing executed with the same formalities as this Lease.

29) NON-DISCRIMINATION. The parties shall comply with all applicable state and federal statutes and regulations governing equal employment opportunity, non-discrimination, and immigration.

30) ARBITRATION. The parties agree that any dispute arising under this Agreement involving the sum of FIFTY THOUSAND DOLLARS ($50,000) or less in money damages only shall be resolved by arbitration pursuant to the Arizona Uniform Rules of Procedure for Arbitration. The decision of the arbitrator(s) shall be final.

31) NON APPROPRIATION. The parties recognize that the performance by Landlord may be dependent upon the appropriation of funds by the Board of Supervisors of the County,or the availability of funding from other sources. Should the Board of Supervisors fail to appropriate the necessary funds, or if funding becomes otherwise not legally available to the County to fund its responsibilities under this Lease, the County may terminate this Lease without further duty or obligation. Landlord agrees to notify Tenant as soon as reasonably possible after the unavailability of said funds comes to the Board's attention.

3 2) CONFLICT OF INTEREST. This Lease is subject to cancellation pursuant to the provisions of Arizona Revised Statute § 38-511 regarding Conflict of Interest.

33) LAW TO GOVERN. This Lease is made under and shall be interpreted according to Arizona law.

34) AMERICANS WITH DISABILITIES ACT. Both parties shall comply with all applicable provisions of the Americans with Disabilities Act (Public Law 101-336,42 U.S.C. 1210112213) and applicable federal regulations under the Act as it pertains to facilities and use of the facilities. This shall not obligate Landlord to make any modifications to the Building, as a result of any change in the law or regulations, if such repairs are not otherwise legally required.

35) SUSTAINABILITY PLAN. In accordance with the Landlord's Sustainability Plan, Tenant will use all reasonable efforts to use recycled products or re-use and recycle materials used in the Premises.

IN WITNESS WHEREOF, we have set our hands and seals on the day and date first written above.

 

Page 14 of 22

  

 
 

ACCELR8 TECHNOLOGY CORPORATION, a Colorado corporation   PIMA COUNTY, a political subdivision of the State of Arizona
     
     
By: /s/ Lawrence Mehren   By: 
Lawrence Mehren, President   Chairman of the Board of Supervisors
     
    Date:
     
     ATTEST:
     
     
     
    Robin Brigode
    Clerk of the Board of Supervisors
     
    APPROVED AS TO CONTENT:
     
     
     
    Director, Facilities Management Dept.
     
    APPROVED AS TO FORM:
     
     
     
    Deputy County Attorney

 

Exhibits:

Exhibit A Building and Parking Area
Exhibit B Premises and Expansion Spaces
Exhibit C Hoor Plan for Tenant Improvements
Exhibit D Rules and Regulations

Page 15 of 22

 

 
 

ACCELR8 TECHNOLOGY CORPORATION, a Colorado corporation   PIMA COUNTY, a political subdivision of the State of Arizona
     
     
By:   By:  /s/ Sharon Bronson
Lawrence Mehren, President   Chairman of the Board of Supervisors
     
    Date: Aug 20 2012
     
     ATTEST:
     
     
    Mary Jo Lig, Deputy
    Robin Brigode
    Clerk of the Board of Supervisors
     
    APPROVED AS TO CONTENT:
     
     
    /s/ 
    Director, Facilities Management Dept.
     
    APPROVED AS TO FORM:
     
     
     /s Regina Nassen
    Deputy County Attorney

 

Exhibits:

Exhibit A Building and Parking Area
Exhibit B Premises and Expansion Spaces
Exhibit C Hoor Plan for Tenant Improvements
Exhibit D Rules and Regulations

Page 15 of 22

 

 
 

EXHIBIT A

 

(Graphic Floor Plan of Building and Parking Area Omitted)

 

 

 

Page 16 of 22

 

 

 
 

EXHIBIT B

 

(Graphic Premises and Expansion Spaces 4th Floor Omitted)

 

 

Page 17 of 22

 

 
 

  

EXHIBIT C

(Graphic Floor Plan for Tenant Improvements Omitted) 

 

 

Page 18 of 22

 

 

 
 

EXHIBIT D
LANDLORD'S RULES & REGULATIONS

 

Re: 3950 S. Country Club, Tucson. Arizona
Tenant: Accelr8 Technology

These Rules & Regulations have been adopted by Landlord in order to set forth standards of conduct that will allow all tenants to enjoy a professional working environment that is compatible with the general character of the building. Landlord reserves the right to make amendments and/or additions to these Rules and Regulations from time to time. These Rules and Regulations are in addition to and shall not be construed to modify or amend any of the terms, covenants, or agreements and conditions of a tenant's lease. Each tenant shall be responsible for informing its employees and invitees as to the provisions of these Rules and Regulations and to enforce same with respect to its employees and invitees. Landlord may waive compliance with anyone or more of these Rules and Regulations for the benefit of a tenant. Such waiver shall not be construed as a waiver for any other tenant, nor shall it prevent Landlord from enforcing the same against any or all other tenants. These rules may only be enforced by Landlord. The failure of Landlord to enforce any Rule or Regulation shall not give any tenant the right to enforce same against another Building occupant. Any concerns about violations of the Rules and Regulations should be addressed to the Building Manager's office or to such other place as Landlord may designate from time to time.

1 . No sign, placard, picture, advertisement, name or notice shall be inscribed, displayed, printed or affixed on or to any part of the inside of the Building without the prior written consent of Landlord. Landlord shall have the right to remove any unapproved sign, placard, picture, advertisement, name or notice without notice to and at the expense of Tenant. All approved signs must be placed or affixed on the wall adjacent to Tenant's entry doors. All approved signs shall be printed, painted, inscribed, affixed or removed at the expense of Tenant by a person approved by Landlord. All walls or other structures where Tenant's signs have been affixed or attached must be restored to their original condition at Tenant's expense after removal of such signs. Nothing may be mounted on wood doors or finished wood surfaces.

2 . Tenant shall not place anything or allow anything to be placed near any window, door, partition or wall that may appear unsightly from outside the Premises, nor shall Tenant cause any window in the Premises to be color treated.

3. The sidewalks, halls, passages, exits, entrances, elevators and stairways shall not be obstructed by Tenant or used for any purpose other than for ingress and egress from Tenant's Premises.

4. Tenant shall not alter any lock or install any new or additional locks or any bolts on any doors or windows of the Premises without prior written consent of Landlord, which will not be unreasonably withheld. Landlord shall have no obligation to open Tenant's Premises due to the loss of keys by Tenant. All requests to open Tenant's Premises to guests or employees must be made by Tenant to Landlord. If Tenant needs to have its leased Premises rekeyed for any reason, Tenant shall use the Landlord's authorized building locksmith. Any rekeying shall keep the applicable lock on the existing building master keyway. Tenant shall bear the entire cost of rekeying, unless the rekeying is requested by Landlord. Any installation or repair of specialty locks shall be at Tenant's expense. Tenant assumes all responsibility for protecting its Premises from theft, robbery, and pilferage, including but not limited to, keeping all means of entry to Premises closed and locked.

 

Page 19 of 22

 

 
 

5. The plumbing facilities shall not be used for any purpose other than that for which they were constructed and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting from a violation of this provision shall be borne by the Tenant whose employee, agent or invitee shall have caused it.
6. Tenant shall not deface the Premises or any part thereof. Tenant will not install, affix or fasten to the rooftop any signs, satellites, or antennas without the prior written approval ofLandlord. Landlord may require design drawings, specifications and/or weight load structural tests prior to granting approval for any rooftop installation. Tenant shall bear the entire expense of any drawings or tests to be submitted to Landlord for approval.
7. No furniture, freight or equipment of any kind shall be brought into the Building without prior notice to Landlord. All moving of items into or out of the Building shall be done at such time and in such manner as Landlord shall designate. Any damage to the elevators, doors, frames, walls or hallway surfaces caused by Tenant or Tenant's invitees or moving contractors shall be repaired at Tenant's expense to Landlord's satisfaction. Landlord shall have the right to prescribe the weight, size and position of all heavy equipment brought into the Building. Heavy objects shall stand on supports of such thickness as is necessary to properly distribute the weight.

8. Tenant shall not use, keep or permit to be used or kept any foul or noxious gas or substance in the Premises, or permit or allow the Premises to be occupied or used in a manner offensive or objectionable to the Landlord or other occupants of the Building by reason of noise, odors and/or vibrations, or that would interfere in any way with other Building occupants or those having business therein. No animals shall be brought in or kept in or about the Premises or the Building except service animals.

9. Tenant shall not use or keep in the Premises or the Building any kerosene, gasoline, or flammable or combustible fluid or material, or use any method of heating or air conditioning other than that supplied by Landlord.

10. Tenant acknowledges that periodically the Tucson Fire Department or other contractor or representative of the Landlord will inspect the Premises for Fire Code compliance and fire, sprinkler, and alarm testing. Tenant, and its employees, contractors and invitees shall comply with any fire safety and handicap procedures and regulations established by the Landlord and/or any governmental agency. Tenant shall distribute to its employees, representatives, contractors and invitees a copy of these Rules and Regulations and all fire drill safety and handicap material provided to it from time-to-time by Landlord and/or any governmental agency. If an audible fire alarm is sounded in the Building, Tenant must take immediate and prudent actions to evacuate its employees, guests or patients from the Building through designated exits as posted by Landlord. Tenant shall notify Landlord in writing of the emergency contact information of two on-site employees or representatives who are responsible for emergency evacuations or fire drills for their Premises. Tenant is responsible for notifying the Landlord in writing of any changes to such assignments. Tenant will notify the Landlord of any handicapped occupants or other individuals who may require special assistance in the event of an emergency.

 

Page 20 of 22

 

 
 

 

11. Pursuant to the Smoke-Free Arizona Act, A.R.S. § 36-601.01, no smoking is allowed in any part of the Building, or within 20' of doors outside the Building. Tenant shall instruct its employees of this regulation.

12. Landlord will direct electricians and/or phone installation employees or contractors as to where and how telephone and computer network cables are to be introduced. No boring or cutting for wires will be allowed without the consent of the Landlord. The location of telephones, call boxes and other office equipment affixed to the Premises shall be subject to the approval of Landlord.

13. Landlord reserves the right, in its sole and reasonable discretion, to increase security services for the Building. Tenant shall be responsible for its share of costs associated with such additional security, based on the percentage of the Building's useable square footage occupied.

14. Outside of Business Hours, Tenant and its employees may access the Building or halls, elevators or stairways in the Building or to the Premises by using the security access card assigned by Landlord. Landlord shall in no case be liable for damages with regard to the admission to or exclusion from the Building of any person. In case of invasion, mob, fire alarm, bomb threat, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building during the continuance of the same by closing of the doors or otherwise, for the safety of the Building occupants and the protection of the Building.

15. Landlord reserves the right to exclude or expel from the Building any person who, in the judgment of Land lord, is intoxicated or under the influence of alcohol or drugs, or who shall in any manner do any act in violation of any of the rules and regulations of the Building or impair the safety of any Tenant, employee, or contractor of Landlord.

16. No machines of any description shall be installed, maintained or operated upon the Premises without the written consent of the Landlord.

17. Tenant shall not disturb, solicit, or canvass any occupant of the Building and shall cooperate to prevent same by others.

 

Page 21 of 22

 

 
 
18. Landlord shall have the right to control and operate the Common Area(s), and the public facilities, and heating and air conditioning, as well as facilities furnished for the common use of the Building occupants, in such manner as Landlord deems best for the benefit and safety of the Building occupants generally.

19. All entrance doors in the Premises shall be locked when the Premises are not in use, and all doors opening to public corridors shall be kept closed except for normal ingress and egress from the Premises. All emergency fire exit doors must remain free of debris from both the interior and exterior and remain locked when not in use.

20. The common hallway immediately adjoining the Premises shall be kept clean and free from dirt and rubbish by Tenant and Tenant shall not place or permit any obstruction or merchandise in such areas.

21. All patio areas, including those adjacent to the common break room, may be utilized only by the Building tenants, and their employees, guests or invitees. No unsightly storage shall be placed upon the patios. Tenant agrees to limit the use of the patio to outdoor furniture such as tables and chairs. There shall be no storage, temporary or permanent, of bicycles, refuse containers or other such unsightly materials on any patio.

22. Upon the termination of the tenancy, Tenant shall deliver to Landlord all keys to the Premises and security access cards for the Building that had been furnished to Tenant.

23. No electrical cooking appliances other than microwave ovens and coffee machines are allowed in the Premises.

 

 

Page 22 of 22

 

 

 

 

Exhibit 10.12

 

 

 

Execution Copy

 

 

 

GRANT AGREEMENT

 

 

between

 

 

ARIZONA COMMERCE AUTHORITY,

an agency of the State of Arizona,

 

 

and

 

 

ACCELR8 TECHNOLOGIES CORPORATION,

a Colorado corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

   

Execution Copy

GRANT AGREEMENT

THIS GRANT AGREEMENT (the “Agreement”), dated to be effective as of August __, 2012 (the “ Effective Date ”), is made by and between the ARIZONA COMMERCE AUTHORITY, an agency of the State of Arizona ( together with its successors and assigns, the “ A uthority ”) ; and ACCELR8 TECHNOLOGIES CORPORATION, a Colorado corporation, (“ Accelr8 ”). The Authority and Accelr8 are sometimes referred to individually as a “ Party ,” and collectively, as the “ Parties ”.

RECITALS :

A.                 The Authority was established by the State of Arizona with a mission to provide private sector leadership in growing and diversifying the economy of the State, and creating high quality employment in the State through expansion, attraction and retention of businesses and marketing the State for the purpose of expansion, attraction and retention of business.

B.                  The Authority has the power and authority, inter alia , to provide grants to qualifying businesses that promote the mission of the Authority.

C.                  Accelr8 has proposed the development, operation and expansion of a business enterprise within the State (the “ Project ”). In its first three years from the Relocation Date, Accelr8 anticipates that the Project will involve the creation of a significant number of new Qualified Jobs (as hereinafter defined), with highly competitive average annual wages and a meaningful Capital Investment (as hereinafter defined). The Parties acknowledge that the foregoing Qualified Jobs and Capital Investment may be created and/or funded, as applicable, by Accelr8 or an affiliate thereof, including one of its subsidiaries.

D.                 Accelr8 is currently headquarted in Colorado, has evaluated the feasibility of developing the Project in Arizona, Colorado and Michigan. In reliance upon the Grant (as hereinafter defined) from the Authority, as well as other State- and County-sponsored incentives, Accelr8 has elected, in the exercise of its discretion and without any legal obligation to do so, to locate the Project in Arizona. The Authority, in view of its mission to promote economic development in Arizona, and based upon independent, third-party fiscal and economic impact projections for the Project commissioned and paid for by the Authority (the “ Economic Study ”) , wishes to incentivize Accelr8 to develop the Project in Arizona by offering a grant (pursuant to A.R.S. § 41-1545.02) to Accelr8 in the amount of $1,000,000.00 (the “ Grant ”) for use in the advancement of the Project, subject in full or in part to Accelr8 achieving the conditions set forth herein, including the employment projection s.

E.                  The Authority has determined, in the exercise of its informed judgment, and based upon the Economic Study, that the objective value of the performance obligations of Accelr8 which have been bargained for in this Agreement, including but not limited to Accelr8’s commitment to create the Qualified Jobs, exceeds the benefits conferred on Accelr8 by the Authority under this Agreement.

F.                   The Parties agree and intend that the acts of the Parties described in and required by this Agreement (including those acts which Accelr8 presently is neither obligated nor under any legal compulsion to do), are specifically and expressly “bargained for” by and between the Parties as part of the Parties’ promised performance to each other, and therefore constitute direct “consideration” to support this Agreement.

 

-2-

 

 

 
 

 

Execution Copy 

G.                 The Authority has determined that Accelr8’s anticipated creation of Qualified Jobs (as hereinafter defined) will enhance the economic vitality of Arizona by generating employment opportunities and tax revenues that would not otherwise exist but for Accelr8’s development and implementation of the Project in Arizona pursuant to the terms of this Agreement, and has further determined that the Grant will be of material benefit to Arizona in light of such employment opportunities and revenues generated by the development and implementation of the Project in Arizona and potential future expansion of the Project in this State.

H.                 In furtherance of the benefits it has concluded will be obtained by Arizona as a result of the Grant, the Authority has agreed to make a separate Loan (as hereinafter defined) to Pima County, Arizona for the purpose of funding certain real estate and building improvements to a facility in Tucson, Arizona that will house the Project.

I.                    Based on the Grant and other considerations provided by the Authority, and acting in material reliance thereon, Accelr8 has agreed to locate and develop the Project in Arizona.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants, conditions, representations and warranties herein contained, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE 1: DEFINITIONS

1.1.             Defined Terms . For purposes of this Agreement, the following terms shall have the meanings ascribed to them below, unless the context requires otherwise:

1.1.1.             Accelr8 ” shall have the meaning set forth in the first grammatical paragraph of this Agreement;

1.1.2.             Accelr8 Information ” shall have the meaning set forth in Section 8.6 ;

1.1.3.             Accelr8’s Closing Affidavit ” shall mean Accelr8’s Closing Affidavit in form and substance satisfactory to the Authority, to be executed and delivered by Accelr8 to the Authority at the Closing, substantially in the form attached hereto as Exhibit A ;

1.1.4.             Agreement ” shall mean this Grant Agreement and all exhibits and supplements hereto as it or they may be amended or supplemented from time to time as provided in this Agreement;

1.1.5.             Applicable Laws ” shall mean the federal, state, county and local laws (statutory and common law), ordinances, rules, regulations, permit requirements, and other requirements and official policies of the State of Arizona (or any applicable political subdivision or agency thereof) which apply to the Project as of the Effective Date;

 

-3-

 

 
 

 

Execution Copy

1.1.6.             Arizona Investment ” shall mean compliance with all of the following:

A.     As soon as reasonably practicable but in no case later than one year from the Effective Date, Accelr8 shall relocate substantially all of its existing operations, including its corporate headquarters, to Arizona and shall retain those currently-existing operations, together with expanded operations associated with the Project, in Arizona through the Maturity Date; and

B.      Within three years after the Relocation Date, the Project shall create in Arizona at least 65 new Qualified Jobs (“ Qualified Jobs ”) in Arizona and shall retain the new Qualified Jobs in Arizona through the Maturity Date; and

C.      Within three years after the Relocation Date, Grantee shall make a Capital Investment (as hereinafter defined) in the Project of at least $4,520,000.00.

1.1.7.             Authority ” shall have the meaning set forth in the preamble of this Agreement;

1.1.8.             Business Day ” shall mean any day of the year, excluding Saturday, Sunday and any day which is a legal holiday or a day on which banking institutions are authorized by law or other governmental actions to close and are actually closed in Phoenix, Arizona;

1.1.9.             Capital Investment ” shall mean the aggregate of all expenditures by or on behalf of Accelr8 (or an affiliate thereof) to acquire or lease real property, improve real property, and acquire or lease tangible personal property that is (or will be) used in operating or advancing the Project, including, but not limited to, land, buildings, machinery, equipment (whether located at real property owned or leased by Accelr8 (or an affiliate) or used by Accelr8 (or an affiliate) personnel and fixtures (including but not limited to any lease payments made by Accelr8 prior to the Maturity Date;

1.1.10.         Close Out Report ” shall have the meaning described in Section 6.1.3 ;

1.1.11.         Corporate Succession ” means (i) a sale or transfer of all or substantially all of Accelr8’s business assets, (ii) a change in the form of business entity (or State of domestication) through which Accelr8 conducts its business, or (iii) the merger or consolidation of Accelr8 with another business entity , in each case where such entity assumes all liabilities and obligations of Accelr8 hereunder , or (iv) the acquisition of all the outstanding capital stock of Accelr8 by another entity.

1.1.12.         Default ” shall mean the happening or occurrence of any event or circumstance which, with notice or the lapse of time, or both, would constitute an Event of Default as defined in this Agreement;

1.1.13.         Economic Study ” shall have the meaning set forth in Recital D ;

 

-4-

 

 
 

 

Execution Copy 

1.1.14.         Effective Date ” shall have the meaning set forth in the first grammatical paragraph of this Agreement;

1.1.15.         Event of Default ” shall mean any of the events described in Section 8.1 ;

1.1.16.         Governmental Authority ” shall mean, as applicable, the United States of America, the State of Arizona, and any other political subdivision, agency, or instrumentality exercising jurisdiction over Accelr8;

1.1.17.         Grant ” shall have the meaning set forth in Recital D ;

1.1.18.         Grant Payments ” shall mean the incremental payments of the Grant from the Authority to Accelr8 pursuant to Milestone Grant Payments in accordance with the achievement of Milestones;

1.1.19.         Loan ” shall mean the loan in the amount of $700,000 to be made by the Authority to Pima County, Arizona for the purpose of funding certain real estate and building improvements to a facility in Tucson, Arizona;

1.1.20.         Maturity Date ” shall mean the date which is five years from the Relocation Date;

1.1.21.         Measurement Date ” shall mean the date which is three years from the Relocation Date;

1.1.1.                Milestone ” shall mean generally one of Milestone One, Two, Three or Four (each as hereinafter defined);

1.1.2.                Milestone One ” shall mean Accelr8 completing the following:

(i) Relocation of substantially all existing Accelr8 operations, including its corporate headquarters, to Arizona; and

(ii) Creation of 15 Qualified Jobs;

1.1.3.                Milestone Two ” shall mean Accelr8 having created an aggregate of 30 Qualified Jobs (including Qualified Jobs under Milestone One);

1.1.4.                Milestone Three ” shall mean Accelr8 having created an aggregate of 40 Qualified Jobs (including Qualified Jobs under Milestone One and Milestone Two);

1.1.5.                Milestone Four shall mean the date that is the earlier of the Measurement Date or the date upon which Accelr8 has completed both of the following:

(i) Created in excess of 65 Qualified Jobs (including Qualified Jobs under Milestone One, Milestone Two and Milestone Three); and 

(ii) Made a Capital Investment of at least $4,520,000.00.

-5-

 

 

 
 

 

Execution Copy 

1.1.22.         Milestone One Grant Payment ” shall mean a payment from the Authority (via the Escrow Account) to Accelr8 equal to the product of the Multiplier x $250,000;

1.1.23.         Milestone Two Grant Payment ” shall mean a payment from the Authority (via the Escrow Account) to Accelr8 equal to the product of the Multiplier x $250,000;

1.1.24.         Milestone Three Grant Payment ” shall mean a payment from the Authority (via the Escrow Account) to Accelr8 equal to the product of the Multiplier x $250,000;

1.1.25.         Milestone Four Grant Payment ” shall mean a payment from the Authority (via the Escrow Account) to Accelr8 calculated as follows:

(i) the product of (the product of the total number, not to exceed 65, of Qualified Jobs created and maintained through Milestone Four x $13,076.93) x the Multiplier;

plus

(ii) the product of $150,000 x the quotient of the Capital Investment made to date, up to $4,520,000.00 ÷ $4,520,000;

minus

(iii) total Grant Payments made to date.

In the event that the amount calculated under the foregoing formula is negative, Accelr8 shall be required to pay the additive inverse of that amount to the Authority, which payment shall be due within ten Business Days after written notice thereof to Accelr8 .

1.1.26.         Multiplier ” shall be the lesser of (i) 1 or (ii) the quotient of the average annual wages (including salary, bonuses and other payments designated by any applicable taxing authority as personal income) of all Qualified Jobs created by Accelr8 as of the applicable Milestone ÷ $70,000. For clarification, the determination of average annual wages does not require Accelr8 to include all jobs across its workforce but only those that it designates in its sole discretion as a Qualified Job for purposes of a Milestone;

1.1.27.         Notice and Cure Period ” shall mean, as used in this Agreement, 5:00 p.m. Arizona Time on the 60 th day after the deemed receipt by Accelr8 from the Authority or by the Authority from Accelr8 , in accordance with Section 8.1 , of a written notice of failure to perform any covenant or agreement or to pay when due any payment of principal, interest, fees, late charges, or other sums due under the this Agreement, during which 60-day period the payment may be made or the performance undertaken and completed;

1.1.28.         Party ” or “ Parties ” shall have the meaning set forth in the preamble of this Agreement;

 

-6-

 

 
 

 

Execution Copy 

1.1.29.         Person ” means an individual, partnership, corporation (including a business trust), joint stock company, trust, unincorporated association, joint venture, limited liability company or other entity, or a government or any political subdivision or agency thereof;

1.1.30.         Processing Fee ” shall mean the sum of $10,000.00 due the Authority and paid by Accelr8 from the Grant;

1.1.31.         Progress Report ” shall be provided pursuant to Section 6.1 and in the form set forth on Exhibit B of this Agreement; provided that Accelr8 will endeavor to cooperate with an additional reasonable requests for information made by the Authority;

1.1.32.         Project ” shall have the meaning set forth in Recital C;

1.1.33.         Qualified Job ” shall mean a job that is permanent (i.e., not seasonal, on a contract basis for a prescribed period or otherwise temporary), full-time (designated as such by Accelr8 in its reasonable discretion), new to Arizona, and for which Accelr8 pays average (across all Qualified Jobs identified solely by Accelr8 in its discretion for purposes of a Milestone) annual wages (including salary, bonuses and other payments designated by any applicable taxing authority as personal income) of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums. For clarification, the determination of average annual wages does not require Accelr8 to include all jobs across its workforce but only those that it designates in its sole discretion as a Qualified Job for purposes of a Milestone; and

1.1.34.         Relocation Date ” shall mean the earlier of (i) the one year anniversary of the Effective Date or (ii) the date that Accelr8 officially changes its headquarters to Arizona as evidenced by the Kino facility being completed and Accelr8 employees working there.

1.1.35.         State ” shall mean the state of Arizona.

ARTICLE 2: AUTHORITY’S AGREEMENT TO MAKE THE GRANT AND LOAN

2.1 Agreement to Pay the Grant Funds into Escrow . Within three Business Days after execution and delivery to the Authority of this Agreement, the Escrow Agreement and the Closing Affidavit by Accelr8 and Escrow Agent (as applicable) , the Authority shall pay the full amount of the Grant ($1,000,000), net of the Processing Fee, into an escrow account (the “ Escrow Account ”), which shall be administered by Alliance Bank of Arizona (the “ Escrow Agent ”) and governed by an Escrow Agreement among the Parties and the Escrow Agent in the form set forth on Exhibit C to this Agreement (“ Escrow Agreement ”).

2.2 Schedule of Grant Payments from Escrow . The Authority shall d irect the Escrow Agent in writing to release the funds in the Escrow Account pursuant to the following schedule (or, in the case of Milestone Four, the Authority shall, if applicable, notify Accelr8 in writing that it owes a payment to the Authority):

2.2.1 The Milestone One Grant Payment following submission of a Progress Report evidencing achievement of Milestone One; provided, however, that if Milestone One has not occurred by the Measurement Date, no Milestone One Grant Payment shall be made .

 

-7-

 

 
 

 

Execution Copy 

2.2.2 The Milestone Two Grant Payment following submission of a Progress Report evidencing achievement of Milestone Two; provided, however, that if Milestone Two has not occurred by the Measurement Date, no Milestone Two Grant Payment shall be made .

2.2.3 The Milestone Three Grant Payment following submission of a Progress Report evidencing achievement of Milestone Three; provided, however, that if Milestone Three has not occurred by the Measurement Date, no Milestone Three Grant Payment shall be made.

2.2.4 The Milestone Four Grant Payment following submission of a Progress Report evidencing achievement of Milestone Four.

2.3 Time Periods for Payments . Within 10 Business Days following submission of a complete Progress Report supporting an applicable Milestone Payment, the Authority must instruct the Escrow Agent in writing (with a copy to Accelr8 in accordance with Section 8.1) to release the applicable Milestone Grant Payment to Accelr8.

2.4 No Further Payments for Activities After the Measurement Date . Except in relation to any dispute between the Parties about any outstanding amounts or payments due Accelr8 and subject to Section 7.1.1 , any unpaid portion of the Grant to which Accelr8 has not become entitled as of the Measurement Date (as reflected in a Progress Report submitted by Accelr8 and accepted as final by the Authority), shall be returned to the Authority by the Escrow Agent and shall no longer be available to Accelr8.

2.5 No Representation or Warranty Regarding Tax Treatment . The Authority expressly disclaims any representation or warranty with respect to the treatment of the Grant to Accelr8 under any state, local, or federal income (or similar) taxation statutes, ordinances, or regulations.

2.6 Loan to Local Jurisdiction . Contemporaneous with the funding of the Grant into the Escrow Account, the Authority shall pay the full amount of the Loan ($700,000) to Pima County. Accelr8 shall be under no obligation to guarantee or repay the Loan.

2.7 Processing Fee . Accelr8 agrees to pay to the Authority the Processing Fee which is and shall be earned by the Authority’s making the Grant, and the Authority’s rights in and to the Processing Fee shall not be contingent upon any other act by the Authority or any event or occurrence whatsoever.

ARTICLE 3: CONDITIONS TO THE GRANT

3.1                 Conditions to the Grant . As a condition to receiving a Grant payment, Accelr8 shall have satisfied (or caused to be satisfied) the conditions and requirements specifically set forth below in this Section 3.1 , provided, however, that the condition set forth in Section 3.1.1(i) below shall apply only to the Milestone One Grant Payment and shall not apply to any other Milestone payments or to Accelr8’s eligibility for any Arizona tax credits except as may be separately required by applicable statute under such tax credit programs:

3.1.1 Accelr8 shall have delivered to the Authority the following documents, duly executed and acknowledged as necessary:

 

-8-

 

 
 

 

Execution Copy  

(i) Accelr8’s Closing Affidavit, for the Milestone One Grant Payment only;

(ii) Certificates of Good Standing, (a) issued by the state in which Accelr8 is domiciled confirming that Accelr8 is in good standing in such state, and (b) issued by the Arizona Corporation Commission confirming that Accelr8 is in good standing as a foreign corporation in the State of Arizona; and

(iv) Evidence, in form and content reasonably satisfactory to the Authority, that Accelr8 owes no delinquent taxes to a taxing jurisdiction in the State; and

(v) Evidence, in form and content reasonably satisfactory to the Authority, that Accelr8 is registered with and is participating in the E-Verify program pursuant to A.R.S. § 23-214.

3.1.2 No Event of Default shall exist.

ARTICLE 4 : REPRESENTATIONS AND WARRANTIES OF THE AUTHORITY

The Authority hereby represents to Accelr8 as of the Effective Date as follows:

4.1                 The Authority is duly created pursuant to A.R.S. §§41-1501 et seq.;

4.2                 The Authority has duly authorized its Interim President and Chief Executive Officer, Sandra Watson, to enter into this Agreement on behalf of the Authority; and

4.3                 The Authority knows of no litigation, proceeding, initiative, referendum, investigation or threat of any of the same contesting the powers of the Authority or its officials with respect to this Agreement that has not been disclosed in writing to Accelr8.

ARTICLE 5: REPRESENTATIONS AND WARRANTIES OF ACCELR8

Accelr8 hereby represents and warrants to the Authority as of the Effective Date as follows:

5.1                 To the best of Accelr8’s knowledge and belief, all information supplied or delivered to the Authority by Accelr8 in connection with the transactions contemplated by this Agreement is materially true, correct, and complete as of the dates specified therein;

5.2                 No material adverse change has occurred in the financial condition of Accelr8 since the dates of the financial statements;

5.3                 Except as may have previously been disclosed, in writing, to the Authority, there are no actions, suits, or proceedings pending or, to Accelr8’s knowledge after due diligence, threatened in any court or before or by any Governmental Authority which materially and adversely affect Accelr8’s ability to pay and perform Accelr8’s obligations under the Agreement, or which involve the validity, enforceability, or priority of any of the Agreement;

5.4                 The Agreement constitutes a valid and binding obligation of Accelr8, enforceable in accordance with its terms. The consummation of the transactions contemplated hereby and the performance of any of the terms and conditions hereof will not result in a breach of or constitute a default under any mortgage, deed of trust, promissory note, credit agreement, judgment or any other agreement to which Accelr8 is a party or by which Accelr8 may be bound;

 

-9-

 

 
 

 

Execution Copy 

5.5                 Accelr8 has examined and is familiar with all conditions associated with the Grant, as set forth herein;

5.6                 Accelr8 is a Colorado corporation, duly formed and validly existing under the laws of the State of Colorado, as currently enacted, and Accelr8 has the full corporate power and authority to enter into this Agreement and to carry out the transactions contemplated to be carried out hereunder. The persons signing this Agreement on behalf of Accelr8 have full corporate power and authority to do so. All necessary consents, approvals, resolutions and other action required to duly authorize, execute and deliver the Agreement and to perform thereunder, to the extent required by Accelr8 for such authorization, execution, delivery and performance thereunder, have been obtained or taken by Accelr8;

5.7                 To the best of Accelr8’s knowledge and belief, there are no attachments, levies, executions, assignments for the benefit of creditors, receiverships, conservatorships or voluntary or involuntary proceedings in bankruptcy or pursuant to any other debt or relief laws pending against Accelr8 or currently contemplated by Accelr8;

5.8                 To the best of Accelr8’s knowledge and belief, Accelr8 has timely filed all material federal, state, and local tax returns due during calendar year 2011, and has paid all of its current material tax-related obligations before delinquent or has obtained an extension therefor, including all material federal, state and local taxes, except for such returns, obligations, and payments which are being contested in good faith; and

5.9                 Accelr8 does not have scrutinized business operations in Iran or Sudan, in accordance with A.R.S. §35-393 et seq. and A.R.S. §35-391 et seq .

Accelr8 acknowledges and agrees that , for Accelr8’s purposes , this Agreement constitutes the written agreement required by and referred to in A.R.S. § 41-1545.02.  

ARTICLE 6: ADDITIONAL COVENANTS AND AGREEMENTS OF ACCELR8

6.1                 Progress Reports ; Close Out Report . Accelr8 shall submit Progress Reports to the Authority in accordance with the following schedule:

6.1.1 Annually, on or before July 31 of each year within the term of this Agreement, reporting on the twelve-month period ending the previous June 30 (the Authority’s fiscal year) ;
6.1.2 Upon or after achievement of each Milestone, reporting on the period from the Effective Date through the date of achievement of the most recent Milestone (these Progress Reports shall hereinafter be referred to as the “ Milestone Reports ”); provided that the Milestone Report due following Milestone Four shall be submitted no later than 20 days after the Measurement Date;
     
-10-
 
 
 
 
     
     
    Execution Copy 
     
6.1.3 Upon the Relocation Date; and
6.1.4 Within 20 Business Days after the Maturity Date, reporting on the period from Effective Date through the Maturity Date (this Progress Report shall hereinafter be referred to as the “ Close Out Report ”).

Except as provided in the preceding sentence, there shall be no filing deadline for Milestone Reports. Accelr8’s failure to timely submit a Progress Report, or to otherwise comply with conditions of receiving Grant Payments under this Agreement, including without limitation those set forth in Article 3 , shall have the effect of correspondingly deferring any time requirements imposed hereunder on the Authority relating to any payment obligations associated with the late Progress Report. Notwithstanding the preceding sentence, if Accelr8 fails to submit a required Progress Report or to otherwise comply with conditions of receiving Grant Payments under this Agreement, including without limitation those set forth in Article 3 , within three months after such condition being due, then subject to a Notice and Cure Period, Accelr8 shall be required to repay all net Grant proceeds received hereunder, within 10 Business Days following written notice thereof from the Authority, and the Authority shall be forever relieved of its obligations hereunder. Progress Reports shall require Accelr8 to disclose only such information necessary for the Authority to determine whether Accelr8 has satisfied the requirements set forth herein.

6.2        Within 10 Business Days from receipt of each Progress Report, the Authority shall take one of the following actions with respect to the report and convey such action, together with a statement of the reasons for such action, to Accelr8 in writing (including by E-mail, notwithstanding anything herein to the contrary): (i) accept the contents of the report in whole, (ii) accept the contents of the report in part and reject the contents of the report in part, (iii) reject the contents of the report in whole, or (iv) reasonably request additional information to assist with the Authority’s review of the report. In the event the Authority does not timely respond to a Progress Report, then, subject to a Notice and Cure Period, the Progress Report will be deemed accepted and the Parties’ rights will be established as provided herein based on the information in the Progress Report . In the event the Authority does request additional information to assist with its review of a Progress Report, the Parties shall work in good faith to resolve any open issues, and the Authority’s response obligations with respect to the original Progress Report shall apply to each receipt, in writing, of such additional information requested by the Authority; provided, however, that the Authority shall use best efforts to address and notify Accelr8 of all open issues at each step and shall not request additional information from Accelr8 for the purposes of avoiding its timing obligations under this section. Under no circumstances shall the Authority have longer than 45 days in which to make a final decision with respect to a Progress Report so long as Accelr8 has timely responded to all reasonable information requests during the preceding time period. If the Authority rejects the contents of a Progress Report, in whole or part, Accelr8 shall have such appeal rights with respect to such decision as are available for Authority actions.

6.3                 Accelr8 shall pay when due all of its own costs and expenses required by or incident to this Agreement and the Project, including, without limitation all taxes and assessments applicable to the Project, other than such taxes and assessments as are actively contested by Accelr8, in good faith, by appropriate proceedings.

6.4                 Accelr8, at the Authority’s cost, shall permit the Authority, upon reasonable notice during normal business hours and subject to Accelr8’s security policies, while this Agreement is in effect, and for one (1) year thereafter, to examine and audit such books and records of Accelr8 as are necessary for the Authority to determine whether Accelr8 has performed the Arizona Investment and the other conditions set forth herein.

 

-11-

 

 
 

 

Execution Copy 

ARTICLE 7: EVENTS OF DEFAULT; REMEDIES

7.1 Event of Default . The occurrence of any of the following shall constitute an Event of Default by Accelr8 under this Agreement:

7.1.1 Subject to the Notice and Cure Period, the failure by Accelr8 to comply with, perform and discharge, fully and timely, any material covenant, agreement, condition or obligation to be performed by Accelr8 hereunder; provided, however, that if such cure shall require more than 60 days to complete, Accelr8 shall not be in default hereunder so long as Accelr8 shall commence such cure within the 60-day period and thereafter diligently prosecute such cure to completion; and further provided, that such cure is completed within 60 days thereafter .

7.1.2 The appointment of a receiver, trustee, conservator, or liquidator for Accelr8, or in respect of any of the Project, or any material part of any other property of Accelr8;

7.1.3 The filing of a voluntary petition in bankruptcy against or by Accelr8, or by the filing of any petition or answer seeking or acquiescing in any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief for or against Accelr8, under any present or future federal, state or other statute, law or regulation relating to bankruptcy, insolvency, or other relief for debtors; the filing of an involuntary petition in bankruptcy for or against Accelr8, which is not dismissed within 60 days following such filing; if Accelr8 becomes “insolvent” as that term is defined in Section 101(26) of the Bankruptcy Code, Title 11 of the United States Code, 11 U.S.C. 101, et seq .; or if Accelr8 shall make any general assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts generally as they become due; or if Accelr8 shall solicit any creditors of Accelr8 to file an involuntary petition against Accelr8.

7.1.4 The validity or enforceability of the Agreement, at law or in equity, or before any Governmental Authority, is challenged by Accelr8.

7.2 Remedies of Authority . Upon the occurrence of an Event of Default by Accelr8, the Authority shall have the following remedies available to it:

7.2.1            Failure to deliver the Arizona Investment . In the event Accelr8 does not continuously maintain the Qualified Jobs for which Accelr8 receives Milestone Grant Payments through the Maturity Date (as reflected in a final Close Out Report), Accelr8 shall owe the Authority all or a portion of the Grant calculated as follows (assuming it is a positive number): the number of Qualified Jobs for which Accelr8 received a Grant Payment but which were not retained through the Maturity Date multiplied by $12,923.

-12-

 

 

 

 
 

Execution Copy 

 

If the Authority determines, following receipt of the Close Out Report, that Accelr8 owes any amounts to the Authority under this Section, the Authority shall give written notice thereof to Accelr8 and Accelr8 shall pay such amounts within 30 Business Days following receipt of such notice. Notwithstanding anything herein to the contrary, r equiring repayment by Accelr8 under Section 1.1.23 or this Section are the exclusive remedies of the Authority for Accelr8’s failure to deliver the Arizona Investment. In the event of any action by the Authority to recover any such amounts required to be repaid by Accelr8, in whole or in part, the Authority shall be entitled to recover interest on such amounts at the rate of 5% per annum from the Maturity Date , plus its reasonable attorneys fees and costs if it is the prevailing party in such action.

7.2.2 Other Breaches; Remedies of Authority Cumulative . Except as set forth herein, i n the event of any other uncured breach of any provision of this Agreement by Accelr8 , except as provided herein , the Authority shall have all of the rights and remedies granted herein and all other rights and remedies available at law or in equity, and these same rights and remedies shall be cumulative and may be pursued separately, successively, or concurrently against Accelr8.

7.4 Remedy of Accelr8 . Upon the occurrence of any breach of this Agreement by the Authority, Accelr8, as its sole and exclusive remedy against the Authority, subject to the Notice and Cure Period, may seek specific performance of the Authority’s obligations arising under this Agreement.

7.5 Nonliability of Authority’s Officials . Notwithstanding anything in this Agreement to the contrary, no officer, representative, agent, attorney or employee of the Authority shall be personally liable to any other Party hereto, or to any successor in interest to such Party, in the event of any non-performance or breach by the Authority with respect to any obligation of the Authority under the terms of this Agreement.

7.6 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES ARISING OUT OF THIS AGREEMENT. IN NO EVENT SHALL AN AWARD OF DAMAGES EXCEED THE AMOUNT OF THE GRANT, BUT SUCH AWARD TO THE AUTHORITY MAY, IN ADDITION, INCLUDE ITS REASONABLE ATTORNEY’S FEES AND COSTS.

ARTICLE 8: GENERAL TERMS AND CONDITIONS

8.1                 Notices . All notices, demands, requests, and other communications required or permitted hereunder shall be in writing and shall be delivered by hand, telegram, facsimile or deposited with the United States Postal Service postage prepaid, registered or certified mail, return receipt requested, or delivered by courier or personal delivery addressed as follows:

If to the Authority: Arizona Commerce Authority
  333 North Central Avenue, Suite 1900
  Phoenix, Arizona 85004
  Attn: Greg Linaman
  Telephone No.: 602-845-1255
  Facsimile No.: 602-845-1201
   

 

-13-

 

 

 

 

 
 

 

Execution Copy

 

with a required copy to: Mariscal, Weeks, McIntyre & Friedlander, P.A.
  2901 North Central Avenue, Suite 200
  Phoenix, Arizona 85012
  Attn: David I. Thompson, Esq.
  Telephone No.: 602-285-5021
  Facsimile No.: 602-285-5100
   
If to Accelr8: Accelr8 Technologies Corporation
   
   
  Attn: Lawrence Mehren, CEO
  Telephone No.:
  Facsimile No.:
   
with a required copy to: Snell & Wilmer L.L.P.
  One Arizona Center
  Phoenix, AZ 85004-2202
  Attn: Daniel M. Mahoney, Esq.
  Telephone No.: 602-382-6000
  Facsimile No.: 602-382-6070

 

All notices, requests, demands or other communications that are required or may be given pursuant to the terms of this Agreement will be in writing and will be deemed to have been duly given: (i) on the date of delivery, if personally delivered by hand, (ii) upon the fifth day after such notice is deposited in the United States mail, if mailed by registered or certified mail, postage prepaid, return receipt requested, (iii) upon the date scheduled for delivery after such notice is sent by a nationally recognized overnight express courier if the delivery date is a Business Day, or otherwise on the next Business Day or (iv) if delivered by facsimile, courier or by personal delivery, then notice is deemed delivered upon the date and time of confirmed, actual receipt or refusal of delivery by the representative’s agents and employees of Accelr8. Any Party may designate a different address or person to whom such notices should be sent by giving notice thereof as provided in this Section 8.1 , which change of address shall be effective upon receipt.

8.2                 Indemnity . To the fullest extent permitted by law, Accelr8 hereby indemnifies, and agrees to defend, pay and hold harmless the Authority and the Authority’s directors, officers, agents and employees for, from and against any and all liability, expense or damage of any kind or nature and from any suits, claims or demands, including reasonable legal fees and expenses, arising from the gross negligence or willful misconduct of Accelr8 in connection with this Agreement. Upon receiving knowledge of any suit, claim or demand asserted by a third party that the Authority believes is covered by this indemnity, the Authority shall give Accelr8 prompt notice of the matter and an opportunity to defend the Authority, at Accelr8’s sole cost and expense. The Authority shall be responsible for complete and active cooperation with Accelr8 in defense of such claims, without compensation from Accelr8. The Authority shall not settle any such claims, suits, or demands without prior written consent of Accelr8. Accelr8 shall pay any and all valid claims of any brokers or agents with whom it has dealt who claim a right to any fees in connection with arranging the financing created pursuant to this Agreement, and shall hold the Authority harmless from such claims, whether or not they are valid. The obligations of Accelr8 in this Section 8.2 shall survive the termination of the Agreement and the repayment (if any) thereof for a period of one year. . No provision of this Agreement may be amended or modified, except by written instrument executed by the Party against whom such amendment or modification is sought to be enforced.

 

-14-

 

 

 
 

Execution Copy

 

8.4                 Limited Severability . The Authority and Accelr8 each believes that the execution, delivery and performance of this Agreement are in compliance with all Applicable Laws. However, in the unlikely event that any provision of this Agreement is declared void or unenforceable (or is construed as requiring the Authority to do any act in violation of any Applicable Laws, constitutional provision, law, regulation, code or charter), such provision shall be deemed severed from this Agreement, and this Agreement shall otherwise remain in full force and effect; provided that this Agreement shall retroactively be deemed reformed to the extent reasonably possible in such a manner so that the reformed agreement (and any related agreements effective as of the same date) provide essentially the same rights and benefits (economic and otherwise) to the Parties as if such severance and reformation were not required. Unless prohibited by Applicable Laws, the Parties further shall perform all acts and execute all amendments, instruments and consents necessary to accomplish and to give effect to the purposes of this Agreement, as reformed.

8.5                 No Waiver; the Authority’s Standard for Consents . No waiver by the Authority or Accelr8 of any of its respective rights or remedies hereunder, shall be considered a waiver of any other or subsequent right or remedy; no delay or omission in the exercise or enforcement by the Authority or Accelr8 of any rights or remedies shall be construed as a waiver of any other right or remedy; and, to the extent permitted by applicable law, no exercise of enforcement of any such rights or remedies shall be held to exhaust any right or remedy of the Authority or Accelr8. Unless otherwise provided in this Agreement, all consents of the Authority or Accelr8 permitted or required under this Agreement shall be given or withheld in such Party’s sole discretion.

8.6                 Confidentiality . The Authority may not disclose to any Person any confidential, proprietary or non-public information of Accelr8 furnished to the Authority by Accelr8 or its representatives (such information being referred to collectively herein as the “ Accelr8 Information ”), except that the Authority may disclose Accelr8 Information (i) to its and its affiliates’ employees, officers, directors, agents and advisors who have a need to know (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Accelr8 Information and instructed to keep such Accelr8 Information confidential on substantially the same terms as provided herein and provided further that the Authority shall be responsible for any disclosure by such Persons to whom the Authority makes disclosure), (ii) to the extent required by Applicable Laws or regulations or by any subpoena or similar legal process, (iii) in connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this Agreement or the enforcement of rights hereunder, and (iv) with the consent of Accelr8. The obligations under this Section 8.6 shall survive the termination of this Agreement.

8.7                 No Third Party Beneficiary . This Agreement is for the sole benefit of the Authority and Accelr8 and is not for the benefit of any third party, other than the indemnified parties referenced in Section 8.2 .

 

-15-

 

 
 

   

Execution Copy

8.8                 Number and Gender . Whenever used herein, the singular number shall include the plural and the singular and the use of any gender shall be applicable to all genders.

8.9                 Captions . The captions, headings, and arrangements used in this Agreement are for convenience only and do not in any way affect, limit, amplify, or modify the terms and provisions hereof.

8.10             Governing Law; Venue . This Agreement shall be deemed to be made under, shall be construed in accordance with, and shall be governed by the internal, substantive laws of the State of Arizona (without reference to conflict of law principles). Any action brought to interpret, enforce or construe any provision of this Agreement shall be commenced and maintained solely and exclusively in the Superior Court of the State of Arizona in and for the County of Maricopa (or, as may be appropriate, in the Justice Courts of Maricopa County, Arizona, or in the United States District Court for the District of Arizona). The Parties irrevocably consent to sole and exclusive jurisdiction and venue in such courts for such purposes and waive all rights to seek transfer or removal of any action commenced under or in connection with this Agreement.

8.11             Time of the Essence . Time is of the essence with respect to each and every term and condition of this Agreement to be performed by the Parties hereunder.

8.12             Attorneys’ Fees . In the event of a breach by any Party of any provision of this Agreement and commencement of a subsequent legal action in an appropriate forum, or in the event of an action seeking a declaration of the rights or liabilities of the Parties, the prevailing Party in any such dispute shall be entitled to reimbursement of its reasonable attorney's fees and court costs, including, but not limited to, its costs of expert witnesses, transportation, lodging and meal costs of the parties and witnesses, costs of transcript preparation and other reasonable and necessary direct and incidental costs of such dispute.

8.13             Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall be deemed one and the same document.

8.14             Recitals . The Recitals are incorporated herein by this reference and made an integral part hereof.

8.15             Successors Bound . This Agreement shall inure to the benefit of, and shall be binding upon, each of the Parties and their successors and assigns hereunder.

8.16             Publicity . Accept as otherwise required by applicable laws, rules or regulation, neither Party shall issue any press release or make any other public announcement concerning this Agreement without the prior written consent of the other Party, which consent may be granted or withheld for any or no reason.

8.17             Protection of Confidential Information . The Authority acknowledges that information submitted by Accelr8 or made available by Accelr8 to the Authority prior to the date hereof, and information which Accelr8 may submit or make available to the Authority after the date hereof (including all information contained on any progress report submitted by Accelr8 to the Authority as required by this Agreement and/or A.R.S. §41-1545.03), includes or will include when submitted or made available in the future highly confidential information (“ Accelr8 Confidential Information ”), the disclosure of which to parties other than the Authority would divulge trade secrets of Accelr8, would harm Accelr8’s competitive position related to business development opportunities and strategies (and otherwise), and/or could result in a material adverse effect on the business, results of operations, financial condition and/or prospects of Accelr8. The Authority agrees (i) that, unless otherwise expressly agreed in writing by Accelr8, such Accelr8 Confidential Information shall not be subject to disclosure to any third party, including disclosure under A.R.S. §39-101 et seq., unless compelled by a court of law, and (ii) to use its best efforts to maintain the confidentiality of all information relating to Accelr8 in its possession, including notifying Accelr8 within two days of the Authority’s receipt of any request or demand for disclosure of any information relating to Accelr8 pursuant to a public records request or otherwise. Upon such notice by the Authority, Accelr8 shall, within 10 Business Days, communicate to the Authority, in writing, what parts, if any, of the information requested is deemed by Accelr8 to be Accelr8 Confidential Information.

-16-

 

 
 

 

Execution Copy

8.18             Conflict of Interest . The requirements of A.R.S. § 38-511 apply to the Agreement.

8.19             No Assignment . The Parties acknowledge that this Agreement, and the Grant made to Accelr8, is personal to Accelr8 and is based solely and exclusively upon factors relevant to Accelr8’s unique business history, qualifications, financial structure and experience, and that, except as provided for in this Agreement, Accelr8 may not assign or transfer (which shall include but not be limited to encumbering or hypothecating), in whole or in part, this Agreement, or its rights or obligations arising under this Agreement (including its right to receive any funds or grant monies payable hereunder) , in whole or in part, to any other person or entity , or for any purpose not specified herein, without the prior written consent of the Authority, which may be granted, withheld, delayed or conditioned in the Authority’s sole, absolute and unfettered discretion. Any assignment, or attempted or purported assignment, in violation of this Section 9.20 shall be void, and not voidable, and shall vest no rights in the purported assignee or transferee. Notwithstanding anything herein to the contrary, Accelr8 shall be permitted to complete a Corporate Succession so long as Accelr8’s successor-in-interest assumes its obligations under this Agreement by operation of law or otherwise.

 

[ Signatures are on the following page .]

 

 

 

-17-

 

 
 

 

Execution Copy  

 

IN WITNESS WHEREOF, this Agreement has been executed and delivered by the Parties to be effective as of the Effective Date.

ACCELR8 : ACCELR8 TECHNOLOGIES CORPORATION,
  a Colorado corporation
   
   
  By: Lawrence Mehren
  Its: President and CEO
   
AUTHORITY : ARIZONA COMMERCE AUTHORITY,
  an agency of the State of Arizona
   
   
  By: ______________________________________
  Sandra Watson
  Its: Interim President and CEO
   
   

 

 

  -18-

 

 

 

 

 
 

 

 

Execution Copy

 

Exhibit A

 

CLOSING AFFIDAVIT

 

The undersigned hereby declares that he is the President and Chief Executive Officer of Accelr8 Technologies Corporation, a Colorado corporation (“ Accelr8 ”), and further declares, solely in such capacity for Accelr8 and not individually, that:

 

1. The undersigned has examined the Grant Agreement, executed and effective as of _____________ , 2012, by and between Accelr8 and the Arizona Commerce Authority , an agency of the State of Arizona (the “ Agreement ”); and

 

2. To the knowledge of the undersigned, without an independent investigation, the representations and warranties of Accelr8 set forth in Article 5 of the Agreement are true and correct in all material respects, or true and correct where such representations and warranties are already qualified by materiality or material adverse change in the business, operations or financial condition of Accelr8; , except that if a representation and warranty is made as of a specific date and such date is expressly referred to therein, such representation or warranty shall be true and correct (or true and correct in all material respects, as applicable) as of the date thereof.

 

Executed this ___ day of ______________2012.

 

   
  By: ___________________________________________
  Name: _________________________________________
  Its:____________________________________________
   

 

 

STATE OF ARIZONA )
  ) ss
County of Maricopa )
   

 

On ________________________, 2012, before me, the undersigned Notary Public, personally appeared ____________________________________, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person or the entity upon behalf of which the person acted, executed the instrument.

 

WITNESS my hand and official seal.  
 
  Notary Public
 
My Commission Expires:  

 

 

 

-2-

 

 

 

 

 

 

 
 

 

 

Execution Copy

 

 

Exhibit B

 

FORM OF PROGRESS REPORT

 

 

 

 

 

-2-

 

 

 

 
 

 

 

 

Exhibit C

 

 

ESCROW AGREEMENT FOR GRANT

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lawrence Mehren, certify that:

 

1. I have reviewed this annual report on Form 10-K of Accelr8 Technology Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchanged Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

  a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b)  designed such internal control over financial reporting, caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s)  and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  /s/ Lawrence Mehren
 October 26, 2012 Lawrence Mehren, Chief Executive Officer
  (Principal Executive Officer)

  

 

 

  

 

 

 

 

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Steve Reichling, certify that:

 

1. I have reviewed this annual report on Form 10-K of Accelr8 Technology Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s)  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s)  and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect our ability to record, process, summarize and report financial information; and
  b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  /s/ Steve Reichling
 October 26, 2012 Steve Reichling, Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Each of the undersigned officers of Accelr8 Technology Corporation (the "Company") hereby certifies that, to his or her knowledge, the Company's Annual Report on Form 10-K to which this certification is attached (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Lawrence Mehren
  Lawrence Mehren, Chief Executive Officer
  (Principal Executive Officer)
 October 26, 2012  
  /s/ Steve Reichling
  Steve Reichling, Chief Financial Officer
  (Principal Financial and Accounting Officer)